<SEC-DOCUMENT>0001513162-22-000122.txt : 20221013
<SEC-HEADER>0001513162-22-000122.hdr.sgml : 20221013
<ACCEPTANCE-DATETIME>20221013161220
ACCESSION NUMBER:		0001513162-22-000122
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20220831
FILED AS OF DATE:		20221013
DATE AS OF CHANGE:		20221013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		221309196

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bmra-20220831.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:33 UTC 2022 -->
<html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:bmra="http://www.biomerica.com/20220831" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head><title>Form 10-Q</title>
<meta content="text/html" http-equiv="Content-Type" />
</head> <body><div style="WORD-WRAP:break-word"><div> </div><div style="page:WordSection1"> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">SECURITIES AND EXCHANGE COMMISSION</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">WASHINGTON, D.C. 20549</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">[<ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">X</ix:nonNumeric>] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">AUGUST 31, 2022</ix:nonNumeric> </span></b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">or</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">[ ]</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Commission File Number:&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-37863</ix:nonNumeric></span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b><span style="text-decoration:underline"><span style="FONT-SIZE:14pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC.</span></span></b></ix:nonNumeric></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">(Exact name of registrant as specified in its charter)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <div style="TEXT-ALIGN:left"> <div style="page:WordSection1"> <div style="TEXT-ALIGN:center"> <table cellpadding="0" cellspacing="0" style="BORDER-LEFT-WIDTH:0px; BORDER-RIGHT-WIDTH:0px; WIDTH:6.25in; BORDER-BOTTOM-WIDTH:0px; BORDER-COLLAPSE:collapse; MARGIN-LEFT:auto; BORDER-TOP-WIDTH:0px; MARGIN-RIGHT:auto" width="600"> <tr> <td style="WIDTH:40%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><strong><span style="FONT-SIZE:10pt; COLOR:black">Delaware</span></strong></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">(State or other jurisdiction of</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Incorporation of organization)</span></p></td> <td style="WIDTH:20%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; MARGIN:0in">&#160;</p></td> <td style="WIDTH:40%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in 0in 0in 1.5pt; TEXT-INDENT:-1.5pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><strong><span style="FONT-SIZE:10pt; COLOR:black">95-2645573</span></strong></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">(I.R.S. Employer <br/>Identification No.)</span></p></td></tr> <tr style="HEIGHT:1.9pt"> <td colspan="3" style="HEIGHT:1.9pt; WIDTH:40%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; MARGIN:0in"><br/><br/></p></td></tr> <tr> <td style="WIDTH:40%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><strong><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">17571 Von Karman Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Irvine</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></strong></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">(Address of principal executive offices)</span></p></td> <td style="WIDTH:20%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="top"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; MARGIN:0in">&#160;</p></td> <td style="WIDTH:40%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><strong><span style="FONT-SIZE:10pt; COLOR:black">92614</span></strong></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Times New Roman',serif; TEXT-ALIGN:center; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">(Zip Code)</span></p></td></tr></table></div></div></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">REGISTRANT'S TELEPHONE NUMBER:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">(<b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">949</ix:nonNumeric>) <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">645-2111</ix:nonNumeric></b></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Securities registered under Section 12(b) of the Exchange Act:</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in; TEXT-INDENT:0.5in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:black">(Title of each class)</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><b><span style="FONT-SIZE:10pt; COLOR:black">COMMON STOCK, PAR VALUE $0.08</span></b></ix:nonNumeric></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="text-decoration:underline"><span style="FONT-SIZE:10pt; COLOR:black">(Name of each exchange on which registered)</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif"><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Capital Market</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">(Trading symbol)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BMRA</span></ix:nonNumeric></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> [X] No [_]</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> [X] No [_]</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer,", "accelerated filer,", "smaller reporting company", and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:0.5in" width="600"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:122.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Large accelerated filer <span style="text-decoration:underline">[ &#160;]</span></span></p></td> <td style="HEIGHT:15pt; WIDTH:189.6pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:137.5pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Accelerated filer&#160;&#160;&#160;[<span style="text-decoration:underline">&#160; </span>]</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> &#160;&#160;<span style="COLOR:black">[X]</span></span></p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Smaller reporting company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">[X]</ix:nonNumeric></span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">[<span style="text-decoration:underline">&#160; </span>]</ix:nonNumeric></span></p></td></tr></table> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; COLOR:black">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">[_]</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes [_] No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">[X]</ix:nonNumeric></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 69.65pt 0in 0in">&#160;</p> <p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 69.65pt 0in 0in;"><span style="font-family: 'Times New Roman',serif;">The number of shares of the registrant's common stock <span style="color: black;">outstanding as of <span style="background: white;">October 11, 2022</span></span><span style="background: white;"> was <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">13,427,651</ix:nonFraction>.</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <div style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <a id="TOC"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">INDEX</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:635.05pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="847"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#P1">PART I </a></span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#P1">Financial Information</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#I1">Item 1.</a>&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#I1">Financial Statements:</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:12.8pt"> <td style="HEIGHT:12.8pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.8pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#BS">Condensed Consolidated Balance Sheets (unaudited) &#8211;August 31, 2022 and May 31, 2022</a></span></p></td> <td style="HEIGHT:12.8pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">1</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt"><a href="#IS">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) &#8211; Three Months Ended August 31, 2022 and 2021</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr> <td style="WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#SHEQ">Condensed Consolidated Statements of Shareholders&#8217; Equity (unaudited) &#8211; Three Months Ended August 31, 2022 and 2021</a></span></p></td> <td style="WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">3</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:14.85pt"> <td style="HEIGHT:14.85pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:14.85pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#CFS">Condensed Consolidated Statements of Cash Flows (unaudited) &#8211; Three Months Ended August 31, 2022 and 2021</a></span></p></td> <td style="HEIGHT:14.85pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">4</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Notes">Notes to Condensed Consolidated Financial Statements (unaudited)</a> </span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">5 - 13 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#MDNA">Item 2.</a> </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#MDNA">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">13 - 16</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#QQD">Item 3.</a> </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#QQD">Quantitative and Qualitative Disclosures about Market Risk</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">17</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#CP">Item 4.</a>&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#CP">Controls and Procedures</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">17</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#P2">PART II </a></span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#P2">Other Information</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#LP">Item 1.</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#LP">Legal Proceedings</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">17</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#RAU">Item 1A.</a> </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#RAU">Risks and Uncertainties</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">17</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#OI">Item 5.</a> </span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#OI">Other Information</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">17</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Ex">Item 6.</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Ex">Exhibits</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">18</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:80%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 80%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><a href="#Sig">Signatures</a></span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">19</span></p></td></tr></table></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="font-family: Times New Roman;"><a href="#TOC">Table of Contents</a></span></p></div><div><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span></span></div><div> </div><div style="page:WordSection2"> <a id="P1"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">PART I - FINANCIAL INFORMATION</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">SUMMARIZED FINANCIAL INFORMATION</span></p> <a id="I1"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 1. FINANCIAL STATEMENTS</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC. AND SUBSIDIARIES</span></p> <a id="BS"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:750pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="1000"> <tr style="HEIGHT:0.2in"> <td rowspan="2" style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Assets</span></b></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Current Assets:</span></b></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,075,037</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,916,983</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accounts receivable, less allowance for doubtful accounts </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160; of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">383,106</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">153,231</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">932,273</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">773,818</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Inventories, net of inventory reserves<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160; of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">981,814</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">845,549</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"> <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">1,921,734</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"> <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,416,447</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Prepaid expenses and other</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">238,762</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">320,283</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total current assets</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,167,806</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,427,531</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Property and equipment, net of accumulated depreciation and amortization </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160; of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,325,561</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,305,360</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">227,908</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">214,487</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right of use assets, net of accumulated amortization </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="bmra:AccumulatedAmortizationRightOfUseAssets" scale="0" unitRef="usd">791,859</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="bmra:AccumulatedAmortizationRightOfUseAssets" scale="0" unitRef="usd">724,802</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,234,777</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,301,834</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Investments</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,324</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,324</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets, net of accumulated amortization </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">21,271</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">18,994</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">160,750</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">169,516</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Other assets</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">93,509</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">95,588</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total Assets</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">11,050,074</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">11,374,280</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Liabilities and Shareholders' Equity</span></b></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Current Liabilities:</span></b></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accounts payable and accrued expenses</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">671,240</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">972,372</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accrued compensation</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd">591,948</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd">646,944</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Advance from customers</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd">150,523</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd">50,670</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Lease liability, current portion</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">343,889</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">341,296</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total current liabilities</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,757,600</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,011,282</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Lease liability, net of current portion</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">970,890</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,038,284</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total Liabilities</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,728,490</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">3,049,566</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Commitments and contingencies (Notes 5 and 6)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-0"> </div></td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1"></div></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Shareholders' Equity:</span></b></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:0.2in"> <td colspan="2" style="HEIGHT:0.2in; WIDTH:76%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 76%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Common stock, $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></ix:nonFraction> par value, </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">13,406,901</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">12,867,924</ix:nonFraction></ix:nonFraction> issued and outstanding at </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022 and May 31, 2022,&#160; respectively</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">1,072,550</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">1,029,432</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Additional paid-in-capital</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">44,484,752</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">42,446,597</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accumulated other comprehensive loss</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">86,463</ix:nonFraction>)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">73,936</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.35in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Accumulated deficit</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">37,149,255</ix:nonFraction>)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">35,077,379</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total Shareholders' Equity</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,321,584</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,324,714</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total Liabilities and Shareholders' Equity</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">11,050,074</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">11,374,280</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td colspan="6" style="HEIGHT:15pt; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 100%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td colspan="6" style="HEIGHT:0.2in; WIDTH:100%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 100%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The accompanying notes are an integral part of these statements.</span></p></td></tr></table></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">1</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC. AND SUBSIDIARIES</span></p> <a id="IS"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">AND COMPREHENSIVE LOSS (UNAUDITED)</span></p> <div style="page:WordSection1"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p> <div style="text-align: left;"> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="width: 750pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="1000">

<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 26%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Three Months Ended</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">August 31, 2022</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: windowtext 1pt solid; height: 13.2pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: center; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">August 31, 2021</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net sales</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,637,435</ix:nonFraction> </span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,261,787</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Cost of sales</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,692,390</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,350,757</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.3in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Gross loss</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd">54,955</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd">88,970</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Operating expenses:</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in 0in 0in 0.3in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Selling, general and administrative</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,653,821</ix:nonFraction> </span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,069,855</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.3in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Research and development</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">361,171</ix:nonFraction> </span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">381,544</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in 0in 0in 0.5in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total operating expenses</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">2,014,992</ix:nonFraction> </span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">1,451,399</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Loss from operations</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,069,947</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">1,540,369</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Other income:</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.3in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Dividend and interest income</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd">28</ix:nonFraction></span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="0" unitRef="usd">6,805</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in 0in 0in 0.3in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">Interest expense</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-2; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">-</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-3; font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif;">-</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in 0in 0in 0.5in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Total other income</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">28</ix:nonFraction></span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">6,805</ix:nonFraction></span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Loss before income taxes</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,069,919</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,533,564</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Provision for income taxes</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">1,957</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">9,017</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net loss</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,071,876</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,542,581</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Basic net loss per common share</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.16</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.12</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Diluted net loss per common share</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.16</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.12</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Weighted average number of common and<br/>common equivalent shares:</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Basic</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">13,100,407</ix:nonFraction> </span></p>
</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">12,426,784</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Diluted</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">13,100,407</ix:nonFraction> </span></p>
</td>
<td style="height: 13.8pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">12,426,784</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.8pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Net loss</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,071,876</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,542,581</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 13.2pt; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Other comprehensive loss, net of tax:</span></p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Foreign currency translation</span></p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">12,527</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.2pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.2pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">5,613</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.2pt;">
<td style="height: 13.2pt; width: 74%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
<td style="height: 13.2pt; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;">&#160;</p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td style="height: 13.8pt; width: 74%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">Comprehensive loss</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">2,084,403</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.8pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 13.8pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; text-align: right; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">1,548,194</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.8pt;">
<td colspan="6" style="height: 13.8pt; width: 100%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
</tr>
<tr style="height: 13.2pt;">
<td colspan="6" style="height: 13.2pt; width: 100%; white-space: nowrap; padding: 0in;">
<p style="font-size: 11pt; font-family: 'Calibri',sans-serif; margin: 0in; line-height: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman',serif; color: black;">The accompanying notes are an integral part of these statements.</span></p>
</td>
</tr>

</table></div></div> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in 0in 0pt; L"></p></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">2</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">B<span style="COLOR:black">IOMERICA, INC. AND SUBSIDIARIES</span></span></p> <a id="SHEQ"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <a id="new_id"></a><table cellpadding="0" cellspacing="0" style="WIDTH:738.25pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="984"> <tr style="HEIGHT:15.75pt"> <td colspan="17" style="HEIGHT:15.75pt; WIDTH:99.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">For the Three Months Ended August 31, 2021</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td></tr> <tr style="HEIGHT:15.75pt"> <td colspan="17" style="HEIGHT:15.75pt; WIDTH:99.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" rowspan="3" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accumulated Other</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Comprehensive</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Loss</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23.88%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Common Stock&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Additional </span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;Paid-in Capital</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accumulated</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Deficit</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in 0in 8pt; L">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Shares</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.98%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Amount</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.08%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Total</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Balances, May 31, 2021, restated</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">12,307,157</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">984,571</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">38,836,743</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">47,956</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">30,546,335</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,227,023</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Exercise of stock options</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">1,500</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">120</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">3,775</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">3,895</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net proceeds from ATM</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">201,553</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">16,124</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">784,586</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">800,710</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Foreign currency translation</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">5,613</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">5,613</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Stock option expense</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">319,622</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">319,622</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net loss</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,542,581</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,542,581</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Balances, August 31, 2021</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">12,510,210</ix:nonFraction> </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,000,815</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">39,944,726</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">53,569</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">32,088,916</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.16%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,803,056</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:16.5pt"> <td colspan="17" style="HEIGHT:16.5pt; WIDTH:99.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:16.5pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:16.5pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td colspan="17" style="HEIGHT:15.75pt; WIDTH:99.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">For the Three Months Ended August 31, 2022</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td colspan="17" style="HEIGHT:15.75pt; WIDTH:99.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" rowspan="3" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accumulated Other</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Comprehensive</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Loss</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:23.88%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Common Stock&#160;&#160;</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Additional </span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;Paid-in Capital</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" rowspan="2" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Accumulated</span></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Deficit</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:10.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in 0in 8pt; L">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Shares</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.98%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Amount</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12.08%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:center; MARGIN:0in; ; text-align: center;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Total</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Balances, May 31, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">12,867,924</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,029,432</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">42,446,597</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">73,936</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c22" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">35,077,379</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,324,714</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Exercise of stock options</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">15,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">1,200</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">12,750</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">13,950</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net proceeds from ATM</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">523,977</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">41,918</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">1,721,650</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">1,763,568</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Foreign currency translation</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.9%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">12,527</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.08%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:10.16%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd">12,527</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Stock option expense</span></p></td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.9%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">303,755</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.08%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:10.16%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">303,755</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:20.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Net loss</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.9%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">-</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,071,876</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.92%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:1.92%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10.16%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,071,876</ix:nonFraction>)</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:20.14%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Balances, August 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">13,406,901</ix:nonFraction> </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.9%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,072,550</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">44,484,752</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; ">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">86,463</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.08%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">(<ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">37,149,255</ix:nonFraction>)</span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.92%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.92%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10.16%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; TEXT-ALIGN:right; MARGIN:0in; ; text-align: right;"><b><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,321,584</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15.75pt"> <td colspan="17" style="HEIGHT:15.75pt; WIDTH:99.74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"></td> <td style="HEIGHT:15.75pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15.75pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td colspan="17" style="HEIGHT:15pt; WIDTH:99.74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&#34;Calibri&#34;,sans-serif; MARGIN:0in; "><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">The accompanying notes are an integral part of these statements.</span></p></td> <td style="HEIGHT:15pt; WIDTH:0.14%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td> <td style="HEIGHT:15pt; WIDTH:0.04%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">3</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span></span> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC. AND SUBSIDIARIES</span></p> <a id="CFS"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">(UNAUDITED)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="width: 750.25pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="1000">

<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="5" style="border-top: 0px; height: 12.75pt; border-right: 0px; width: 30%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">Three Months Ended</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="height: 12.75pt; width: 14%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">August 31, 2022</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: windowtext 1pt solid; height: 12.75pt; border-right: 0px; width: 14%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">August 31, 2021</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from operating activities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: windowtext 1pt solid; height: 12.75pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: 0px; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: windowtext 1pt solid; height: 12.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: 0px; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: windowtext 1pt solid; height: 12.75pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: 0px; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net loss </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">2,071,876</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,542,581</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Depreciation and amortization </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">28,971</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">34,722</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Provision for allowance on accounts receivable </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">229,875</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">94,891</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Inventory reserve </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd">136,265</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" unitRef="usd">179,744</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Stock option expense </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">303,755</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">319,622</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Amortization of right-of-use asset </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">67,057</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">62,897</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Changes in assets and liabilities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accounts receivable </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">388,330</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">777,752</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Inventories </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">358,448</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">164,732</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Prepaid expenses and other </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">81,521</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">55,069</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Reduction in lease liability </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseDecreaseInLeaseLiability" scale="0" sign="-" unitRef="usd">64,801</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="bmra:IncreaseDecreaseInLeaseLiability" scale="0" sign="-" unitRef="usd">55,649</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Other assets </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" sign="-" unitRef="usd">2,076</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" unitRef="usd">2,431</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accounts payable and accrued expenses </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">301,132</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">58,024</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Accrued compensation </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="0" sign="-" unitRef="usd">54,996</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="0" unitRef="usd">118,826</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Advance from customers </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd">99,853</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-4; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash (used in) provided by operating activities </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,573,314</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd">75,836</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from investing activities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Expenditures related to intangibles </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-5; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd">72,375</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Purchases of property and equipment </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">33,623</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">5,141</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash used in investing activities </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">33,623</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">77,516</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash flows from financing activities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Gross proceeds from sale of common stock </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,810,927</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">838,333</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Costs from sale of common stock </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">47,359</ix:nonFraction>)</span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">37,622</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Proceeds from exercise of stock options </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">13,950</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">3,895</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net cash provided by financing activities </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">1,777,518</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">804,606</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Effect of exchange rate changes in cash </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">12,527</ix:nonFraction>)</span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd">5,613</ix:nonFraction>)</span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Net increase in cash and cash equivalents </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; border: 0px; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">158,054</ix:nonFraction> </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; border: 0px; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">797,313</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Cash and cash equivalents at beginning of year </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,916,983</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,199,311</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Cash and cash equivalents at end of the period </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">6,075,037</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,996,624</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Supplemental Disclosure of Cash Flow Information: </span></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Cash paid during the period for: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Income taxes </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">1,957</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">9,017</ix:nonFraction> </span></p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 13.5pt; width: 12%; background: #b4c6e7; white-space: nowrap; border: 0px; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 12.75pt;">
<td style="height: 12.75pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><strong><span style="font-size: 10pt; color: black;">Non-cash investing and financing activities: </span></strong></p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 12.75pt; width: 12%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 13.5pt;">
<td style="height: 13.5pt; width: 68%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of intangible assets, cost </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfIntangibleAssetsCost" scale="0" unitRef="usd">6,489</ix:nonFraction> </span></p>
</td>
<td style="height: 13.5pt; width: 2%; background: #b4c6e7; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 2%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$ </span></p>
</td>
<td style="border-top: 0px; height: 13.5pt; border-right: 0px; width: 12%; background: #b4c6e7; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-6; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 14.25pt;">
<td style="height: 14.25pt; width: 68%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Write off of intangible assets, accumulated amortization </span></p>
</td>
<td style="height: 14.25pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 14.25pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 14.25pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">850</ix:nonFraction> </span></p>
</td>
<td style="height: 14.25pt; width: 2%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 14.25pt; border-right: 0px; width: 2%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 14.25pt; border-right: 0px; width: 12%; background: white; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="-sec-ix-hidden: hidden-fact-7; font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-</span></p>
</td>
</tr>
<tr style="height: 14.25pt;">
<td colspan="7" style="height: 14.25pt; width: 100%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;">&#160;</p>
</td>
</tr>
<tr style="height: 14.25pt;">
<td colspan="7" style="height: 14.25pt; width: 100%; background: white; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0in;"><span style="font-family: 'Times New Roman',serif; color: black;">The accompanying notes are an integral part of these statements.</span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">4</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">BIOMERICA, INC. AND SUBSIDIARIES</span></p> <a id="Notes"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccounting-c0_cont_1" escape="true" name="us-gaap:BasisOfAccounting"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 1: &#160;BASIS OF PRESENTATION</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_BasisOfAccounting-c0_cont_2" id="_BasisOfAccounting-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="FONT-SIZE:10pt"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</span><span style="FONT-SIZE:10pt"> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="FONT-SIZE:10pt; COLOR:black">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="FONT-SIZE:10pt"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk115702344"></a><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_3" id="_BasisOfAccounting-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products based on our InFoods<sup>&#174;</sup> Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other inflammatory diseases. These InFoods<sup>&#174;</sup> based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented InFoods Technology is our InFoods&#174; IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. We are currently in discussions with key gastroenterology (GI) physician groups who are interested in offering this product to their patients. As such, we are expecting to begin generating revenues from the launch of our InFoods<sup>&#174;</sup> IBS product during our fiscal third quarter. &#160;&#160;</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_BasisOfAccounting-c0_cont_4" id="_BasisOfAccounting-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk111716322"></a><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_5" id="_BasisOfAccounting-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> and 2023 have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, less than 12% of our revenues during the three months ended August 31, 2022 were from sales of our COVID-19 related products. <span style="COLOR:black">&#160;</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <a id="_Hlk111716362"></a><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_6" id="_BasisOfAccounting-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our non-COVID-19 products that accounted for over 88% of our revenues during the three months ended August 31, 2022, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation>  <ix:continuation id="_BasisOfAccounting-c0_cont_6"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">The unaudited consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2022. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2023. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on August 29, 2022. Management has evaluated all subsequent events and transactions through the date of filing this report.</span></p></ix:continuation> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">5</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 2: &#160;SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_MarketsAndMethodsOfDistributionPolicyTextBlock-c0_cont_1" escape="true" name="bmra:MarketsAndMethodsOfDistributionPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_MarketsAndMethodsOfDistributionPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the Coronavirus global pandemic, and the economic disruptions that have followed, the Company&#8217;s operations have been negatively impacted.<span style="COLOR:black"> The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions have materially negatively impacted the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_LiquidityPolicyTextBlock-c0_cont_1" escape="true" name="bmra:LiquidityPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_2" id="_LiquidityPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" sign="-" unitRef="usd">37.1</ix:nonFraction> million as of August 31, 2022. Management expects to continue to incur significant costs as it advances its clinical trials and product development activities. As of August 31, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,075,000</ix:nonFraction> and working capital of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="bmra:WorkingCapital" scale="0" unitRef="usd">7,410,000</ix:nonFraction>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_3" id="_LiquidityPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">On July 21, 2020, the Company filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" scale="0" unitRef="usd">90,000,000</ix:nonFraction>.&#160; Shares of the Company&#8217;s common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, the Company filed a prospectus supplement for the sale of up to $<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" scale="0" unitRef="usd">15,000,000</ix:nonFraction> of shares of our common stock in an at-the-market offering (&#8220;ATM Offering&#8221;) under the shelf registration statement, of which approximately $<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">9,600,000</ix:nonFraction>, remains available for sale under the prospectus supplement.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_4" id="_LiquidityPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_5" id="_LiquidityPolicyTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The sales agent under the ATM Offering agrees to use commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend offers under, or terminate the ATM Offering.</span></p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_6" id="_LiquidityPolicyTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the quarter ended August 31, 2022, the Company sold <ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">523,977</ix:nonFraction> shares of its common stock at prices ranging from $<ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">3.15</ix:nonFraction> to $<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">3.55</ix:nonFraction> under its ATM Offering which resulted in gross proceeds of approximately $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,811,000</ix:nonFraction> and net proceeds to the Company approximately of $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">1,764,000</ix:nonFraction> after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.</span></p></ix:continuation></ix:continuation> <a id="_Hlk80862558"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_LiquidityPolicyTextBlock-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand <span style="COLOR:black">at August 31, 2022, </span>and the ability to raise additional funds, including through the ATM Offering noted above,<span style="COLOR:black"> management</span> believes the Company has sufficient funds to operate through at least November 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">6</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. <span style="COLOR:black">As of August 31, 2022,</span> the Company had approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashUninsuredAmount" scale="0" unitRef="usd">5,834,000</ix:nonFraction> of uninsured cash. <span style="COLOR:black">The Company does not believe it is exposed to any significant credit risks.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <a id="_Hlk99112124"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Consolidated net sales were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,637,000</ix:nonFraction> for the <span style="COLOR:black">three months ended August 31, 2022, as compared to $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,262,000</ix:nonFraction> for the three months ended August 31, 2021. </span>For <span style="COLOR:black">the three months ended August 31, 2022 and 2021,</span> the Company had <span style="COLOR:black">two</span> key customers who are located in foreign countries which accounted <span style="COLOR:black">for <ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">64</ix:nonFraction>%</span> and <span style="COLOR:black"><ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">60</ix:nonFraction>%</span> of net consolidated sales, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd">1,315,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd">927,000</ix:nonFraction>, respectively. On August 31, 2022</span><span style="FONT-SIZE:10pt"> and <span style="COLOR:black"> May 31, 2022,</span> the Company had two and <span style="COLOR:black">one</span> key customers who are located in foreign countries which accounted for a total of <ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">67</ix:nonFraction>% and <span style="COLOR:black"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">50</ix:nonFraction>%,</span> respectively, of gross accounts receivable. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">For the three months ended August 31, 2022 and 2021, the</span><span style="FONT-SIZE:10pt"> Company had one <span style="COLOR:black">k</span>ey vendor which accounted for <ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">9</ix:nonFraction>% <span style="COLOR:black">and <ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">17</ix:nonFraction>%</span> of the purchases of raw materials, respectively. <span style="COLOR:black">As of August 31, 2022 and May 31, 2022,</span> the Company had one and two key vendors which accounted for <ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">11</ix:nonFraction>% <span style="COLOR:black">and <ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure">69</ix:nonFraction>%, respectively</span>, of accounts payable.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CASH AND CASH EQUIVALENTS </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less <span style="COLOR:black">than three months</span>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria,&#160;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of August 31, 2022 and May 31, 2022, the Company has established a reserve of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">383,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">153,000</ix:nonFraction>, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_PrepaidsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="bmra:PrepaidsPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAID EXPENSES AND OTHER</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_PrepaidsPolicyPolicyTextBlock-c0_cont_2" id="_PrepaidsPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaid expenses and other, until either the inventory is physically received, or the insurance and other items are expensed.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_PrepaidsPolicyPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022 and May 31, 2022, the</span><span style="FONT-SIZE:10pt"> prepaid expenses and other were approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">239,000</ix:nonFraction> and <span style="COLOR:black">$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">320,000</ix:nonFraction>, respectively</span>, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INVENTORIES, NET </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">7</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_3" id="_InventoryPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Net inventories are approximately the following:</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_4" id="_InventoryPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Raw materials</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" unitRef="usd">1,732,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" unitRef="usd">1,717,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Work in progress</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" unitRef="usd">723,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" unitRef="usd">763,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Finished products</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" unitRef="usd">449,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" unitRef="usd">782,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross inventory</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">2,904,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">3,262,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Inventory reserves</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">982,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">846,000</ix:nonFraction>)</span></p></td></tr> <tr style="HEIGHT:13.8pt"> <td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net inventory </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">1,922,000</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,416,000</ix:nonFraction> </span></b></p></td></tr></table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in 2.7pt 0in 0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_4"><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2022, and May 31, 2022, inventory reserves were approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">982,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">846,000</ix:nonFraction>, respectively. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from <ix:nonNumeric contextRef="c44" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c45" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">10 years</ix:nonNumeric>, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment were approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">20,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">28,000</ix:nonFraction> for the three months ended <span style="COLOR:black">August 31, 2022 and 2021, </span>respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">&#160; </span></p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <a id="OLE_LINK6"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed <ix:nonNumeric contextRef="c46" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">18</ix:nonNumeric> years for marketing and distribution rights, <ix:nonNumeric contextRef="c47" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric> years for purchased technology use rights, and <ix:nonNumeric contextRef="c48" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric> years for patents. Amortization expense was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">9,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">7,000</ix:nonFraction> for the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of August 31, 2022 and 2021, an impairment adjustment was made of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd">6,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd">0</ix:nonFraction>, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately <ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>% of the investee and invested approximately $<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="0" unitRef="usd">165,000</ix:nonFraction> into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p></ix:continuation></ix:continuation> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of August 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the period ended August 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">8</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <a id="_Hlk17621381"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">304,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">320,000</ix:nonFraction> of stock-based compensation during the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">The following summary presents the options granted, exercised, expired, canceled and outstanding for the three months <span style="COLOR:black">ended August 31, 2022:</span></span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Option Shares</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Exercise Price</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Weighted Average</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Outstanding May 31, 2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,321,616</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.72</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">146,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.37</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercised</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">15,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.95</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cancelled or expired</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(<ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">64,000</ix:nonFraction>)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">4.78</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Outstanding August 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,388,616</ix:nonFraction> </span></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.69</ix:nonFraction> </span></b></p></td></tr></table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in 2.7pt 0in 0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, options to purchase <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">15,000</ix:nonFraction> shares of common stock were exercised at prices ranging from $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.82</ix:nonFraction> to $<ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.20</ix:nonFraction>. Total net proceeds to the Company were approximately $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">14,000</ix:nonFraction>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, the Company granted <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">146,000</ix:nonFraction> options to purchase common stock at an average purchase price of $<ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.37</ix:nonFraction>, with the majority of those options issued to the Company&#8217;s new Chief Commercial Officer, who is managing the commercialization and roll-out of the InFoods IBS test. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company does not typically allow for returns from international customers except in the event of defective merchandise and therefore does not establish an allowance for returns. The Company does allow for a return merchandise allowance of approximately one percent of sales to certain domestic retailers. This allowance reduces revenue recognition by approximately one percent, and is included in sales discounts. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts during the three months ended August 31, 2022 and 2021, and does not believe that any additional discounts will be given through the end of the contract periods. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <a id="_Hlk49511094"></a><a id="_Hlk49511094-0"></a><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Services for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022, the Company had approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="0" unitRef="usd">151,000</ix:nonFraction> of advances from certain foreign customers. The majority of these advances are prepayments on orders that are expected to ship during our second quarter ended November 30, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">9</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <a id="_Hlk49511094-1"></a><a id="_Hlk49511094-2"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <a id="_Hlk49511094-3"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></ix:continuation></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31,</span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical lab</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,146,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">886,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">213,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">79,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Physician's office</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">183,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">257,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">95,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">40,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,637,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,262,000</ix:nonFraction> </span></p></td></tr></table></ix:continuation></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in 2.7pt 0in 0in; text-align: center;">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 4 for additional information regarding revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHIPPING AND HANDLING FEES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Research and development costs are expensed as incurred. The Company expensed approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">361,000</ix:nonFraction> and <span style="COLOR:black">$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">382,000</ix:nonFraction> </span>of research and development costs during the <span style="COLOR:black">three months ended August 31, 2022 and 2021, respectively.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has provided a full valuation allowance on deferred income tax assets of approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">7,402,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">6,967,000</ix:nonFraction> as of August 31, 2022 and May 31, 2022, respectively. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">18,000</ix:nonFraction></span> and $<span style="BACKGROUND:white"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">8,000</ix:nonFraction></span> for the three months ended August 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the three months ended August 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases.&#160; The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">10</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <a id="_Hlk49511094-4"></a><a id="_Hlk49511094-5"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <a id="_Hlk49511094-6"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">NET LOSS PER SHARE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per <span style="COLOR:black">share calculation at August 31, 2022 and 2021 was <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,388,616</ix:nonFraction> and <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,081,116</ix:nonFraction>, respectively. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p></ix:continuation></ix:continuation>  <ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECLASSIFICATIONS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric></ix:continuation>  <ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. </span></p></ix:continuation></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 18.7pt">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 3:&#160; SHAREHOLDERS&#8217; EQUITY</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric>  <a id="_Hlk49511094-7"></a><a id="_Hlk49188299"></a><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Stock option expense during the three months ended August 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">304,000</ix:nonFraction> and $<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">320,000</ix:nonFraction>, respectively.</span><span style="FONT-SIZE:10pt; COLOR:black"> </span></p></ix:continuation> <ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the three months ended August 31, 2022, the Company sold <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">523,977</ix:nonFraction> shares of its common stock at prices ranging from $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">3.15</ix:nonFraction> to $<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">3.55</ix:nonFraction> under its Form S-3 Registration Statement and ATM Offering which resulted in gross proceeds of approximately $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">1,811,000</ix:nonFraction> and net proceeds to the Company of approximately $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">1,764,000</ix:nonFraction> after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_1" escape="true" name="bmra:GeographicInformationDisclosureTextBlock"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 4: &#160;GEOGRAPHIC INFORMATION</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_2" id="_GeographicInformationDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company operates as <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure">one</ix:nonFraction> segment. Geographic information regarding net sales is approximately as follows: </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_3" id="_GeographicInformationDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="5" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31, </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Revenues from sales to unaffiliated customers:</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Asia</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">814,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">675,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Europe</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">552,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">471,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">North America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">268,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">105,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">South America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">3,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">3,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Middle East</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">8,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,637,000</ix:nonFraction> </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,262,000</ix:nonFraction> </span></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_GeographicInformationDisclosureTextBlock-c0_cont_4" id="_GeographicInformationDisclosureTextBlock-c0_cont_3"><p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-family: 'Times New Roman',serif; color: black;">As of August 31, 2022, and May 31, 2022, a</span><span style="font-family: 'Times New Roman',serif;">pproximately $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">725,000</ix:nonFraction> <span style="color: black;">and $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">621,000</ix:nonFraction> </span>of Biomerica&#8217;s gross inventory was located in Mexicali, Mexico, respectively. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation>  <ix:continuation id="_GeographicInformationDisclosureTextBlock-c0_cont_4"><p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-family: 'Times New Roman',serif; color: black;">As of August 31, 2022, and May 31, 2022,</span><span style="font-family: 'Times New Roman',serif;"> approximately $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">20,000</ix:nonFraction> <span style="color: black;">and $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">17,000</ix:nonFraction> </span>of Biomerica&#8217;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.</span></p></ix:continuation> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">11</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 5: &#160;LEASES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><span style="FONT-SIZE:10pt">The Company leases its facilities. On August 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">26,000</ix:nonFraction> per month. The security deposit is approximately $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">22,000</ix:nonFraction>.<span style="COLOR:black">&#160;</span> </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><span style="FONT-SIZE:10pt">In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="0" unitRef="usd">3,400</ix:nonFraction> per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the United States for the three months ended August 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">78,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">78,000</ix:nonFraction>, respectively.&#160; Rent expense for the Mexico facility for the three months ended August 31, 2022 and 2021 was approximately $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">11,000</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd">10,000</ix:nonFraction>, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"><span style="FONT-SIZE:10pt">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred. &#160;</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Supplemental cash flow information related to leases for the three months <span style="COLOR:black">ended August 31, 2022: </span>&#160;</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_8" id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd">86,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:25.5pt"> <td style="HEIGHT:25.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160; new operating lease liabilities</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p> <p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.02</ix:nonNumeric> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">6.50</ix:nonFraction>%</span></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_9" id="_LesseeOperatingLeasesTextBlock-c0_cont_8"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">The approximate maturity of lease <span style="COLOR:black">liabilities as of August 31, 2022 are as</span> follows:</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:continuation>  <div style="text-align: left;"> <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_10" id="_LesseeOperatingLeasesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less than 1 year</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" unitRef="usd">354,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">1 to 2 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd">364,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2 to 3 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">375,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">3 to 4 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd">387,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">4 to 5 years </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd">8,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total undiscounted lease payments</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">1,488,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less imputed interest</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd">173,000</ix:nonFraction> </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total operating lease liabilities</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">1,315,000</ix:nonFraction> </span></p></td></tr></table></ix:nonNumeric></ix:continuation></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_11" id="_LesseeOperatingLeasesTextBlock-c0_cont_10"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_11"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">12</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">NOTE 6: &#160;COMMITMENTS AND CONTINGENCIES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p></ix:nonNumeric>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LITIGATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:continuation>  <ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of August 31, 2022.</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="Form_8_K"></a><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">NOTE 7:&#160; SUBSEQUENT EVENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p></ix:nonNumeric>  <ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On September 29, 2022, the Company announced that its Aware&#174; Breast Self Exam device and EZ Detect Colon Disease test are being sold on Amazon and fulfilled by Amazon.&#160; &#160;</span></p></ix:continuation> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="MDNA"></a><a id="OLE_LINK3"></a><a id="OLE_LINK4"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 2. &#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">You should read the following discussion and analysis in conjunction with our unaudited condensed consolidated financial statements and the accompanying notes thereto included in Part I, Item 1 of this Report and <span style="BACKGROUND:white">the audited consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended May 31, 2022 (our 2022 Annual Report)</span>. This discussion and analysis contains forward-looking statements that are based on our management&#8217;s current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in &#8220;Risk Factors&#8221; included in Part I, Item 1A of our 2022 Annual Report.&#160;</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OVERVIEW</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="_Hlk53571612"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="FONT-SIZE:10pt"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</span><span style="FONT-SIZE:10pt"> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="FONT-SIZE:10pt; COLOR:black">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="FONT-SIZE:10pt"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products based on our InFoods<sup>&#174;</sup> Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These InFoods<sup>&#174;</sup> based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented InFoods Technology is our InFoods&#174; IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. We are currently in discussions with key gastroenterology (GI) physician groups who are interested in offering this product to their patients. As such, we are expecting to begin generating revenues from the launch of our InFoods<sup>&#174;</sup> IBS product during our fiscal third quarter. &#160;</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we completed an endpoint determination clinical trial on our InFoods&#174; IBS product. This trial was conducted at the Mayo Clinic centers in Florida and Arizona, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, University of Texas Health Science Center at Houston, Houston Methodist, the University of Michigan, and other institutions. This trial monitored IBS patients over an 8-week period to determine the efficacy of our InFoods&#174; IBS product to improve the patients&#8217; IBS symptoms or endpoints. The top-line trial results were reported in February 2022. Multiple endpoints demonstrated statistically significant improvements, indicating that the elimination of specific foods may meaningfully reduce the symptoms of IBS in all patient subtypes (including patients with IBS-Constipation, IBS-Diarrhea &amp; IBS-Mixed). The greatest clinical improvements, including but not limited to abdominal pain and bloating, were seen in patients diagnosed with IBS-Mixed and IBS-Constipation, in the top line data. The purpose of the endpoint study was to validate efficacy, and determine the primary symptom endpoint, or endpoints to be used in a final pivotal trial that will be conducted to attain the validation data needed to apply for U.S. Food and Drug Administration (&#8220;FDA&#8221;) clearance for the product. We are now in the process of reviewing the complete dataset and selecting the target endpoint(s) to be used in the pivotal trial. We are also preparing the protocols for this trial and expect to present these protocols to the FDA during fiscal 2023, with the intention of beginning the trial by June 30, 2023. The trial is expected to include the large medical institution participants that conducted the endpoint trial, in addition to other new institutions and a clinical research organization. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">13</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Following the successful completion and positive results from the Company&#8217;s InFoods<sup>&#174;</sup> IBS clinical trial, we&#8217;ve seen significant interest from Gastroenterology (GI) physicians who would like to provide the InFoods<sup>&#174;</sup> IBS Product to their patients immediately.&#160; Therefore, while we are proceeding with the work needed to seek FDA clearance for this product, we also are currently preparing to launch the InFoods<sup>&#174;</sup> IBS product through a CLIA-certified, high-complexity laboratory facility that will be offering the product as a laboratory developed test (LDT). Our expectation is that we will begin to generate revenues from this product during our fiscal third quarter. In preparation for the launch of this LDT, we are in negotiations with large physician groups that would like to offer the LDT to their IBS patients.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We are also beginning the work of selecting and validating at least one new disease (such as ulcerative colitis or migraines), where there is evidence that certain foods can trigger or contribute to the symptoms found in these indications. We expect any new disease we target will follow a similar development pathway as InFoods IBS in simultaneously seeking FDA clearance of the product while also initially launching the product as an LDT.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">We will also continue to evaluate partnership/licensing opportunities, as they arise, with </span><span style="FONT-SIZE:10pt">U.S. and multinational companies that could help us commercialize the InFoods products in the U.S and overseas. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores like Walmart and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During fiscal 2022, we finalized development of our H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. H. Pylori infection is extremely common, and if left untreated, can lead to ulcers and possibly stomach cancers. During our fourth quarter of fiscal 2022, we applied for FDA clearance of this product though a 510(k) premarket submission. We have been in communications with the FDA answering certain follow-up questions and providing additional data as requested. We are currently awaiting FDA clearance of the product. Once cleared, we will begin marketing the product in the U.S. market.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> and 2023 have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, less than 12% of our revenues during the three months ended August 31, 2022 were from sales of our COVID-19 related products.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">While limited sales continue to occur in our COVID-19 products, </span><span style="FONT-SIZE:10pt">virtually all our research and development efforts are focused on development and commercialization of non-COVID-19 related products such as our H. Pylori product, and our InFoods&#174; IBS product. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our non-COVID-19 products that accounted for over 88% of our revenues during the three months ended August 31, 2022, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="_Hlk53149431"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">14</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">RESULTS OF OPERATIONS</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; BACKGROUND:white; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Three months ended August 31, 2022</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Net Sales and Cost of Sales</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="width: 550pt; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733">

<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">Three Months Ended August 31,</span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="5" style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">Increase (Decrease)</span></p>
</td>
</tr>
<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2022</span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: windowtext 1pt solid; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">2021</span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td colspan="2" style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in;"><span style="font-size: 10pt; color: black;">%</span></p>
</td>
</tr>
<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Clinical lab</span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,146,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">886,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;&#160;&#160; 260,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">&#160;&#160;&#160;&#160;&#160; 29%</span></p>
</td>
</tr>
<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Over-the-counter</span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">213,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">79,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 10%; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">134,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="height: 0.2in; width: 10%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">170%</span></p>
</td>
</tr>
<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Physician's office</span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">183,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">257,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">(74,000)</span></p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="height: 0.2in; width: 10%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">-29%</span></p>
</td>
</tr>
<tr style="height: 0.2in;">
<td style="height: 0.2in; width: 46%; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Contract Manufacturing</span></p>
</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">95,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">40,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">55,000 </span></p>
</td>
<td style="height: 0.2in; width: 2%; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">&#160;</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 0.2in; border-right: 0px; width: 10%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">138%</span></p>
</td>
</tr>
<tr style="height: 15pt;">
<td style="height: 15pt; width: 46%; background: #b8cce4; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">Total</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,637,000 </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">1,262,000 </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;"><span style="font-size: 10pt; color: black;">$</span></p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 2.9pt 0in 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">375,000 </span></p>
</td>
<td style="height: 15pt; width: 2%; background: #b8cce4; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in 5.4pt 0in 5.4pt;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
<td style="border-top: 0px; height: 15pt; border-right: 0px; width: 10%; background: #b8cce4; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in;"><span style="font-size: 10pt; color: black;">30%</span></p>
</td>
</tr>

</table></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="_Hlk113529372"></a><p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-family: 'Times New Roman',serif;">Consolidated net sales were approximately $1,637,000 for the <span style="color: black;">three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021, </span>an increase of approximately $375,000, or 30%. This <span style="color: black;">increase for the three months ended August 31, 2022, was driven primarily by demand for our clinical lab products in Asia and OTC products in the United States. Periodic and infrequent orders may cause volatility in quarterly sales.</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p> <p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-size: 10pt;">Consolidated cost of sales were approximately $1,692,000, or 103% of net sales, for the three months ended August 31, 2022, as compared to $1,351,000, or 107% of net sales, for the three months ended August 31, 2021, an increase of approximately $342,000, or 25%. The increase for the three months ended August 31, 2022, was driven primarily by an increase in volume of our food intolerance product and product cost inflation.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Operating Expenses</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a summary of operating expenses:</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:700pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="933"> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:25.5%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="9" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:59%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; width: 59%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31,</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td style="HEIGHT:15.75pt; WIDTH:2.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15.75pt; WIDTH:5.86%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15.75pt; WIDTH:1.74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:15.75pt; WIDTH:3.8%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:25.5%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:28.64%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2023</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td colspan="4" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:28.64%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:13.76%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Increase (Decrease)</span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:25.5%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.86%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Operating Expense</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.74%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15.06%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">As a % of Total Revenues</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.86%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Operating Expense</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:1.74%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:15.06%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">As a % of Total Revenues</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:8.24%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:3.8%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:25.5%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Selling, General and Administrative Expenses</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:9.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,654,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">101%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:9.46%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,070,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15.06%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">85%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:5.86%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">584,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.8%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160; 55%</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:25.5%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Research and Development</span></p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:9.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">361,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">22%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:9.46%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">381,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:15.06%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">30%</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:2.38%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$ </span></p></td> <td style="HEIGHT:15pt; WIDTH:5.86%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(20,000)</span></p></td> <td style="HEIGHT:15pt; WIDTH:1.74%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.8%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-5%</span></p></td></tr></table></div> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Selling, General and Administrative Expenses</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="_Hlk53409686"></a><p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Consolidated selling, general and administrative expenses were approximately $1,654,000 for the three months ended August 31, 2022, as compared to $1,070,000 for the three months ended August 31, 2021, an increase of approximately $584,000, or 55%.</span><span style="FONT-SIZE:10pt"><span style="COLOR:black"> The increase in the three months ended August 31, 2022, was primarily due to approximate increases in bad debt expense of $300,000, compensation of $73,000, and legal expense of $65,000.</span></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Research and Development</span></i></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Consolidated research and development expenses were <span style="COLOR:black">approximately</span> $361,000 for <span style="COLOR:black">the three months ended August 31, 2022,</span> as compared <span style="COLOR:black">to $381,000 for</span> the three months <span style="COLOR:black">ended August 31, 2021,</span> a decrease of <span style="COLOR:black">approximately </span>$20,000, or 5%. <span style="COLOR:black">The decrease in the three months ended August 31, 2022, was primarily due to a reduction in COVID-19 research.</span></span></p><div style="FONT-SIZE:10pt"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Interest and Dividend Income</span></i></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Interest and dividend income were approximately $0 for the <span style="COLOR:black">three months ended August 31, 2022, as compared to $7,000 for the three months ended August 31, 2021, </span>a decrease of $7,000, or 100%. <span style="COLOR:black">The $7,000 decrease was due to lower dividend payment from our investment. </span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">LIQUIDITY AND CAPITAL RESOURCES</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">The following are the principal sources of liquidity:</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <div style="text-align: left;"> <table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:72%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:12.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:12.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"></p></td></tr> <tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:72%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cash and cash equivalents</span></p></td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6,075,000 </span></p></td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:windowtext 1pt solid; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">5,917,000 </span></p></td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:72%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 72%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Working capital including cash and cash equivalents</span></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">7,410,000 </span></p></td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">7,416,000 </span></p></td></tr></table></div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">15</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">As of August 31, 2022 and May 31, 2022, the Company had cash and cash equivalents of approximately</span><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif"> $6,075,000 and <span style="COLOR:black">$5,917,000,</span> respectively. &#160;<span style="COLOR:black">As of August 31, 2022 and May 31, 2022, the Company had </span>working capital of approximately $7,410,000 <span style="COLOR:black">and $7,416,000,</span> respectively. <span style="COLOR:black">We believe that the aggregate of our existing cash and cash equivalents is sufficient to meet our operating cash requirements and strategic objectives for growth for at least the next year. To satisfy our capital requirements beyond the next year, including ongoing future operations, we may seek to raise additional financing through debt and equity financings, including use of our ATM offering.</span></span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Operating Activities</span></i></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, cash used in operating activities was approximately $1,573,000. The primary factors that contributed to this was a loss of approximately $2,072,000, non-cash expenses of $766,000, <span style="BACKGROUND:white">primarily associated with stock-based compensation, account receivables provision, and inventory reserves</span>. This was partially offset by changes in asset and liability accounts of $(267,000).</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2021, cash provided by operating activities was approximately $76,000. The primary factors that contributed to this was a loss of approximately $1,543,000, non-cash expenses of $502,000, <span style="BACKGROUND:white">primarily associated with stock-based compensation and inventory reserves</span>. In addition, we benefited from a decrease in accounts receivable of $778,000, and changes in other asset and liability accounts of $339,000.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Investing Activities</span></i></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, cash used in investing activities was approximately $34,000 for purchases of property and equipment. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2021, cash used in investing activities was approximately $78,000 for purchases of property and equipment, and expenditures related to patents.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><i><span style="FONT-SIZE:10pt; COLOR:black">Financing Activities</span></i></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, cash provided by financing activities was approximately $1,778,000 which was a result of net proceeds from the sale of common stock of $1,764,000, and stock option exercises of $14,000.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2021, cash provided by financing activities was approximately $805,000 which was a result of net proceeds from the sale of common stock of $801,000, and stock option exercises of $4,000.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">OFF BALANCE SHEET ARRANGEMENTS</span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no off-balance sheet arrangements as of August 31, 2022.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">CRITICAL ACCOUNTING POLICIES</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates under different future conditions.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, bad debts, inventory overhead application, inventory reserves, lease liabilities and right-of-use assets. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial conditions or results of operations. We suggest that our significant accounting policies be read in conjunction with this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Please refer to Note 2 for information on Significant Accounting Policies. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended May 31, 2022.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">16</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="QQD"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="CP"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 4.&#160; CONTROLS AND PROCEDURES</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at the "reasonable assurance" level. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective to ensure that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms; and (2) accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during our last fiscal quarter that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="P2"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">PART II. &#160;OTHER INFORMATION</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <a id="LP"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 1. &#160;LEGAL PROCEEDINGS</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of August 31, 2022.</span>&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p> <a id="RAU"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 1A. &#160;RISKS AND UNCERTAINTIES.</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">An investment in our common stock involves risks. Before making an investment decision, you should carefully consider all the information within this Quarterly Report, including the information contained in Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as in our condensed consolidated financial statements and the related notes contained in Part I, Item 1 within this Quarterly Report. In addition, you should carefully consider the risks and uncertainties described in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our <span style="COLOR:black">2022 Annual</span> Report on Form 10-K, as well as in our other public filings with the SEC. If any of the identified risks are realized, our business, results of operations, financial condition, liquidity, and prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other risks of which we are currently unaware, or which we do not currently view as material, could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">During the three months ended <span style="COLOR:black">August 31, 2022, there were no material changes to the risks and uncertainties described in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our 2022 Annual Report on Form 10-K. </span></span></p> <a id="Signature"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p><a id="Signature-0"> </a><a id="Signature-1"></a><a id="OI"></a><a id="OI-0"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 5.&#160; OTHER INFORMATION</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; COLOR:black">On October 11, 2022, the board of directors of the Company approved and adopted the Amended and Restated Bylaws of the Company, which became effective the same day, in order to, among other things (i) update the name of the Company from &#8220;Nuclear Medical Systems, Inc.&#8221; to &#8220;Biomerica, Inc.&#8221;, (ii) change the annual meeting date from October 15 to any such date that the Board shall fix each year, (iii) change the voting standard for all matters other than election of directors from a plurality vote to a majority vote, (iv) update the requirements for the list of stockholders, (v) revise the indemnification provisions, and (vi) add new forum selection provisions.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">The preceding summary of the Amended and Restated Bylaws is qualified in its entirety by reference to, and should be read in connection with, the complete copy of the Amended and Restated Bylaws filed herewith as Exhibit 3.1. </span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">17</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <a id="Signature-2"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif; color: #0066cc;"><a href="#TOC">Table of Contents</a></span></p> <a id="Signature-3"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <a id="Signature-4"></a><a id="Ex"></a><a id="Ex-0"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">ITEM 6.&#160; EXHIBITS. </span></b></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-SIZE:10pt">The following exhibits are filed or furnished as part of this quarterly report on Form 10-Q: </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <table cellpadding="0" cellspacing="0" style="width: 70%;" width="60%">

<tr>
<td colspan="5" style="border-top: 0px; border-right: 0px; width: 16%; border-bottom: black 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: center; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">Exhibit No.</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="border-top: 0px; border-right: 0px; width: 80.72%; border-bottom: black 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">Description</span></p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160; <a href="exhibit3_1.htm">3.1</a></span></p>
</td>
<td style="width: 4.52%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">*</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit3_1.htm">Amended and Restated Bylaws of the Company</a> </span></p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit31_1.htm">31.1</a></span></p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">**</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit31_1.htm">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act &#8212; Zackary S. Irani</a></span></p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit31_2.htm">31.2</a></span></p>
</td>
<td style="width: 4.52%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">**</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit31_2.htm">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act &#8212; Steve Sloan</a></span></p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit32_1.htm">32.1</a></span></p>
</td>
<td style="width: 4.52%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">**</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit32_1.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act &#8212; Zackary S. Irani</a></span></p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 4.52%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="2" style="width: 4.74%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: right; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 6.74%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit32_2.htm">32.2</a></span></p>
</td>
<td style="width: 4.52%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">**</span></p>
</td>
<td style="width: 3.28%; padding: 0in;" valign="bottom">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 80.72%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;"><a href="exhibit32_2.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act &#8212; Steve Sloan</a></span></p>
</td>
</tr>
<tr>
<td style="width: 3.28%; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 3.22%; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="5" style="width: 93.5%; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td style="width: 3.28%; white-space: nowrap; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="2" style="width: 3.22%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
<td colspan="5" style="width: 93.5%; padding: 0in;" valign="top">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">101&#160;&#160;&#160;&#160;&#160;&#160; Interactive data files pursuant to Rule 405 Regulation S-T, as follows:</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="7" style="width: 98.26%; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;101.INS-XBRL Instance Document</span></p>
</td>
<td style="width: 1%; border: 0px; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr>
<td colspan="7" style="width: 98.26%; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;101.SCH-XBRL Taxonomy Extension Schema Document</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 101.CAL-XBRL Taxonomy Extension Calculation Linkbase Document</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 101.DEF&#8211;XBRL Taxonomy Extension Definition Linkbase Document</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;101.LAB-XBRL Taxonomy Extension Label Linkbase Document</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 101.PRE-XBRL Taxonomy Extension Presentation Linkbase Document </span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)</span></p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;">&#160;</p>
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in 16.2pt 0in 0in;"><span style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;* Filed herein.</span></p>
</td>
<td style="width: 1%; border: 0px; padding: 0in;">
<p style="font-size: 12pt; font-family: 'Times New Roman',serif; margin: 0in;">&#160;</p>
</td>
</tr>
<tr>
<td style="width: 17px; border: 0px;">&#160;</td>
<td style="width: 11px; border: 0px;">&#160;</td>
<td style="width: 14px; border: 0px;">&#160;</td>
<td style="width: 33px; border: 0px;">&#160;</td>
<td style="width: 35px; border: 0px;">&#160;</td>
<td style="width: 25px; border: 0px;">&#160;</td>
<td style="width: 288px; border: 0px;">&#160;</td>
<td style="width: 2px; border: 0px;">&#160;</td>
</tr>

</table> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in; TEXT-INDENT:0.5in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">&#160; &#160;&#160;** Filed herewith.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">18</span></p> <div style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"> <hr/> <div style="PAGE-BREAK-BEFORE: always; margin-left: auto; margin-right: auto;"></div> </div> <a id="Signature-5"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif"><a href="#TOC"><span style="color: #0066cc;">Table of Contents</span></a><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span><strong>&#160;</strong></span></p><a id="Signature-6"> </a><a id="Signature-7"></a><a id="Sig"></a><p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">SIGNATURES</span></b></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p></div></div><div style="FONT-SIZE:10pt"><span style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif"><span style="PAGE-BREAK-BEFORE:none; clear: both;"><br/></span></span> <div style="page:WordSection3"> <table cellpadding="0" cellspacing="0" style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" width="600"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td colspan="2" style="HEIGHT:15pt; WIDTH:50.42%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">BIOMERICA, INC.</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Date:&#160; October 13, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">By:&#160; </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:46.58%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">/S/ Zackary S. Irani</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:2.9pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Zackary S. Irani</span></p></td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:53.42%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:2.9pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Chief Executive Officer</span></p></td></tr> <tr style="HEIGHT:15pt"> <td colspan="2" style="HEIGHT:15pt; WIDTH:53.42%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">(Principal Executive Officer)</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Date:&#160; October 13, 2022</span></p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">By:&#160;</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:46.58%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">/S/ Steve Sloan</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Steve Sloan</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">Chief Financial Officer</span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:49.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:3.84%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:15pt; WIDTH:46.58%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&#34;Times New Roman&#34;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt">(Principal Financial Officer)</span></p></td></tr></table> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; MARGIN:0in 16.2pt 0in 0in">&#160;</p> <p style="FONT-SIZE:10pt; FONT-FAMILY:&#34;Times New Roman&#34;; TEXT-ALIGN:center; MARGIN:0in 16.2pt 0in 0in; text-align: center;"><span style="FONT-FAMILY:&#34;Times New Roman&#34;,serif">19</span></p></div></div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-2" name="us-gaap:InterestExpenseOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:InterestExpenseOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="bmra:WriteOffOfIntangibleAssetsCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--05-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0000073290</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="bmra-20220831.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7betmTGCjVz2Sw5NRMlGi5/YjRsRioXLULk=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bmra:PolishDistributorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-11-01</xbrli:startDate>
    <xbrli:endDate>2016-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
<!-- EDGAR Validation Code: B2DEB88D -->
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit3_1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<head> <title>Exhibit 3.1</title></head> <body style=WORD-WRAP:break-word lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:8.25pt 0in 12pt; TEXT-AUTOSPACE:' align=center><b>A<a name=_Hlk48817577>MENDED AND RESTATED BYLAWS</a></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:8.25pt 0in 12pt; TEXT-AUTOSPACE:' align=center><b>OF</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:8.25pt 0in 12pt; TEXT-AUTOSPACE:' align=center><b>BIOMERICA, INC.</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in 0in 12pt;  TEXT-AUTOSPACE:' align=center>(a Delaware corporation)</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in 0in 12pt;  TEXT-AUTOSPACE:' align=center>Adopted by the Board of Directors on October 11, 2022</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in 0in 12pt;  TEXT-AUTOSPACE:' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in 0in 12pt;  TEXT-AUTOSPACE:' align=center><b>ARTICLE I</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in 0in 12pt;  TEXT-AUTOSPACE:' align=center><b>Offices</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:9.95pt 0in 12pt;  TEXT-AUTOSPACE:; TEXT-INDENT:1in'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:9.95pt 0in 12pt;  TEXT-AUTOSPACE:; TEXT-INDENT:1in'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Corporation may also have an office or offices at such other place or places, within or without the State of Delaware, as the Board of Directors of the Corporation (the &#147;<b>Board</b>&#148;) may from time to time designate or the business of the Corporation may require.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:9pt 0in 12pt; TEXT-AUTOSPACE:' align=center><b>ARTICLE II</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11pt 0in 12pt; TEXT-AUTOSPACE:' align=center><b>Stockholders' Meeting</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>1.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Meetings of the stockholders of the Corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board. The Board may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (the &#147;<b>DGCL</b>&#148;).</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>2.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Unless members of the Board are elected by written consent in lieu of an annual meeting, as permitted by Section 211 of the Delaware General Corporation Law (the &#147;<b>DGCL</b>&#148;) and these Bylaws, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board shall each year fix. At such meeting the stockholders may elect the directors and transact any business properly brought before the meeting.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>3.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Special meetings of the stockholders shall be held upon call of the Board, and shall be called by the Chairperson of the Board or the President or the Secretary at the request in writing of the stockholders owning of record at least twenty-five percent of the issued and outstanding capital stock of the Corporation entitled to vote thereat.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>4.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Notice of the purpose or purposes and of the time and place within or without the State of Delaware of every meeting of stockholders shall be given by the Chairperson of the Board or the President or the Secretary or an Assistant Secretary either personally or by mail or by telegraph or by any other lawful means of communication not less than ten nor more than fifty days before the meeting, to each stockholder of record entitled to vote at such meeting.&nbsp; If mailed, such notice shall be directed to each stockholder at such stockholder&#146;s address as it appears on the stock book unless such stockholder shall have filed with the Secretary of the Corporation a written request that notices intended for him or her be mailed to some other address, in which case it shall be mailed or transmitted to the address designated in such request.&nbsp; Such further notice shall be given as may be required by law.&nbsp; <font style=>Except as otherwise expressly provided by statute, no publication of any notice of meeting of stockholders shall be required to be given any stockholder who shall attend such meeting in person or by proxy, or who shall, in person or by attorney thereunto authorized, waive notice in writing or by wireless communication either before or after such meeting.&nbsp; Except where otherwise required by law, notice of any adjourned meeting of the stockholders of the Corporation shall not be required to be given</font>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>1</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>5.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>A quorum at all meetings of stockholders shall consist of the holders of record of a majority of the shares of stock of the Corporation, issued and outstanding, entitled to vote at the meeting, present in person or by proxy, except as otherwise provided by statute or the Certificate of Incorporation.&nbsp; In the absence of a quorum at any meeting or any adjournment thereof, a majority of those present in person or by proxy and entitled to vote may adjourn such meeting from time to time.&nbsp; At any such adjourned meeting at which a quorum is present any business may be transacted which might have been transacted at the meeting as originally called.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>6.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style=>Meetings of the stockholders shall be presided over by a chairperson which shall be the chief executive officer (the &#147;<b>CEO</b>&#148;).&nbsp; If the CEO is not present, the meetings of the stockholders shall be presided over by the Chairperson of the Board (the &#147;<b>Chairperson</b>&#148;). If neither the CEO or the Chairperson is present, the meeting may be presided over by a chairperson to be chosen by a majority of the stockholders entitled to vote who are present in person or by proxy at the meeting.&nbsp; The Secretary of the Corporation, or in his or her absence, an Assistant Secretary, shall act as secretary of every meeting, but if neither the Secretary nor an Assistant Secretary is present, the meeting shall choose any person present to act as secretary of the meeting</font>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>7.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Except as otherwise provided in these Bylaws, the Certificate of Incorporation, or in the laws of the State of Delaware, at every meeting of the stockholders, each stockholder of the Corporation entitled to vote at such meeting shall have one vote in person or by proxy for each share of stock having voting rights held by him or her and registered in his or her name on the books of the Corporation at the time of such meeting.&nbsp; Any vote on shares of stock of the Corporation may be given by the stockholder entitled thereto in person or by proxy appointed by an instrument in writing, subscribed by such stockholder or by his or her attorney thereunto authorized and delivered to the secretary of the meeting.&nbsp; Except as otherwise required by statute, by the Certificate of Incorporation or these Bylaws, all matters coming before any meeting of the stockholders shall be decided by a <a name=_Hlk115361900>majority vote of the stockholders of the Corporation present in person or by proxy at such meetings and entitled to vote thereat</a>, a quorum being present.&nbsp; At all elections of directors, the voting may but need not be by ballot and a plurality of votes cast thereat shall elect the directors.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>8.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>A complete list of the stockholders entitled to vote at a meeting of stockholders, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder shall be prepared by the Secretary or other officer of the Corporation having charge of the stock ledger.&nbsp; Such list shall be open to the examination of any stockholder for any purpose germane to the meeting, for a period of at least ten days ending on the day before the meeting, either on a reasonably accessible electronic network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>9.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>At all elections of directors, or in any other case in which inspectors may act, two inspectors of election shall be appointed by the chairperson of the meeting, except as otherwise provided by law.&nbsp; The inspectors of election shall take and subscribe an oath faithfully to execute the duties of inspectors at such meeting with strict impartiality, and according to the best of their ability and shall take charge of the polls and after the vote shall have been taken shall make a certificate of the result thereof.&nbsp; If there be a failure to appoint inspectors or if any inspector appointed be absent or refuse to act, or if his or her office becomes vacant, the stockholders present at the meeting, by a per capita vote, may choose temporary inspectors of the number required.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>2</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE III</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Directors</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>1.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The property, affairs and business of the Corporation shall be managed by the Board, consisting of not less than three nor more than nine persons.&nbsp; The exact number of directors within the maximum and minimum limitations specified shall be fixed from time to time by resolution of the Board. &nbsp;Except as hereinafter provided, directors shall be elected at the annual meeting of the stockholders by plurality vote of the stockholders of the Corporation present in person or by proxy at such meeting and entitled to vote thereat, and each director shall be elected to serve for one year and until his or her successor shall be elected and shall qualify.&nbsp; Directors need not be stockholders.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>2.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Meetings of the Board shall be held at such place within or outside the State of Delaware as may from time to time be fixed by resolution of the Board, or as may be specified in the notice of the meeting.&nbsp; Regular meetings of the Board shall be held at such times as may from time to time be fixed by resolution of the Board, and special meetings may be held at any time upon the call of the Chairperson of the Board, the President, or a majority of the directors by oral, electronic or written notice duly served on or sent or mailed to each director not less than one day before such meeting.&nbsp; A meeting of the Board may be held without notice immediately after annual meeting of the stockholders.&nbsp; Notice need not be given of regular meetings of the Board.&nbsp; Meetings may be held at any time without prior notice if all the directors are present, or if at any time before or after the meeting those not present waive notice of the meeting in writing.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>3.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>A majority of the members of the Board then acting at a meeting duly assembled, shall constitute a quorum for the transaction of business, but if at any meeting of the Board there shall be less than a quorum present, a majority of those present may adjourn the meeting, without further notice, from time to time until a quorum shall have been obtained.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>4.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>In case one or more vacancies shall occur or exist in the Board by reason of death, resignation, increase in the number of directors or otherwise except in so far as otherwise provided in these Bylaws, the remaining directors, even if less than a quorum, may, by a majority vote, elect a successor or successors for the unexpired term or terms.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>5.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>At any special meeting of the stockholders, duly called as provided in these Bylaws, any director or directors may by the affirmative vote of the holders of a majority of all the shares of stock outstanding and entitled to vote for election of directors be removed from office, either with or without cause, and his or her successor or their successors may be elected at such meeting; or the remaining directors may, to the extent vacancies are not filled by such election, fill any vacancy or vacancies created by such removal.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>6.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><u>Indemnification</u></b>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 1in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Obligation and Power to Indemnify</b>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'><font style="FONT-SIZE:11.5pt; LETTER-SPACING:-0.05pt; ">a)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><u>Actions, Suits, and Proceedings Other than By or In the Right of the Corporation</u>.&nbsp; Subject to the limitations set forth in <u>Section 6.2</u>, the Corporation will indemnify any Director or Executive Officer, and will indemnify and hold harmless any employee or agent of the Corporation who is not a Director or Executive Officer, who was or is a party or is threatened to be made a party, including as a witness, to any Proceeding (other than an action by or in the right of the Corporation) by reason of such person&#146;s Corporate Status from and against all Expenses and Liabilities actually and reasonably incurred or paid by or on behalf of such person in connection with such Proceeding or any claim, issue or matter therein, if such indemnitee acted in good faith and in a manner the indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful, to the fullest extent permitted by law as the same exists or may hereafter be amended; <i>provided, however</i>, that except with respect to Proceedings to enforce rights to indemnification, the Corporation will indemnify any such indemnitee in connection with a Proceeding (or part thereof) initiated by such indemnitee only if such Proceeding (or part thereof) was authorized by the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>3</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'><font style="FONT-SIZE:11.5pt; LETTER-SPACING:-0.05pt; ">b)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><u>Actions, Suits, and Proceedings By or In the Right of the Corporation</u>. Subject to the limitations set forth in <u>Section 6.2</u>, the Corporation will indemnify any Director or Executive Officer, and will indemnify and hold harmless any employee or agent of the Corporation who is not a Director or Executive Officer, who was or is a party or is threatened to be made a party to any Proceeding (including as a witness) by or in the right of the Corporation to procure a judgment in its favor by reason of such person&#146;s Corporate Status from and against all Expenses actually and reasonably incurred or paid by or on behalf of such person in connection with such Proceeding or any claim, issue or matter therein, if such indemnitee acted in good faith and in a manner the indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation; <i>provided, however</i>, that no indemnification will be made under this <u>Section&nbsp;6.1(b)</u> in respect of any claim, issue or matter as to which such person has been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of Delaware or another court in which such Proceeding was brought determines upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'><font style="FONT-SIZE:11.5pt; LETTER-SPACING:-0.05pt; ">c)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><u>No Presumption</u>.&nbsp; The termination of any Proceeding by a judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, will not, of itself create a presumption that such person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s conduct was lawful.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 1in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Limitation on Indemnification</b>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 1.5in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>a)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><u>Requirement for Determination of Eligibility for Indemnification by Disinterested Directors</u>.&nbsp; Any indemnification to be provided under <u>Section 6.1</u> will (unless ordered by a court) be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the indemnitee is proper in the circumstances because such person has met the applicable standard of conduct set forth in <u>Section 6.1</u>. Such determination will be made (a) by a majority vote of the Disinterested Directors (even though less than a quorum); (b) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors (even though less than a quorum); (c) if there are no Disinterested Directors or if the Disinterested Directors so direct, by independent legal counsel in a written opinion; or (d) by the vote of a majority of the stockholders of the Corporation entitled to vote and voting on the matter. To the extent, however, that the indemnitee has been successful on the merits or otherwise in defense of any Proceeding described in <u>Section 6.1</u>, or in defense of any claim, issue or matter therein, such person will (in the case of a Director or Executive Officer) and will (in the case of an employee or agent of the Corporation who is not a Director or Executive Officer) be indemnified against Expenses actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0in 107.35pt; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>b)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><u>No Indemnification for Matters Initiated by Indemnitee</u>.&nbsp; Notwithstanding the provisions of <u>Section 6.1</u>, the Corporation will indemnify any person seeking indemnification in connection with a Proceeding initiated by such person only if such Proceeding (including any parts of such Proceeding not initiated by such person) was authorized in advance by the Board, unless such Proceeding was brought to enforce such person&#146;s rights to indemnification or advancement of Expenses under these Bylaws in accordance with the provisions set forth herein.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>4</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>c)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The Corporation&#146;s obligation, if any, to indemnify or provide advancement of Expenses to any person under this <u>Section 6</u> as a result of such person&#146;s Corporate Status will be reduced by any amount such person may collect as indemnification or advancement of Expenses from another corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the &#147;<b>Primary Indemnitor</b>&#148;). Any indemnification or advancement of Expenses under this <u>Section 6</u> owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise will only be in excess of, and will be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Indemnification by a Court</b>. Notwithstanding any contrary determination in the specific case under <u>Section 6.2</u>, and notwithstanding the absence of any determination thereunder, any party to a Proceeding by reason of their Corporate Status may apply to any court of competent jurisdiction in the State of Delaware for indemnification to the extent otherwise permissible under <u>Section 6.1</u>. The basis of such indemnification by a court will be a determination by such court that indemnification of the person is proper in the circumstances because such person has met the applicable standards of conduct set forth in <u>Section 6.1</u>. Neither a contrary determination in the specific case under <u>Section 6.2</u> nor the absence of any determination thereunder will be a defense to such application or create a presumption that the person seeking indemnification has not met any applicable standard of conduct. The person seeking application for indemnification pursuant to this <u>Section 6.3</u> must give notice of such filing to the Corporation before or promptly after the filing of such application. If the person seeking indemnification pursuant to the foregoing is successful, in whole or in part, the Corporation will also be obligated to pay such person&#146;s Expense of prosecuting such application.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Expenses Payable in Advance</b>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 1in; ; TEXT-AUTOSPACE:; TEXT-INDENT:-0.25in'>a)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><u>Advancement of Expenses to Directors and Executive Officers Prior to Final Disposition</u>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>i.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The Corporation will advance all Expenses incurred by or on behalf of any Director or Executive Officer in connection with any Proceeding in which such person is involved by reason of such person&#146;s Corporate Status within 30 days after the receipt by the Corporation of a written statement from such person requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements must reasonably evidence the Expenses incurred by such person and be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it is ultimately determined that such person is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation will advance all Expenses incurred by or on behalf of any Director or Executive Officer seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director or Executive Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (A)&nbsp;authorized by the Board, or (B) brought to enforce such Director&#146;s or Executive Officer&#146;s rights to indemnification or advancement of Expenses under these Bylaws.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><a name=_AEIOULastRenderedPageBreakAEIOU19 /><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>ii.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>If a claim for advancement of Expenses hereunder by a Director or Executive Officer is not paid in full by the Corporation within 30 days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director or Executive Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director or Executive Officer will also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this <u>Section 6</u> will not be a defense to an action brought by a Director or Executive Officer for recovery of the unpaid amount of an advancement claim and will not create a presumption that such advancement is not permissible. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>5</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>iii.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The burden of proving that a Director or Executive Officer is not entitled to an advancement of Expenses will be on the Corporation.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>iv.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>In any suit brought by the Corporation to recover an advancement of Expenses pursuant to the terms of an undertaking, the Corporation will be entitled to recover such Expenses upon a final adjudication that the Director or Executive Officer has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 67.5pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:-22.5pt'>b)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><u>Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition</u>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>i.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The Corporation may, at the discretion of the Board, advance any or all Expenses incurred by or on behalf of any employee or agent of the Corporation that is not a Director or Executive Officer in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status upon the receipt by the Corporation of a statement or statements from such person requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements must reasonably evidence the Expenses incurred by such person and be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it is ultimately determined that such person is not entitled to be indemnified against such Expenses. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'><font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>ii.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation will be entitled to recover such expenses upon a final adjudication that the employee or agent of the Corporation that is not a Director or Executive Officer has not met any applicable standard for indemnification set forth in the DGCL.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 1in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>6.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Contractual Nature of Rights</b>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>a)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The provisions of this <u>Section 6</u> constitute a contract between the Corporation and each Director and Executive Officer entitled to the benefits hereof at any time while this <u>Section 6</u> is in effect, in consideration of such person&#146;s past or current and any future performance of services in their Corporate Status. Neither amendment, repeal or modification of any provision of this <u>Section 6</u>, nor the adoption of any provision of the Certificate of Incorporation inconsistent with this <u>Section 6</u> will eliminate or reduce any right conferred by this <u>Section 6</u> in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a Proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission will vest at the time of the act or omission in question, regardless of when or if any Proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of Expenses provided by, or granted pursuant to, this <u>Section 6</u> will continue notwithstanding that the person has ceased to be a Director or Executive Officer and will inure to the benefit of the estate, heirs, executors, administrators, legatees and distributes of such person.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If a claim for indemnification hereunder by a Director or Executive Officer is not paid in full by the Corporation within 60 days after receipt by the Corporation of a written claim for indemnification, such Director or Executive Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Executive Officer will also be entitled to be paid the Expenses of prosecuting such claim. The failure of the Corporation (including its Board or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this <u>Section 6</u> will not be a defense to an action brought by a Director or Executive Officer for recovery of the unpaid amount of an indemnification claim and will not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Executive Officer is not entitled to indemnification will be on the Corporation.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>6</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In any suit brought by a Director or Executive Officer to enforce a right to indemnification hereunder, it will be a defense that such Director or Executive Officer has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Non-exclusivity</b>.&nbsp; The indemnification and advancement of expenses permitted by this <u>Section 6</u> are exclusive of any other rights to which any person may be entitled under any statute, the Corporation&#146;s Amended and Restated Certificate of Incorporation or these Bylaws, any agreement, vote of stockholders or Disinterested Directors or otherwise, both as to action in such person&#146;s official capacity and as to action in another capacity while holding an office, and will continue as to a person who has ceased to be a Director, Executive Officer, employee or agent of the Corporation and will inure to the benefit of the heirs, executors and administrators of such person.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Indemnification Agreements</b>.&nbsp; The Corporation may enter into agreements with any person described in this <u>Section 6</u> for the purpose of providing for the indemnification set forth in <u>Section 6.1(a)</u> and <u>Section 6.1(b)</u>.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Insurance</b>.&nbsp; The Corporation has the power to purchase and maintain insurance to protect itself and any person who is or was a Director, Executive Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust or other enterprise against any Expenses or Liabilities asserted against such person and incurred by such person by reason of their Corporate Status, whether or not the Corporation would have the power to indemnify such person against such Expense or Liability under the provisions of this <u>Section 6</u> or otherwise.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Certain Definitions</b>.&nbsp; For purposes of this <u>Section 6</u>, references to:</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>a)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>a person&#146;s &#147;<b>Corporate Status</b>&#148; describes the status of a person who is serving or has served (i) as a Director, (ii) as an Executive Officer, (iii) as an employee or agent of the Corporation, or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity that such person is or was serving at the request of the Corporation. For purposes of this <u>Section 6</u>, a Director, Executive Officer, employee or agent of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary will be deemed to be serving at the request of the Corporation;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>b)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>the &#147;<b>Corporation</b>&#148; means the current Corporation and includes any (i)&nbsp;resulting corporation in a merger of the Corporation and (ii) constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, executive officers, employees or agents, so that any person who is or was a director, executive officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, executive officer, employee or agent of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust or other enterprise, will stand in the same position under the provisions of this <u>Section 6</u> with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>7</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>c)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>a &#147;<b>Director</b>&#148; means any person who serves or has served the Corporation as a director on the Board;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>d)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>a &#147;<b>Disinterested Director</b>&#148; means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not a party to such Proceeding;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>e)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>an &#147;<b>Executive Officer</b>&#148; means executive officer, as such term is defined in Rule 405 promulgated under the Securities Act of 1933, as amended, of the Corporation;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>f)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>&#147;<b>Expenses</b>&#148; means all attorneys&#146; fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>g)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>a &#147;<b>Proceeding</b>&#148; means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>h)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>&#147;<b>Liabilities</b>&#148; means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement; and</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in; TEXT-AUTOSPACE:; TEXT-INDENT:1.5in'>i)<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>&#147;<b>Subsidiary</b>&#148; means any corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) 50% or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) 50% or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>6.10.&nbsp;&nbsp;&nbsp; <b>Severability</b>.&nbsp; If any word, clause, provision or provisions of this <u>Section 6</u> is held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this <u>Section 6 </u>(including each portion of any section of this <u>Section 6</u> containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) will not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this <u>Section 6</u> (including each such portion of any section of this <u>Section 6</u> containing any such provision held to be invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>7.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Any action required or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if prior to such action a written consent thereto is signed by all members of the Board or of the committee, as the case may be, and such written consent is filed with the minutes of proceedings of the Board or the committee.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>8.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Directors may, by resolution of the Board, be allowed a fixed sum and expenses of attendance for attendance at regular or special meetings of the Board; provided that nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity and receiving compensation therefor.&nbsp; Members of special or standing committees, and others who attend pursuant to direction, may, by vote of the Board, be allowed a like fixed sum and expenses of attendance for attending committee meetings.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>8</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>9.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Board, in its discretion, may appoint an Executive Committee consisting of three or more directors of the corporation, one of whom shall be the President of the corporation, who shall serve during the pleasure of the Board for the terms fixed by it.&nbsp; Two members of the Executive Committee shall constitute a quorum for the transaction of business.&nbsp; The Executive Committee shall have and may exercise the powers of the Board in the management of the business and affairs of the corporation and may authorize the seal of the corporation to be affixed to all papers.&nbsp; The Executive Committee shall meet at such intervals between regular meetings. The Board, as may from time to time be fixed by the Board, shall keep regular records of its meetings and report the same to the Board when required.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE IV</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Officers</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>1.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The officers of the Corporation shall be chosen by the Board and shall be a President, one or more Vice Presidents, a Secretary and a Treasurer.&nbsp; From time to time the Board may appoint a Chairperson of the Board, such Assistant Secretaries, Assistant Treasurers and such other officers, agents and employees as it may deem proper.&nbsp; Any number of offices, except the offices of President and Secretary, may be held by the same person.&nbsp; The Chairperson of the Board, if such office exists, and the President shall be chosen from among the directors.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>2.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The term of office of all officers shall be one year or until their respective successors are elected and qualify by the Board, but any officer may be removed from office, either with or without cause at any time by the affirmative vote of a majority of the members of the Board then in office.&nbsp; A vacancy in any office arising from any cause may be filled for the unexpired portion of the term by the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>3.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>Unless otherwise ordered by the Board, the President shall have full power and authority on behalf of the Corporation to attend and to act and to vote at any meetings of security holders of the corporations in which the Corporation may hold securities, and at such meeting shall possess and may exercise any and all rights and powers incident to the ownership of such securities, and which as the owner thereof the Corporation might have possessed and exercised, if present.&nbsp; The Board by resolution from time to time may confer like power upon any other person or persons.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE V</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Duties of Officers</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>1.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The President shall be chief executive officer of the Corporation and as such shall have general and active direction of the management and supervision of the business operations of the Corporation.&nbsp; The President shall have such other duties and powers as may be assigned from time to time by the Board and shall preside at all meetings of the stockholders and Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>2.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>During the absence or disability of the President, the Vice Presidents, in the order designated by the Board, shall exercise all the functions of the President.&nbsp; Each Vice President shall have such powers and discharge such duties as may be assigned to him or her from time to time by the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>9</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>3.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Treasurer shall have the custody of all the funds and securities of the Corporation.&nbsp; When necessary or proper, the Treasurer shall endorse on behalf of the Corporation, for collection, checks, notes and other obligations and shall deposit the same to the credit of the Corporation in such bank, or banks, or depositories as may be designated by the Board, or by any officer acting under authority conferred by the Board.&nbsp; The Treasurer shall enter regularly in books to be kept for the purpose a full and accurate account of all monies received and paid on account of the Corporation.&nbsp; Whenever required by the Board, the Treasurer shall render an account of all transactions as Treasurer and of the financial condition of the Corporation.&nbsp; The Treasurer shall at all reasonable times exhibit his or her books and accounts to any director of the Corporation upon application at the office of the Corporation during business hours and shall perform all things incident to the position of Treasurer, subject to the control of the Board.&nbsp; The Treasurer shall give bond for the faithful discharge of his or her duties if the Board so require.&nbsp; <a name=_Hlk115364680>The Treasurer </a>shall do and perform such other duties as may be assigned from time to time by the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>4.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Assistant Treasurers, in the order of their seniority, shall, in the absence of or disability of the Treasurer, perform the duties and exercise the powers of the Treasurer and shall perform such other duties as the Board shall prescribe.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>5.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Secretary shall attend all meetings of the stockholders and all meetings of the Board, and record all votes and the minutes of all proceedings in a book to be kept for that purpose; and shall perform like duties for other committees when so required.&nbsp; The Secretary shall give, or cause to be given, notice of all meetings of stockholders and the Board and of committees and shall perform such other duties as may be prescribed by the Board.&nbsp; The Secretary shall keep in safe custody the seal of the Corporation and affix the same to any instrument whose execution has been authorized.&nbsp; The Secretary shall be sworn to the faithful discharge of his or her duties.&nbsp; The Secretary shall do and perform such other duties as may be assigned from time to time by the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>6.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Assistant Secretaries, in the order of their seniority, shall in the absence of or disability of the Secretary, perform the duties and exercise the powers of the Secretary and shall perform such other duties as the Board shall prescribe.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>7.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>In the case of absence or inability to act of any officer of the Corporation and of any person herein authorized to act in his or her place, the Board may from time-to-time delegate the powers and duties of such officer to any other officer or any director or any other person whom it may select.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE VI</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Certificates of Stock</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>1.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock certifying the number of shares represented thereby and in such form not inconsistent with the Certificate of Incorporation as the Board may from time to time prescribe.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>Except as otherwise required by law, transfers of shares of stock of the Corporation shall be made only on the books of the Corporation by the registered holder thereof, or by his or her attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the Corporation, or with a transfer clerk or a transfer agent appointed as in <u>Section 4</u> of this Article provided, and on surrender of the certificate or certificates for such shares properly endorsed and the payment of all taxes thereon.&nbsp; The person in whose name. Shares of stock stand on the books of the Corporation shall be deemed the owner thereof for all purposes as regards the Corporation.&nbsp; The Board may, from time to time, make such additional rules and regulations as it may deem expedient, not inconsistent with these Bylaws, concerning the issue, transfer, and registration of certificates for shares of the capital stock of the Corporation.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>The certificates of stock shall be signed by the President or a Vice President and by the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer, and sealed with the seal of the Corporation.&nbsp; Such seal may be a facsimile, engraved or printed.&nbsp; Where any such certificate is signed by a transfer agent other than the Corporation or its employee, or by a registrar other than the Corporation or its employee, the signatures of the President, Vice President, Secretary, Assistant Secretary, Treasurer or Assistant Treasurer upon such certificate may be facsimiles, engraved or printed.&nbsp; In case any such officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such certificate is issued, it may be issued by the Corporation with the same effect as if such officer had not ceased to be such at the time of its issue.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>10</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>2.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 60 days prior to any other action.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt 1in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0in'>If no record date is fixed:</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>The record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>The record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjournment meeting.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>3.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>No certificate for shares of stock of the Corporation shall be issued in place of any certificate alleged to have been lost, destroyed or stolen, except on production of such evidence of such loss, destruction or theft and on delivery to the Corporation, if the Board shall so require, of a bond of indemnity in such amount (not exceeding twice the value of the shares represented by such certificate), upon such terms and secured by such surety as the Board may in its discretion require.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>4.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The Board may appoint one or more transfer clerks or one or more transfer agents and one or more registrars, and may require all certificates for shares of stock to bear the signature or signatures of any of them.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0pt; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'><font style=LETTER-SPACING:-0.05pt>5.<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font>The books, accounts and records of the Corporation, except as may otherwise be required by statute, may be kept outside of the State of Delaware, at such place or places as the Board may from time to time appoint.&nbsp; The Board shall determine whether and to what extent the books, accounts and records of the Corporation, or any of them, other than the stock ledger, shall be open to the inspection of stockholders, and no stockholder shall have any right to inspect any book, account or record of the Corporation except as conferred by statute or by resolution of the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE VII</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Corporate Seal</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>The corporate seal of the Corporation shall consist of two concentric circles, between which shall be the name of the Corporation, and its state of incorporation, and in the center shall be inscribed the words, &#147;Corporate Seal.&#148;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>11</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE VIII</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Amendments</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>The Bylaws of the Corporation shall be subject to alteration, amendment or repeal, and new Bylaws not inconsistent with any provision of the Certificates of Incorporation or statute, may be made, either by the affirmative vote of the holders of a majority in interest of the stockholders of the Corporation present in person or by proxy at any annual or special meeting of the stockholders and entitled to vote thereat, a quorum being present, provided that notice of such proposed action shall have been given in the call for the meeting, or by the affirmative vote of a majority of the whole Board, given at any regular or special meeting of the Board.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE IX</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Fiscal Year</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:11.6pt 0in 0pt 0.5in; ; TEXT-AUTOSPACE:; TEXT-INDENT:0.5in'>The fiscal year of the Corporation shall end on the last day of May in each year.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>ARTICLE X</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><b>Forum</b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Forum for Adjudication of Disputes</b>. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state or federal court located within the State of Delaware) shall be the sole and exclusive forum for: (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (c) any action or proceeding asserting a claim against the Corporation or any director, officer or other employee of the Corporation arising pursuant to, or seeking to enforce any right or remedy under, any provision of the DGCL, the Corporation&#146;s Certificate of Incorporation or these Bylaws (in each case, as they may be amended and restated from time to time), (d) any action or proceeding asserting a claim against the Corporation or any director, officer or other employee of the Corporation governed by the internal affairs doctrine, or (e) any action or proceeding to interpret, apply, enforce, or determine the validity of any provision or provisions of the Corporation&#146;s Certificate of Incorporation or these Bylaws (in each case, as they may be amended and restated from time to time), in all cases to the full extent permitted by applicable law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. Any person or entity purchasing, otherwise acquiring, or continuing to own any interest in shares of capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions of this <u>Section 1</u> of Article X.</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:; TEXT-INDENT:1in'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Federal Forum Selection</b>. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing, otherwise acquiring, or continuing to own any interest in shares of capital stock of the Corporation shall be deemed to have notice of and to have consented to the provisions of this <u>Section 2</u> of Article X. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>12</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center><font style="FONT-SIZE:12pt; "> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in; TEXT-AUTOSPACE:' align=center><b>CERTIFICATION OF BYLAWS </b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in; TEXT-AUTOSPACE:' align=center><b>OF </b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0in; TEXT-AUTOSPACE:' align=center><b>BIOMERICA, INC. </b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:' align=center>a Delaware Corporation </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:'>I, Allen Barbieri, certify that I am Secretary of Biomerica, Inc., a Delaware corporation (the &#147;<b>Corporation</b>&#148;), that I am duly authorized to make and deliver this certification and that the attached Bylaws are a true and complete copy of the Bylaws of the Corporation in effect as of the date of this certificate. </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:12pt 0in 0in; TEXT-AUTOSPACE:'>Dated: _____________, 2022</p> <div align=right> <table width=40% bordercolor=transparent style="WIDTH:40%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=PAGE-BREAK-INSIDE:none> <td style="PADDING-BOTTOM:0.25pt; BORDER-BOTTOM:windowtext 1pt solid;PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /></tr> <tr style=PAGE-BREAK-INSIDE:none> <td style="PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in; TEXT-AUTOSPACE:'><font style=COLOR:black>Name:&nbsp; Allen Barbieri</font></p></td></tr></table></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0in; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:11.6pt 0in 0in; ; TEXT-AUTOSPACE:' align=center>13</p></div></body>
<!-- EDGAR Validation Code: 058B5356 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<head> <title>Exhibit 31.1</title> </head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><b>Exhibit 31.1</b></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">I, Zackary S. Irani, certify that:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="justify">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</p> <p style="MARGIN:0px" align="justify"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)

 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with accounting principles generally
accepted in the United States of America;</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px; TEXT-INDENT:48px">b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:210.75pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" width="281" cellspacing="0" cellpadding="0" bordercolor="transparent"> <tr style="HEIGHT:22pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Date: October 13, 2022</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="BORDER-TOP:0px; HEIGHT:14.75pt; BORDER-RIGHT:0px; WIDTH:210.75pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">/s/ Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:14.75pt"> <td style="HEIGHT:14.75pt; WIDTH:210.75pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:5.4pt" width="281" nowrap="nowrap"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;; COLOR:black">(Principal Executive Officer)</font></p></td></tr></table> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px">&nbsp;</p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<head> <title>Exhibit 31.2</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="left"><font style="FONT-SIZE:9pt"><b>EXHIBIT 31.2</b></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt"><b>CERTIFICATION PURSUANT TO</b></font></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">18 U.S.C. SECTION 1350,</font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><font style="FONT-SIZE:9pt">AS ADOPTED PURSUANT TO</font></p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b><font style="FONT-SIZE:9pt">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></b><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">I, Steve Sloan, certify that:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><font style="FONT-SIZE:9pt">1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">2.
 Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">3.
 Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects, the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">4.
 The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this
report is being prepared;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)

 designed such internal control over financial reporting, or caused such
 internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with accounting principles generally
accepted in the United States of America;</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)
 evaluated the effectiveness of the registrant's disclosure controls and
 procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)
 disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth quarter in the case
of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over
financial reporting; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">5.
 The registrant's other certifying officer and I have disclosed, based
on our most recent evaluation of our internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or other persons performing the
equivalent functions):</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)
 all significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record, process, summarize and report financial information; and</font></p> <p style="MARGIN:0px"><font style="FONT-SIZE:9pt"><br></font></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify; MARGIN:0px"><font style="FONT-SIZE:9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)
 any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control over financial reporting.</font></p> <p style="MARGIN:0px">&nbsp;</p> <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="HEIGHT:22pt; WIDTH:179pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" width="239"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Date: October 13, 2022</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">/s/ Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0pt; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;serif&quot;">(Principal Financial Officer)</font></p></td></tr></table> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<head> <title>Exhibit 32.1</title></head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.1</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Quarterly Report of Biomerica, Inc. (the "Company")
 on Form 10-Q for the period ending August 31, 2022, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Zackary Irani, Chief Executive Officer of the Company, certify, to the
best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes
Oxley Act of 2002,</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <table style="WIDTH:167pt; BORDER-COLLAPSE:collapse" width="223" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:167pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="223"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">/s/ Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Zackary S. Irani</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Executive Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: October 13, 2022</font></p></td></tr></table> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p> <p style="MARGIN:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<head> <title>Exhibit 32.2</title> </head> <body> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px"><b>EXHIBIT 32.2</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>CERTIFICATION PURSUANT TO</b></p><b> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">18 U.S.C. SECTION 1350,</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center">AS ADOPTED PURSUANT TO</p> </b><p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px" align="center"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; TEXT-ALIGN:justify;MARGIN:0px">In
 connection with the Quarterly Report of Biomerica, Inc. (the "Company")
 on Form 10-Q for the period ending August 31, 2022, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
 Steve Sloan, Chief Financial Officer of the Company, certify, to the
best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18
U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes
Oxley Act of 2002,</p> <p style="MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">i. &nbsp;&nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:9pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Times New Roman'; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">ii. &nbsp;</p> <p style="FONT-SIZE:9pt; FONT-FAMILY:'Times New Roman'; MARGIN:0px; TEXT-INDENT:-2px">The
 information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="MARGIN:0px"><br></p>  <table style="WIDTH:179pt; BORDER-COLLAPSE:collapse" width="239" cellspacing="0" cellpadding="0" bordercolor="transparent"><tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:179pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" width="239" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">/s/ Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Steve Sloan</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Chief Financial Officer</font></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign="bottom"> <p style="FONT-SIZE:11pt; FONT-FAMILY:&quot;Times New Roman&quot;,&quot;sans-serif&quot;; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal"><font style="FONT-SIZE:9pt; FONT-FAMILY:&quot;Times New Roman&quot;">Date: October 13, 2022</font></p></td></tr></table><p style="MARGIN:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br><br></p></body>
<!-- EDGAR Validation Code: 237E9F32 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bmra-20220831.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:32 UTC 2022 -->
<xs:schema xmlns:bmra="http://www.biomerica.com/20220831" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.biomerica.com/20220831" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220831_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220831_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220831_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20220831_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet" id="bmra_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bmra_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement" id="bmra_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatementAlt0" id="bmra_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3" id="bmra_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow" id="bmra_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/BASISOFPRESENTATION" id="bmra_r_BASISOFPRESENTATION">
        <link:definition>006 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES" id="bmra_r_SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY" id="bmra_r_SHAREHOLDERSEQUITY">
        <link:definition>008 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION" id="bmra_r_GEOGRAPHICINFORMATION">
        <link:definition>009 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/LEASES" id="bmra_r_LEASES">
        <link:definition>010 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES" id="bmra_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS" id="bmra_r_SUBSEQUENTEVENTS">
        <link:definition>012 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy" id="bmra_r_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" id="bmra_r_SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables" id="bmra_r_GEOGRAPHICINFORMATIONTables">
        <link:definition>015 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/LEASESTables" id="bmra_r_LEASESTables">
        <link:definition>016 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" id="bmra_r_SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/InventoriesTable" id="bmra_r_InventoriesTable">
        <link:definition>018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/OptionsActivityTable" id="bmra_r_OptionsActivityTable">
        <link:definition>019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable" id="bmra_r_RevenuefromcontractswithcustomersTable">
        <link:definition>020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7bdsVRMyUJFAfmVi9n7DfsW/] CSR-->
      <link:roleType roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails" id="bmra_r_SHAREHOLDERSEQUITYDetails">
        <link:definition>021 - Disclosure - SHAREHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails" id="bmra_r_GEOGRAPHICINFORMATIONDetails">
        <link:definition>022 - Disclosure - GEOGRAPHIC INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable" id="bmra_r_GeographicinformationregardingnetsalesTable">
        <link:definition>023 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/LEASESDetails" id="bmra_r_LEASESDetails">
        <link:definition>024 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable" id="bmra_r_SupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>025 - Disclosure - LEASES (Details) - Supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable" id="bmra_r_ThematurityofleaseliabilitiesTable">
        <link:definition>026 - Disclosure - LEASES (Details) - The maturity of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="InventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_InventoriesAbstract"/>
  <xs:element name="OptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OptionsActivityAbstract"/>
  <xs:element name="RevenueFromContractsWithCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenueFromContractsWithCustomersAbstract"/>
  <xs:element name="GeographicInformationDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureAbstract"/>
  <xs:element name="GeographicInformationRegardingNetSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationRegardingNetSalesAbstract"/>
  <xs:element name="SupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="TheMaturityOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract10"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract24"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract25"/>
  <xs:element name="ForTheThreeMonthsEndedAugust312022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ForTheThreeMonthsEndedAugust312022Abstract"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract28"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_UnlabeledAbstract36"/>
  <xs:element name="TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2"/>
  <xs:element name="RevenuesFromSalesToUnaffiliatedCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
  <xs:element name="AccumulatedAmortizationRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_AccumulatedAmortizationRightOfUseAssets"/>
  <xs:element name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bmra_IncreaseDecreaseInLeaseLiability"/>
  <xs:element name="WriteOffOfIntangibleAssetsCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfIntangibleAssetsCost"/>
  <xs:element name="WriteOffOfIntangibleAssetsAccumulatedAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
  <xs:element name="GeographicInformationDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GeographicInformationDisclosureTextBlock"/>
  <xs:element name="MarketsAndMethodsOfDistributionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
  <xs:element name="LiquidityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LiquidityPolicyTextBlock"/>
  <xs:element name="PrepaidsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PrepaidsPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_WorkingCapital"/>
  <xs:element name="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_SHAREHOLDERSEQUITYDetailsTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_GEOGRAPHICINFORMATIONDetailsTable"/>
  <xs:element name="GEOGRAPHICINFORMATIONDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_GEOGRAPHICINFORMATIONDetailsLineItems"/>
  <xs:element name="PropertySubjectToOrAvailableForOperatingLease_Domain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
  <xs:element name="LEASESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bmra_LEASESDetailsTable"/>
  <xs:element name="LEASESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_LEASESDetailsLineItems"/>
  <xs:element name="ATMAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ATMAgreementMember"/>
  <xs:element name="BuildingInIrvineCaliforniaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_BuildingInIrvineCaliforniaMember"/>
  <xs:element name="ClinicalLabMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ClinicalLabMember"/>
  <xs:element name="ContractManufacturingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ContractManufacturingMember"/>
  <xs:element name="ForeignMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_ForeignMember"/>
  <xs:element name="OneVendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OneVendorMember"/>
  <xs:element name="OverthecounterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_OverthecounterMember"/>
  <xs:element name="PhysiciansOfficeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PhysiciansOfficeMember"/>
  <xs:element name="PolishDistributorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PolishDistributorMember"/>
  <xs:element name="PurchasedTechnologyRightsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_PurchasedTechnologyRightsMember"/>
  <xs:element name="TwoVendorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_TwoVendorsMember"/>
  <xs:element name="CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_CashPaidDuringThePeriodForAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bmra_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bmra-20220831_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:32 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Investments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7bfvWuCVyMklC/IoblikV1EyDfbwfJIVFj0=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220831.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bmra-20220831_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:32 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_BASISOFPRESENTATION" roleURI="http://www.biomerica.com/role/BASISOFPRESENTATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASES" roleURI="http://www.biomerica.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASESTables" roleURI="http://www.biomerica.com/role/LEASESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_OptionsActivityTable" roleURI="http://www.biomerica.com/role/OptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASESDetails" roleURI="http://www.biomerica.com/role/LEASESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_AccumulatedAmortizationRightOfUseAssets" xlink:href="bmra-20220831.xsd#bmra_AccumulatedAmortizationRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="bmra_AccumulatedAmortizationRightOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220831.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bmra_IncreaseDecreaseInLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220831.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfIntangibleAssetsCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/BASISOFPRESENTATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASES">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_LiquidityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_LiquidityPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220831.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20220831.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OptionsActivityTable">
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7bf3YAnSkky15kPBTnkr4iY3TO5cRWWt1kk=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20220831.xsd#bmra_ClinicalLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ClinicalLabMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20220831.xsd#bmra_OverthecounterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_OverthecounterMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20220831.xsd#bmra_PhysiciansOfficeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_PhysiciansOfficeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20220831.xsd#bmra_ContractManufacturingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="bmra_ContractManufacturingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SouthAmericaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_MiddleEastMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20220831.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220831.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20220831.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PolishDistributorMember" xlink:href="bmra-20220831.xsd#bmra_PolishDistributorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="bmra_PolishDistributorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20220831.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bmra_PurchasedTechnologyRightsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsTotalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ForeignMember" xlink:href="bmra-20220831.xsd#bmra_ForeignMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="bmra_ForeignMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20220831.xsd#bmra_OneVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_OneVendorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20220831.xsd#bmra_TwoVendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bmra_TwoVendorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20220831.xsd#bmra_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="bmra_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_WorkingCapital" xlink:href="bmra-20220831.xsd#bmra_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_WorkingCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220831.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Revenues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Investments" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromCustomers" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASESDetails">
    <loc xlink:type="locator" xlink:label="bmra_LEASESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bmra_LEASESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="bmra_LEASESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_LEASESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20220831.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" xlink:href="bmra-20220831.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bmra_LEASESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MX" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220831.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_BuildingInIrvineCaliforniaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="us-gaap_SecurityDeposit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bmra-20220831_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:32 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, less allowance for doubtful accounts of $383,106 and $153,231 as of August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net of inventory reserves of $981,814 and $845,549 as of August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Net inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl1" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $1,325,561 and $1,305,360 as of August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net of accumulated amortization of $791,859 and $724,802 as of August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_AccumulatedAmortizationRightOfUseAssets" xlink:href="bmra-20220831.xsd#bmra_AccumulatedAmortizationRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_AccumulatedAmortizationRightOfUseAssets_lbl" xml:lang="en-US">Accumulated amortization, Right of Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AccumulatedAmortizationRightOfUseAssets" xlink:to="bmra_AccumulatedAmortizationRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $21,271 and $18,994 as of August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization, Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 5 and 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.08 par value, 25,000,000 shares authorized, 13,406,901 and 12,867,924 issued and outstanding at August 31, 2022 and May 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Dividend and interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Option Exercised, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Net proceeds from ATM (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for allowance on accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220831.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Reduction in lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditures related to intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfIntangibleAssetsCost_lbl" xml:lang="en-US">Write off of intangible assets, cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsCost" xlink:to="bmra_WriteOffOfIntangibleAssetsCost_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Write off of intangible assets, accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Total gross inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options Outstanding, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option Outstanding, Exercise Price Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Option Outstanding, Exercise Price Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Option Granted, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option Granted, Exercise Price Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option Exercised, Exercise Price Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Option Cancelled or expired, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option Cancelled or expired, Exercise Price Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue From Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Less than 1 year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">1 to 2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2 to 3 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">3 to 4 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">4 to 5 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract" xlink:to="bmra_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract0" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract0" xlink:to="bmra_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract1" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract1" xlink:to="bmra_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract2" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract2" xlink:to="bmra_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract3" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract3" xlink:to="bmra_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract4" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract4" xlink:to="bmra_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract5" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract5" xlink:to="bmra_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract6" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract6" xlink:to="bmra_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract7" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract7" xlink:to="bmra_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract8" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract8" xlink:to="bmra_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract9" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract9" xlink:to="bmra_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract10" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract10" xlink:to="bmra_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:href="bmra-20220831.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract11" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract11" xlink:to="bmra_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract12" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract12" xlink:to="bmra_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract13" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract13" xlink:to="bmra_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract14" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract14" xlink:to="bmra_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract15" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract15" xlink:to="bmra_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract16" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract16" xlink:to="bmra_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract17" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract17" xlink:to="bmra_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract18" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract18" xlink:to="bmra_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract19" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract19" xlink:to="bmra_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of common and common equivalent shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract20" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract20" xlink:to="bmra_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract21" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract21" xlink:to="bmra_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract22" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract22" xlink:to="bmra_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract23" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract23" xlink:to="bmra_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract24" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract24" xlink:to="bmra_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0" xlink:href="bmra-20220831.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract25" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract25" xlink:to="bmra_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ForTheThreeMonthsEndedAugust312022Abstract" xlink:href="bmra-20220831.xsd#bmra_ForTheThreeMonthsEndedAugust312022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ForTheThreeMonthsEndedAugust312022Abstract_lbl" xml:lang="en-US">For the Three Months Ended August 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ForTheThreeMonthsEndedAugust312022Abstract" xlink:to="bmra_ForTheThreeMonthsEndedAugust312022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract26" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract26" xlink:to="bmra_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract27" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract27" xlink:to="bmra_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract28" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract28" xlink:to="bmra_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1" xlink:href="bmra-20220831.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract29" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract29" xlink:to="bmra_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract30" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract30" xlink:to="bmra_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract31" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract31" xlink:to="bmra_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract32" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract32" xlink:to="bmra_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract33" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract33" xlink:to="bmra_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract34" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract34" xlink:to="bmra_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220831.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract35" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract35" xlink:to="bmra_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_UnlabeledAbstract36" xlink:href="bmra-20220831.xsd#bmra_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract36" xlink:to="bmra_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2" xlink:href="bmra-20220831.xsd#bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2_lbl" xml:lang="en-US">The accompanying notes are an integral part of these statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl" xml:lang="en-US">Geographic Information Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20220831.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl" xml:lang="en-US">Revenues from sales to unaffiliated customers:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220831.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ClinicalLabMember" xlink:href="bmra-20220831.xsd#bmra_ClinicalLabMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ClinicalLabMember_lbl" xml:lang="en-US">Clinical Lab [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OverthecounterMember" xlink:href="bmra-20220831.xsd#bmra_OverthecounterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OverthecounterMember_lbl" xml:lang="en-US">Over-the-counter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PhysiciansOfficeMember" xlink:href="bmra-20220831.xsd#bmra_PhysiciansOfficeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PhysiciansOfficeMember_lbl" xml:lang="en-US">Physicians Office [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ContractManufacturingMember" xlink:href="bmra-20220831.xsd#bmra_ContractManufacturingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ContractManufacturingMember_lbl" xml:lang="en-US">Contract Manufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US">North America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SouthAmericaMember_lbl" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MiddleEastMember_lbl" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xml:lang="en-US">Equity Interest Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_WorkingCapital" xlink:href="bmra-20220831.xsd#bmra_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_WorkingCapital_lbl" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220831.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl" xml:lang="en-US">Shelf Registration Statement Maximum Authorized Common Stock Issuance Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7bfIQArfpu/oa2vvJfBb1cmg5PObFwT64MY=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl" xml:lang="en-US">Markets And Methods of Distribution Policy [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LiquidityPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity Policy [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaids Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ATMAgreementMember" xlink:href="bmra-20220831.xsd#bmra_ATMAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_ForeignMember" xlink:href="bmra-20220831.xsd#bmra_ForeignMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_ForeignMember_lbl" xml:lang="en-US">Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ForeignMember" xlink:to="bmra_ForeignMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US">Credit Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_OneVendorMember" xlink:href="bmra-20220831.xsd#bmra_OneVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_TwoVendorsMember" xlink:href="bmra-20220831.xsd#bmra_TwoVendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_TwoVendorsMember_lbl" xml:lang="en-US">Two Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DistributionRightsMember_lbl" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PurchasedTechnologyRightsMember" xlink:href="bmra-20220831.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl" xml:lang="en-US">Purchased Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PolishDistributorMember" xlink:href="bmra-20220831.xsd#bmra_PolishDistributorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_PolishDistributorMember_lbl" xml:lang="en-US">Polish Distributor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PolishDistributorMember" xlink:to="bmra_PolishDistributorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_MX_lbl" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220831.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl" xml:lang="en-US">Building In Irvine California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsTable" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="bmra_SHAREHOLDERSEQUITYDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsTable_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsTable" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GEOGRAPHICINFORMATIONDetailsLineItems_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="bmra_GEOGRAPHICINFORMATIONDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20220831.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl" xml:lang="en-US">PropertySubjectToOrAvailableForOperatingLease_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:to="bmra_PropertySubjectToOrAvailableForOperatingLease_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LEASESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LEASESDetailsTable_lbl" xml:lang="en-US">LEASES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LEASESDetailsTable" xlink:to="bmra_LEASESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bmra_LEASESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LEASESDetailsLineItems_lbl" xml:lang="en-US">LEASES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LEASESDetailsLineItems" xlink:to="bmra_LEASESDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_AccumulatedAmortizationRightOfUseAssets_lbl0" xml:lang="en-US">Amount of accumulated amortization of right-of-use asset from operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_AccumulatedAmortizationRightOfUseAssets" xlink:to="bmra_AccumulatedAmortizationRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for reporting segments according to the geographic areas.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_IncreaseDecreaseInLeaseLiability_lbl0" xml:lang="en-US">The increase (decrease) during the reporting period in LeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_IncreaseDecreaseInLeaseLiability" xlink:to="bmra_IncreaseDecreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_LiquidityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity position during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Markets And Methods Of Distribution during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for prepaids.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of supplemental cash flow information related to lease for the periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0" xml:lang="en-US">Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WorkingCapital_lbl0" xml:lang="en-US">Amount of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Write off of intangible assets, accumulated amortization in non cash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:to="bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_WriteOffOfIntangibleAssetsCost_lbl0" xml:lang="en-US">Write off of intangible assets, cost in noncash investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WriteOffOfIntangibleAssetsCost" xlink:to="bmra_WriteOffOfIntangibleAssetsCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl0" xml:lang="en-US">No definition available</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl1" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_WorkingCapital" xlink:to="bmra_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0" xml:lang="en-US">The Accompanying Notes Are An Integral Part Of These Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MiddleEastMember_lbl0" xml:lang="en-US">Middle East [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MiddleEastMember" xlink:to="us-gaap_MiddleEastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PhysiciansOfficeMember_lbl0" xml:lang="en-US">Physicians Office Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PhysiciansOfficeMember" xlink:to="bmra_PhysiciansOfficeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl0" xml:lang="en-US">Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PurchasedTechnologyRightsMember_lbl0" xml:lang="en-US">Purchased Technology Rights Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PurchasedTechnologyRightsMember" xlink:to="bmra_PurchasedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1" xml:lang="en-US">Shelf Registration Statement Maximum Authorized Common Stock Issuance Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl0" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_LiquidityPolicyTextBlock" xlink:to="bmra_LiquidityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OverthecounterMember_lbl0" xml:lang="en-US">Overthecounter Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OverthecounterMember" xlink:to="bmra_OverthecounterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PrepaidsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Prepaids Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PrepaidsPolicyPolicyTextBlock" xlink:to="bmra_PrepaidsPolicyPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220831.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl0" xml:lang="en-US">Asia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract18" xlink:to="bmra_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract19" xlink:to="bmra_UnlabeledAbstract19_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20220831.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">The Maturity Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="bmra_TheMaturityOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract16" xlink:to="bmra_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract17" xlink:to="bmra_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20220831.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US">Revenue From Contracts With Customers Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenueFromContractsWithCustomersAbstract" xlink:to="bmra_RevenueFromContractsWithCustomersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_PolishDistributorMember_lbl0" xml:lang="en-US">Polish Distributor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_PolishDistributorMember" xlink:to="bmra_PolishDistributorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract21" xlink:to="bmra_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract22" xlink:to="bmra_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract20" xlink:to="bmra_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract25" xlink:to="bmra_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract26" xlink:to="bmra_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract23" xlink:to="bmra_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract24" xlink:to="bmra_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract29" xlink:to="bmra_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract27" xlink:to="bmra_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract28" xlink:to="bmra_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract32" xlink:to="bmra_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract33" xlink:to="bmra_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract30" xlink:to="bmra_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract31" xlink:to="bmra_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract36" xlink:to="bmra_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract34" xlink:to="bmra_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract35" xlink:to="bmra_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ContractManufacturingMember_lbl0" xml:lang="en-US">Contract Manufacturing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ContractManufacturingMember" xlink:to="bmra_ContractManufacturingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ForeignMember_lbl0" xml:lang="en-US">Foreign Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ForeignMember" xlink:to="bmra_ForeignMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ForTheThreeMonthsEndedAugust312022Abstract_lbl0" xml:lang="en-US">For The Three Months Ended August312022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ForTheThreeMonthsEndedAugust312022Abstract" xlink:to="bmra_ForTheThreeMonthsEndedAugust312022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0" xml:lang="en-US">Property Available for Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract10" xlink:to="bmra_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract11" xlink:to="bmra_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract14" xlink:to="bmra_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract15" xlink:to="bmra_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract12" xlink:to="bmra_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract13" xlink:to="bmra_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_CashPaidDuringThePeriodForAbstract_lbl1" xml:lang="en-US">Cash Paid During The Period For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_CashPaidDuringThePeriodForAbstract" xlink:to="bmra_CashPaidDuringThePeriodForAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract2" xlink:to="bmra_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract1" xlink:to="bmra_UnlabeledAbstract1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract4" xlink:to="bmra_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract3" xlink:to="bmra_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract0" xlink:to="bmra_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract9" xlink:to="bmra_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract6" xlink:to="bmra_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract5" xlink:to="bmra_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract8" xlink:to="bmra_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract7" xlink:to="bmra_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl0" xml:lang="en-US">Revenues From Sales To Unaffiliated Customers Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <loc xlink:type="locator" xlink:label="bmra_InventoriesAbstract" xlink:href="bmra-20220831.xsd#bmra_InventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_InventoriesAbstract_lbl" xml:lang="en-US">Inventories Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_InventoriesAbstract" xlink:to="bmra_InventoriesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DistributionRightsMember_lbl0" xml:lang="en-US">Distribution Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureAbstract_lbl" xml:lang="en-US">Geographic Information Disclosure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureAbstract" xlink:to="bmra_GeographicInformationDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ATMAgreementMember_lbl0" xml:lang="en-US">ATMAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ATMAgreementMember" xlink:to="bmra_ATMAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Cash Flow Supplemental Disclosures Related To Lease Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:to="bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl0" xml:lang="en-US">Proceeds from Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_UnlabeledAbstract" xlink:to="bmra_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TwoVendorsMember_lbl0" xml:lang="en-US">Two Vendors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TwoVendorsMember" xlink:to="bmra_TwoVendorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MX_lbl0" xml:lang="en-US">MEXICO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MX" xlink:to="country_MX_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SouthAmericaMember_lbl0" xml:lang="en-US">South America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SouthAmericaMember" xlink:to="srt_SouthAmericaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationRegardingNetSalesAbstract_lbl" xml:lang="en-US">Geographic Information Regarding Net Sales Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationRegardingNetSalesAbstract" xlink:to="bmra_GeographicInformationRegardingNetSalesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_GeographicInformationDisclosureTextBlock_lbl1" xml:lang="en-US">Geographic Information Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_GeographicInformationDisclosureTextBlock" xlink:to="bmra_GeographicInformationDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OneVendorMember_lbl0" xml:lang="en-US">One Vendor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OneVendorMember" xlink:to="bmra_OneVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl0" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_BuildingInIrvineCaliforniaMember_lbl0" xml:lang="en-US">Building In Irvine California Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_BuildingInIrvineCaliforniaMember" xlink:to="bmra_BuildingInIrvineCaliforniaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl0" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl1" xml:lang="en-US">Markets And Methods Of Distribution Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:to="bmra_MarketsAndMethodsOfDistributionPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl0" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1_lbl0" xml:lang="en-US">The Accompanying Notes Are An Integral Part Of These Statements Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0_lbl0" xml:lang="en-US">The Accompanying Notes Are An Integral Part Of These Statements Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2_lbl0" xml:lang="en-US">The Accompanying Notes Are An Integral Part Of These Statements Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2" xlink:to="bmra_TheAccompanyingNotesAreAnIntegralPartOfTheseStatementsAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl0" xml:lang="en-US">Credit Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_ClinicalLabMember_lbl0" xml:lang="en-US">Clinical Lab Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_ClinicalLabMember" xlink:to="bmra_ClinicalLabMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl0" xml:lang="en-US">North America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bmra_OptionsActivityAbstract" xlink:href="bmra-20220831.xsd#bmra_OptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bmra_OptionsActivityAbstract_lbl" xml:lang="en-US">Options Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bmra_OptionsActivityAbstract" xlink:to="bmra_OptionsActivityAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bmra-20220831_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 13 13:55:32 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedBalanceSheet" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedIncomeStatement" roleURI="http://www.biomerica.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ShareholdersEquityType2or3" roleURI="http://www.biomerica.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ConsolidatedCashFlow" roleURI="http://www.biomerica.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_BASISOFPRESENTATION" roleURI="http://www.biomerica.com/role/BASISOFPRESENTATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SHAREHOLDERSEQUITY" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATION" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASES" roleURI="http://www.biomerica.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SUBSEQUENTEVENTS" roleURI="http://www.biomerica.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_AccountingPoliciesByPolicy" roleURI="http://www.biomerica.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATIONTables" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASESTables" roleURI="http://www.biomerica.com/role/LEASESTables"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_InventoriesTable" roleURI="http://www.biomerica.com/role/InventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_OptionsActivityTable" roleURI="http://www.biomerica.com/role/OptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_RevenuefromcontractswithcustomersTable" roleURI="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GeographicinformationregardingnetsalesTable" roleURI="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_ThematurityofleaseliabilitiesTable" roleURI="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_SHAREHOLDERSEQUITYDetails" roleURI="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_GEOGRAPHICINFORMATIONDetails" roleURI="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#bmra_r_LEASESDetails" roleURI="http://www.biomerica.com/role/LEASESDetails"/>
  <roleRef xlink:type="simple" xlink:href="bmra-20220831.xsd#DocumentAndEntityInformation" roleURI="http://www.biomerica.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccumulatedAmortizationRightOfUseAssets" xlink:href="bmra-20220831.xsd#bmra_AccumulatedAmortizationRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="AccumulatedAmortizationRightOfUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLeaseLiability" xlink:href="bmra-20220831.xsd#bmra_IncreaseDecreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:href="bmra-20220831.xsd#bmra_CashPaidDuringThePeriodForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfIntangibleAssetsCost" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfIntangibleAssetsCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfIntangibleAssetsAccumulatedAmortization" xlink:href="bmra-20220831.xsd#bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WriteOffOfIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/BASISOFPRESENTATION">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATION">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureTextBlock" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="GeographicInformationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASES">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketsAndMethodsOfDistributionPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_MarketsAndMethodsOfDistributionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="MarketsAndMethodsOfDistributionPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_LiquidityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidsPolicyPolicyTextBlock" xlink:href="bmra-20220831.xsd#bmra_PrepaidsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidsPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASESTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" xlink:href="bmra-20220831.xsd#bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/InventoriesTable">
    <loc xlink:type="locator" xlink:label="InventoriesAbstract" xlink:href="bmra-20220831.xsd#bmra_InventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/OptionsActivityTable">
    <loc xlink:type="locator" xlink:label="OptionsActivityAbstract" xlink:href="bmra-20220831.xsd#bmra_OptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsActivityAbstract" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt+1Vq3zhhUlfDeP/RQUzUZihDO8dLtQrMZMNe4t6pAivP0axfdFZpsLdRcC6V+fMasrXQSwq+SHkeHdGhqTuYhs3v6XY+sDIxZ3ySQkn+5/v2Yj66s8tZnKkgAUEy29MHOFMUByTmYyBRdDxE7PqcXE30Ku6eSl7bcJc0bmHIUnJKqr7UBremdeJzsKlHUgv7Q=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable">
    <loc xlink:type="locator" xlink:label="RevenueFromContractsWithCustomersAbstract" xlink:href="bmra-20220831.xsd#bmra_RevenueFromContractsWithCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractsWithCustomersAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalLabMember" xlink:href="bmra-20220831.xsd#bmra_ClinicalLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ClinicalLabMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverthecounterMember" xlink:href="bmra-20220831.xsd#bmra_OverthecounterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OverthecounterMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PhysiciansOfficeMember" xlink:href="bmra-20220831.xsd#bmra_PhysiciansOfficeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="PhysiciansOfficeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractManufacturingMember" xlink:href="bmra-20220831.xsd#bmra_ContractManufacturingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ContractManufacturingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable">
    <loc xlink:type="locator" xlink:label="GeographicInformationRegardingNetSalesAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationRegardingNetSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationRegardingNetSalesAbstract" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_AsiaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_AsiaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_EuropeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_NorthAmericaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_SouthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SouthAmericaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SouthAmericaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MiddleEastMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MiddleEastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="us-gaap_MiddleEastMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable" xlink:to="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:href="bmra-20220831.xsd#bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems" xlink:to="RevenuesFromSalesToUnaffiliatedCustomersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesFromSalesToUnaffiliatedCustomersAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="bmra-20220831.xsd#bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="TheMaturityOfLeaseLiabilitiesAbstract" xlink:href="bmra-20220831.xsd#bmra_TheMaturityOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheMaturityOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="bmra-20220831.xsd#bmra_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OneVendorMember" xlink:href="bmra-20220831.xsd#bmra_OneVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="OneVendorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoVendorsMember" xlink:href="bmra-20220831.xsd#bmra_TwoVendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="TwoVendorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PolishDistributorMember" xlink:href="bmra-20220831.xsd#bmra_PolishDistributorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="PolishDistributorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ForeignMember" xlink:href="bmra-20220831.xsd#bmra_ForeignMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="ForeignMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedTechnologyRightsMember" xlink:href="bmra-20220831.xsd#bmra_PurchasedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="PurchasedTechnologyRightsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_CostOfGoodsTotalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CreditConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="bmra-20220831.xsd#bmra_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="WorkingCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:href="bmra-20220831.xsd#bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashUninsuredAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Revenues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_Investments" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCustomers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromCustomers" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsTable" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="SHAREHOLDERSEQUITYDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails">
    <loc xlink:type="locator" xlink:label="GeographicInformationDisclosureAbstract" xlink:href="bmra-20220831.xsd#bmra_GeographicInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsTable" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GEOGRAPHICINFORMATIONDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_GEOGRAPHICINFORMATIONDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicInformationDisclosureAbstract" xlink:to="GEOGRAPHICINFORMATIONDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsTable" xlink:to="GEOGRAPHICINFORMATIONDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_InventoryGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GEOGRAPHICINFORMATIONDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/LEASESDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LEASESDetailsTable" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LEASESDetailsLineItems" xlink:href="bmra-20220831.xsd#bmra_LEASESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LEASESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertySubjectToOrAvailableForOperatingLease_Domain" xlink:href="bmra-20220831.xsd#bmra_PropertySubjectToOrAvailableForOperatingLease_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="PropertySubjectToOrAvailableForOperatingLease_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BuildingInIrvineCaliforniaMember" xlink:href="bmra-20220831.xsd#bmra_BuildingInIrvineCaliforniaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="BuildingInIrvineCaliforniaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyAvailableForOperatingLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyAvailableForOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertyAvailableForOperatingLeaseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_MX" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsTable" xlink:to="LEASESDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsLineItems" xlink:to="us-gaap_SecurityDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASESDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biomerica.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bmra-20220831.xsd#bmra_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776526080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Oct. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,427,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-2645573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17571 Von Karman Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">645-2111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, PAR VALUE $0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776752016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,075,037<span></span>
</td>
<td class="nump">$ 5,916,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, less allowance for doubtful accounts of $383,106 and $153,231 as of August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">932,273<span></span>
</td>
<td class="nump">773,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of inventory reserves of $981,814 and $845,549 as of August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">1,921,734<span></span>
</td>
<td class="nump">2,416,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">238,762<span></span>
</td>
<td class="nump">320,283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,167,806<span></span>
</td>
<td class="nump">9,427,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $1,325,561 and $1,305,360 as of August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">227,908<span></span>
</td>
<td class="nump">214,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net of accumulated amortization of $791,859 and $724,802 as of August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">1,234,777<span></span>
</td>
<td class="nump">1,301,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $21,271 and $18,994 as of August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">160,750<span></span>
</td>
<td class="nump">169,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">93,509<span></span>
</td>
<td class="nump">95,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">11,050,074<span></span>
</td>
<td class="nump">11,374,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">671,240<span></span>
</td>
<td class="nump">972,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">591,948<span></span>
</td>
<td class="nump">646,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">150,523<span></span>
</td>
<td class="nump">50,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">343,889<span></span>
</td>
<td class="nump">341,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,757,600<span></span>
</td>
<td class="nump">2,011,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">970,890<span></span>
</td>
<td class="nump">1,038,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,728,490<span></span>
</td>
<td class="nump">3,049,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 5 and 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.08 par value, 25,000,000 shares authorized, 13,406,901 and 12,867,924 issued and outstanding at August 31, 2022 and May 31, 2022, respectively</a></td>
<td class="nump">1,072,550<span></span>
</td>
<td class="nump">1,029,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">44,484,752<span></span>
</td>
<td class="nump">42,446,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(86,463)<span></span>
</td>
<td class="num">(73,936)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(37,149,255)<span></span>
</td>
<td class="num">(35,077,379)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">8,321,584<span></span>
</td>
<td class="nump">8,324,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="nump">$ 11,050,074<span></span>
</td>
<td class="nump">$ 11,374,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776720592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 383,106<span></span>
</td>
<td class="nump">$ 153,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">981,814<span></span>
</td>
<td class="nump">845,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">1,325,561<span></span>
</td>
<td class="nump">1,305,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_AccumulatedAmortizationRightOfUseAssets', window );">Accumulated amortization, Right of Use Assets</a></td>
<td class="nump">791,859<span></span>
</td>
<td class="nump">724,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization, Intangible Assets</a></td>
<td class="nump">$ 21,271<span></span>
</td>
<td class="nump">$ 18,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="nump">13,406,901<span></span>
</td>
<td class="nump">12,867,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in Shares)</a></td>
<td class="nump">13,406,901<span></span>
</td>
<td class="nump">12,867,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_AccumulatedAmortizationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from operating lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_AccumulatedAmortizationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776298880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 1,637,435<span></span>
</td>
<td class="nump">$ 1,261,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(1,692,390)<span></span>
</td>
<td class="num">(1,350,757)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross loss</a></td>
<td class="num">(54,955)<span></span>
</td>
<td class="num">(88,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,653,821<span></span>
</td>
<td class="nump">1,069,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">361,171<span></span>
</td>
<td class="nump">381,544<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,014,992<span></span>
</td>
<td class="nump">1,451,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,069,947)<span></span>
</td>
<td class="num">(1,540,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend and interest income</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(2,069,919)<span></span>
</td>
<td class="num">(1,533,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,957)<span></span>
</td>
<td class="num">(9,017)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,071,876)<span></span>
</td>
<td class="num">$ (1,542,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in Dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common and common equivalent shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">13,100,407<span></span>
</td>
<td class="nump">12,426,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">13,100,407<span></span>
</td>
<td class="nump">12,426,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,071,876)<span></span>
</td>
<td class="num">$ (1,542,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(12,527)<span></span>
</td>
<td class="num">(5,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (2,084,403)<span></span>
</td>
<td class="num">$ (1,548,194)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776756160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2021</a></td>
<td class="nump">$ 984,571<span></span>
</td>
<td class="nump">$ 38,836,743<span></span>
</td>
<td class="num">$ (47,956)<span></span>
</td>
<td class="num">$ (30,546,335)<span></span>
</td>
<td class="nump">$ 9,227,023<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2021</a></td>
<td class="nump">12,307,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="nump">$ 16,124<span></span>
</td>
<td class="nump">784,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="nump">201,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,542,581)<span></span>
</td>
<td class="num">(1,542,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Aug. 31, 2021</a></td>
<td class="nump">$ 1,000,815<span></span>
</td>
<td class="nump">39,944,726<span></span>
</td>
<td class="num">(53,569)<span></span>
</td>
<td class="num">(32,088,916)<span></span>
</td>
<td class="nump">8,803,056<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at Aug. 31, 2021</a></td>
<td class="nump">12,510,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at May. 31, 2022</a></td>
<td class="nump">$ 1,029,432<span></span>
</td>
<td class="nump">42,446,597<span></span>
</td>
<td class="num">(73,936)<span></span>
</td>
<td class="num">(35,077,379)<span></span>
</td>
<td class="nump">8,324,714<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at May. 31, 2022</a></td>
<td class="nump">12,867,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from ATM</a></td>
<td class="nump">$ 41,918<span></span>
</td>
<td class="nump">1,721,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from ATM (in Shares)</a></td>
<td class="nump">523,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,071,876)<span></span>
</td>
<td class="num">(2,071,876)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Aug. 31, 2022</a></td>
<td class="nump">$ 1,072,550<span></span>
</td>
<td class="nump">$ 44,484,752<span></span>
</td>
<td class="num">$ (86,463)<span></span>
</td>
<td class="num">$ (37,149,255)<span></span>
</td>
<td class="nump">$ 8,321,584<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balances (in Shares) at Aug. 31, 2022</a></td>
<td class="nump">13,406,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926770312640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,071,876)<span></span>
</td>
<td class="num">$ (1,542,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28,971<span></span>
</td>
<td class="nump">34,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance on accounts receivable</a></td>
<td class="nump">229,875<span></span>
</td>
<td class="num">(94,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="nump">136,265<span></span>
</td>
<td class="nump">179,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="nump">303,755<span></span>
</td>
<td class="nump">319,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">67,057<span></span>
</td>
<td class="nump">62,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(388,330)<span></span>
</td>
<td class="nump">777,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">358,448<span></span>
</td>
<td class="nump">164,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">81,521<span></span>
</td>
<td class="nump">55,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_IncreaseDecreaseInLeaseLiability', window );">Reduction in lease liability</a></td>
<td class="num">(64,801)<span></span>
</td>
<td class="num">(55,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="num">(2,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(301,132)<span></span>
</td>
<td class="nump">58,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(54,996)<span></span>
</td>
<td class="nump">118,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advance from customers</a></td>
<td class="nump">99,853<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(1,573,314)<span></span>
</td>
<td class="nump">75,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures related to intangibles</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(72,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(33,623)<span></span>
</td>
<td class="num">(5,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(33,623)<span></span>
</td>
<td class="num">(77,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="nump">1,810,927<span></span>
</td>
<td class="nump">838,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs from sale of common stock</a></td>
<td class="num">(47,359)<span></span>
</td>
<td class="num">(37,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">13,950<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,777,518<span></span>
</td>
<td class="nump">804,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes in cash</a></td>
<td class="num">(12,527)<span></span>
</td>
<td class="num">(5,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">158,054<span></span>
</td>
<td class="nump">797,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">5,916,983<span></span>
</td>
<td class="nump">4,199,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">6,075,037<span></span>
</td>
<td class="nump">4,996,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">9,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfIntangibleAssetsCost', window );">Write off of intangible assets, cost</a></td>
<td class="nump">6,489<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization', window );">Write off of intangible assets, accumulated amortization</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in LeaseLiability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets, accumulated amortization in non cash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WriteOffOfIntangibleAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of intangible assets, cost in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WriteOffOfIntangibleAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926775404112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 1: &#160;BASIS OF PRESENTATION</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="FONT-SIZE:10pt"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</span><span style="FONT-SIZE:10pt"> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="FONT-SIZE:10pt; COLOR:black">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="FONT-SIZE:10pt"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#8220;DGT&#8221;) products based on our InFoods<sup>&#174;</sup> Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome (&#8220;IBS&#8221;), and other inflammatory diseases. These InFoods<sup>&#174;</sup> based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented InFoods Technology is our InFoods&#174; IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#174; IBS product works by identifying a patient&#8217;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. We are currently in discussions with key gastroenterology (GI) physician groups who are interested in offering this product to their patients. As such, we are expecting to begin generating revenues from the launch of our InFoods<sup>&#174;</sup> IBS product during our fiscal third quarter. &#160;&#160;</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#8217;s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> and 2023 have come from international sales of our COVID-19 antigen tests that use a patient&#8217;s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, less than 12% of our revenues during the three months ended August 31, 2022 were from sales of our COVID-19 related products. <span style="COLOR:black">&#160;</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our non-COVID-19 products that accounted for over 88% of our revenues during the three months ended August 31, 2022, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#8217;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif; COLOR:black">The unaudited consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2022. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2023. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on August 29, 2022. Management has evaluated all subsequent events and transactions through the date of filing this report.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926775986608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 2: &#160;SIGNIFICANT ACCOUNTING POLICIES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the Coronavirus global pandemic, and the economic disruptions that have followed, the Company&#8217;s operations have been negatively impacted.<span style="COLOR:black"> The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions have materially negatively impacted the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $37.1 million as of August 31, 2022. Management expects to continue to incur significant costs as it advances its clinical trials and product development activities. As of August 31, 2022, the Company had cash and cash equivalents of approximately $6,075,000 and working capital of approximately $7,410,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">On July 21, 2020, the Company filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; Shares of the Company&#8217;s common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, the Company filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering (&#8220;ATM Offering&#8221;) under the shelf registration statement, of which approximately $9,600,000, remains available for sale under the prospectus supplement.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The sales agent under the ATM Offering agrees to use commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend offers under, or terminate the ATM Offering.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the quarter ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company approximately of $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand <span style="COLOR:black">at August 31, 2022, </span>and the ability to raise additional funds, including through the ATM Offering noted above,<span style="COLOR:black"> management</span> believes the Company has sufficient funds to operate through at least November 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. <span style="COLOR:black">As of August 31, 2022,</span> the Company had approximately $5,834,000 of uninsured cash. <span style="COLOR:black">The Company does not believe it is exposed to any significant credit risks.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Consolidated net sales were approximately $1,637,000 for the <span style="COLOR:black">three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021. </span>For <span style="COLOR:black">the three months ended August 31, 2022 and 2021,</span> the Company had <span style="COLOR:black">two</span> key customers who are located in foreign countries which accounted <span style="COLOR:black">for 64%</span> and <span style="COLOR:black">60%</span> of net consolidated sales, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $1,315,000 and $927,000, respectively. On August 31, 2022</span><span style="FONT-SIZE:10pt"> and <span style="COLOR:black"> May 31, 2022,</span> the Company had two and <span style="COLOR:black">one</span> key customers who are located in foreign countries which accounted for a total of 67% and <span style="COLOR:black">50%,</span> respectively, of gross accounts receivable. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">For the three months ended August 31, 2022 and 2021, the</span><span style="FONT-SIZE:10pt"> Company had one <span style="COLOR:black">k</span>ey vendor which accounted for 9% <span style="COLOR:black">and 17%</span> of the purchases of raw materials, respectively. <span style="COLOR:black">As of August 31, 2022 and May 31, 2022,</span> the Company had one and two key vendors which accounted for 11% <span style="COLOR:black">and 69%, respectively</span>, of accounts payable.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CASH AND CASH EQUIVALENTS </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less <span style="COLOR:black">than three months</span>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria,&#160;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of August 31, 2022 and May 31, 2022, the Company has established a reserve of approximately $383,000 and $153,000, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAID EXPENSES AND OTHER</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaid expenses and other, until either the inventory is physically received, or the insurance and other items are expensed.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022 and May 31, 2022, the</span><span style="FONT-SIZE:10pt"> prepaid expenses and other were approximately $239,000 and <span style="COLOR:black">$320,000, respectively</span>, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INVENTORIES, NET </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">Net inventories are approximately the following:</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Raw materials</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,732,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,717,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Work in progress</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">723,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">763,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Finished products</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">449,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">782,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross inventory</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,904,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,262,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Inventory reserves</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(982,000)</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(846,000)</span></p></td></tr> <tr style="HEIGHT:13.8pt"> <td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net inventory </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">1,922,000 </span></b></p></td> <td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,416,000 </span></b></p></td></tr></table><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2022, and May 31, 2022, inventory reserves were approximately $982,000 and $846,000, respectively. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment were approximately $20,000 and $28,000 for the three months ended <span style="COLOR:black">August 31, 2022 and 2021, </span>respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">&#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization expense was approximately $9,000 and $7,000 for the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of August 31, 2022 and 2021, an impairment adjustment was made of $6,000 and $0, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and invested approximately $165,000 into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of August 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the period ended August 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $304,000 and $320,000 of stock-based compensation during the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">The following summary presents the options granted, exercised, expired, canceled and outstanding for the three months <span style="COLOR:black">ended August 31, 2022:</span></span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Option Shares</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Exercise Price</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Weighted Average</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Outstanding May 31, 2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,321,616 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.72 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">146,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.37 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercised</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(15,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0.95 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cancelled or expired</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(64,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.78 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Outstanding August 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,388,616 </span></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">3.69 </span></b></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, options to purchase 15,000 shares of common stock were exercised at prices ranging from $0.82 to $1.20. Total net proceeds to the Company were approximately $14,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, the Company granted 146,000 options to purchase common stock at an average purchase price of $3.37, with the majority of those options issued to the Company&#8217;s new Chief Commercial Officer, who is managing the commercialization and roll-out of the InFoods IBS test. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company does not typically allow for returns from international customers except in the event of defective merchandise and therefore does not establish an allowance for returns. The Company does allow for a return merchandise allowance of approximately one percent of sales to certain domestic retailers. This allowance reduces revenue recognition by approximately one percent, and is included in sales discounts. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts during the three months ended August 31, 2022 and 2021, and does not believe that any additional discounts will be given through the end of the contract periods. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Services for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022, the Company had approximately $151,000 of advances from certain foreign customers. The majority of these advances are prepayments on orders that are expected to ship during our second quarter ended November 30, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31,</span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical lab</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,146,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">886,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">213,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">79,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Physician's office</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">183,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">257,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">95,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">40,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,637,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,262,000 </span></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 4 for additional information regarding revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHIPPING AND HANDLING FEES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Research and development costs are expensed as incurred. The Company expensed approximately $361,000 and <span style="COLOR:black">$382,000 </span>of research and development costs during the <span style="COLOR:black">three months ended August 31, 2022 and 2021, respectively.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has provided a full valuation allowance on deferred income tax assets of approximately $7,402,000 and $6,967,000 as of August 31, 2022 and May 31, 2022, respectively. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$18,000</span> and $<span style="BACKGROUND:white">8,000</span> for the three months ended August 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the three months ended August 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases.&#160; The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">NET LOSS PER SHARE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per <span style="COLOR:black">share calculation at August 31, 2022 and 2021 was 2,388,616 and 2,081,116, respectively. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECLASSIFICATIONS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926775859760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 3:&#160; SHAREHOLDERS&#8217; EQUITY</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Stock option expense during the three months ended August 31, 2022 and 2021 was approximately $304,000 and $320,000, respectively.</span><span style="FONT-SIZE:10pt; COLOR:black"> </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the three months ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its Form S-3 Registration Statement and ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company of approximately $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926779278048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureTextBlock', window );">Geographic Information Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 4: &#160;GEOGRAPHIC INFORMATION</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company operates as one segment. Geographic information regarding net sales is approximately as follows: </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="5" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31, </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Revenues from sales to unaffiliated customers:</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"/> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Asia</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">814,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">675,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Europe</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">552,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">471,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">North America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">268,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">105,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">South America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Middle East</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8,000 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,637,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,262,000 </span></p></td></tr></table><p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-family: 'Times New Roman',serif; color: black;">As of August 31, 2022, and May 31, 2022, a</span><span style="font-family: 'Times New Roman',serif;">pproximately $725,000 <span style="color: black;">and $621,000 </span>of Biomerica&#8217;s gross inventory was located in Mexicali, Mexico, respectively. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"><span style="font-family: 'Times New Roman',serif; color: black;">As of August 31, 2022, and May 31, 2022,</span><span style="font-family: 'Times New Roman',serif;"> approximately $20,000 <span style="color: black;">and $17,000 </span>of Biomerica&#8217;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments according to the geographic areas.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926784962656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 5: &#160;LEASES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><span style="FONT-SIZE:10pt">The Company leases its facilities. On August 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $26,000 per month. The security deposit is approximately $22,000.<span style="COLOR:black">&#160;</span> </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><span style="FONT-SIZE:10pt">In November 2016, the Company&#8217;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $3,400 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross rent expense in the United States for the three months ended August 31, 2022 and 2021 was approximately $78,000 and $78,000, respectively.&#160; Rent expense for the Mexico facility for the three months ended August 31, 2022 and 2021 was approximately $11,000 and $10,000, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"><span style="FONT-SIZE:10pt">For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#8217;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred. &#160;</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">Supplemental cash flow information related to leases for the three months <span style="COLOR:black">ended August 31, 2022: </span>&#160;</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">86,000 </span></p></td></tr> <tr style="HEIGHT:25.5pt"> <td style="HEIGHT:25.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160; new operating lease liabilities</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.02 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6.50%</span></p></td></tr></table><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">The approximate maturity of lease <span style="COLOR:black">liabilities as of August 31, 2022 are as</span> follows:</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less than 1 year</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">354,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">1 to 2 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">364,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2 to 3 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">375,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">3 to 4 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">387,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">4 to 5 years </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total undiscounted lease payments</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,488,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less imputed interest</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">173,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total operating lease liabilities</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,315,000 </span></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company also has various insignificant leases for office equipment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926775633264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in"><b><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">NOTE 6: &#160;COMMITMENTS AND CONTINGENCIES</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LITIGATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">There were no legal proceedings pending as of August 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926779493664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">NOTE 7:&#160; SUBSEQUENT EVENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">On September 29, 2022, the Company announced that its Aware&#174; Breast Self Exam device and EZ Detect Colon Disease test are being sold on Amazon and fulfilled by Amazon.&#160; &#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776230736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PRINCIPLES OF CONSOLIDATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_MarketsAndMethodsOfDistributionPolicyTextBlock', window );">Markets And Methods of Distribution Policy [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">MARKETS AND METHODS OF DISTRIBUTION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the Coronavirus global pandemic, and the economic disruptions that have followed, the Company&#8217;s operations have been negatively impacted.<span style="COLOR:black"> The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss of contracts and/or customers, closure of the Company&#8217;s manufacturing or distribution facilities or of the facilities of the Company&#8217;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions have materially negatively impacted the Company&#8217;s operations and financial performance and may continue to have significant material negative impacts on the Company.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LiquidityPolicyTextBlock', window );">Liquidity Policy [Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">LIQUIDITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $37.1 million as of August 31, 2022. Management expects to continue to incur significant costs as it advances its clinical trials and product development activities. As of August 31, 2022, the Company had cash and cash equivalents of approximately $6,075,000 and working capital of approximately $7,410,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">On July 21, 2020, the Company filed with the SEC a &#8220;shelf&#8221; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; Shares of the Company&#8217;s common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, the Company filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering (&#8220;ATM Offering&#8221;) under the shelf registration statement, of which approximately $9,600,000, remains available for sale under the prospectus supplement.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The sales agent under the ATM Offering agrees to use commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend offers under, or terminate the ATM Offering.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">During the quarter ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company approximately of $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"><span style="FONT-SIZE:10pt">As a result of cash and cash equivalents on hand <span style="COLOR:black">at August 31, 2022, </span>and the ability to raise additional funds, including through the ATM Offering noted above,<span style="COLOR:black"> management</span> believes the Company has sufficient funds to operate through at least November 2023.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. <span style="COLOR:black">As of August 31, 2022,</span> the Company had approximately $5,834,000 of uninsured cash. <span style="COLOR:black">The Company does not believe it is exposed to any significant credit risks.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Consolidated net sales were approximately $1,637,000 for the <span style="COLOR:black">three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021. </span>For <span style="COLOR:black">the three months ended August 31, 2022 and 2021,</span> the Company had <span style="COLOR:black">two</span> key customers who are located in foreign countries which accounted <span style="COLOR:black">for 64%</span> and <span style="COLOR:black">60%</span> of net consolidated sales, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $1,315,000 and $927,000, respectively. On August 31, 2022</span><span style="FONT-SIZE:10pt"> and <span style="COLOR:black"> May 31, 2022,</span> the Company had two and <span style="COLOR:black">one</span> key customers who are located in foreign countries which accounted for a total of 67% and <span style="COLOR:black">50%,</span> respectively, of gross accounts receivable. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">For the three months ended August 31, 2022 and 2021, the</span><span style="FONT-SIZE:10pt"> Company had one <span style="COLOR:black">k</span>ey vendor which accounted for 9% <span style="COLOR:black">and 17%</span> of the purchases of raw materials, respectively. <span style="COLOR:black">As of August 31, 2022 and May 31, 2022,</span> the Company had one and two key vendors which accounted for 11% <span style="COLOR:black">and 69%, respectively</span>, of accounts payable.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CASH AND CASH EQUIVALENTS </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less <span style="COLOR:black">than three months</span>.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTS RECEIVABLE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria,&#160;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">As of August 31, 2022 and May 31, 2022, the Company has established a reserve of approximately $383,000 and $153,000, respectively, for doubtful accounts. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_PrepaidsPolicyPolicyTextBlock', window );">Prepaids Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PREPAID EXPENSES AND OTHER</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaid expenses and other, until either the inventory is physically received, or the insurance and other items are expensed.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022 and May 31, 2022, the</span><span style="FONT-SIZE:10pt"> prepaid expenses and other were approximately $239,000 and <span style="COLOR:black">$320,000, respectively</span>, composed of prepayments to insurance and various other suppliers. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INVENTORIES, NET </span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black">The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">Net inventories are approximately the following:</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Raw materials</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,732,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,717,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Work in progress</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">723,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">763,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Finished products</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">449,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">782,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross inventory</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,904,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,262,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Inventory reserves</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(982,000)</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(846,000)</span></p></td></tr> <tr style="HEIGHT:13.8pt"> <td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net inventory </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">1,922,000 </span></b></p></td> <td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,416,000 </span></b></p></td></tr></table><p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"><span style="font-size: 10pt; color: black;">Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2022, and May 31, 2022, inventory reserves were approximately $982,000 and $846,000, respectively. </span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">PROPERTY AND EQUIPMENT, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment were approximately $20,000 and $28,000 for the three months ended <span style="COLOR:black">August 31, 2022 and 2021, </span>respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">&#160; </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INTANGIBLE ASSETS, NET</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#8220;ASC&#8221;), ASC 350 Intangibles &#8211; Goodwill and Other (&#8220;ASC 350&#8221;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization expense was approximately $9,000 and $7,000 for the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#8217;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of August 31, 2022 and 2021, an impairment adjustment was made of $6,000 and $0, respectively.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">INVESTMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#8217;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and invested approximately $165,000 into the Polish distributor.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"><span style="FONT-SIZE:10pt; COLOR:black">Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of August 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#8217;s Cost Method Holding during the period ended August 31, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHARE-BASED COMPENSATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company follows the guidance of ASC 718, Share-based Compensation (&#8220;ASC 718&#8221;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#8217;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company expensed approximately $304,000 and $320,000 of stock-based compensation during the three months ended August 31, 2022 and 2021, respectively.</span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:&quot;Times New Roman&quot;,serif">The following summary presents the options granted, exercised, expired, canceled and outstanding for the three months <span style="COLOR:black">ended August 31, 2022:</span></span></p><p style="FONT-SIZE:10pt; FONT-FAMILY:&quot;Times New Roman&quot;; MARGIN:0in 2.7pt 0in 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Option Shares</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Exercise Price</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Weighted Average</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Outstanding May 31, 2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,321,616 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.72 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">146,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.37 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercised</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(15,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0.95 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cancelled or expired</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(64,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.78 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Outstanding August 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,388,616 </span></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">3.69 </span></b></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, options to purchase 15,000 shares of common stock were exercised at prices ranging from $0.82 to $1.20. Total net proceeds to the Company were approximately $14,000.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">During the three months ended August 31, 2022, the Company granted 146,000 options to purchase common stock at an average purchase price of $3.37, with the majority of those options issued to the Company&#8217;s new Chief Commercial Officer, who is managing the commercialization and roll-out of the InFoods IBS test. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">REVENUE RECOGNITION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company does not typically allow for returns from international customers except in the event of defective merchandise and therefore does not establish an allowance for returns. The Company does allow for a return merchandise allowance of approximately one percent of sales to certain domestic retailers. This allowance reduces revenue recognition by approximately one percent, and is included in sales discounts. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts during the three months ended August 31, 2022 and 2021, and does not believe that any additional discounts will be given through the end of the contract periods. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Services for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project progresses. <span style="COLOR:black">The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#8217; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">As of August 31, 2022, the Company had approximately $151,000 of advances from certain foreign customers. The majority of these advances are prepayments on orders that are expected to ship during our second quarter ended November 30, 2022.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Disaggregation of revenue:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The following is a breakdown of revenues according to markets to which the products are sold:</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31,</span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical lab</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,146,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">886,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">213,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">79,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Physician's office</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">183,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">257,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">95,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">40,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,637,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,262,000 </span></p></td></tr></table><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">See Note 4 for additional information regarding revenue concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">SHIPPING AND HANDLING FEES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company includes shipping and handling fees billed to customers in net sales.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RESEARCH AND DEVELOPMENT</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Research and development costs are expensed as incurred. The Company expensed approximately $361,000 and <span style="COLOR:black">$382,000 </span>of research and development costs during the <span style="COLOR:black">three months ended August 31, 2022 and 2021, respectively.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">INCOME TAXES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company has provided a full valuation allowance on deferred income tax assets of approximately $7,402,000 and $6,967,000 as of August 31, 2022 and May 31, 2022, respectively. &#160; </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">ADVERTISING COSTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">The Company reports the cost of advertising as expense in the period in which those costs are incurred. Advertising costs were approximately <span style="BACKGROUND:white">$18,000</span> and $<span style="BACKGROUND:white">8,000</span> for the three months ended August 31, 2022 and 2021, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">FOREIGN CURRENCY TRANSLATION</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the three months ended August 31, 2022 and 2021.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RIGHT-OF-USE ASSETS AND LEASE LIABILITY</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases.&#160; The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#8217;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">NET LOSS PER SHARE</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per <span style="COLOR:black">share calculation at August 31, 2022 and 2021 was 2,388,616 and 2,081,116, respectively. </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">RECENT ACCOUNTING PRONOUNCEMENTS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#8217;s present or future consolidated financial statements. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#183;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#8217;s consolidated results of operations and financial position. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECLASSIFICATIONS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in">&#160;</p><p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity position during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_MarketsAndMethodsOfDistributionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Markets And Methods Of Distribution during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_MarketsAndMethodsOfDistributionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_PrepaidsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for prepaids.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_PrepaidsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926778631088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">August 31, 2022</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">May 31, 2022</span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Raw materials</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,732,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,717,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Work in progress</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">723,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">763,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Finished products</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">449,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">782,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross inventory</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,904,000 </span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,262,000 </span></p></td></tr> <tr style="HEIGHT:13.2pt"> <td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Inventory reserves</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(982,000)</span></p></td> <td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(846,000)</span></p></td></tr> <tr style="HEIGHT:13.8pt"> <td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Net inventory </span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">1,922,000 </span></b></p></td> <td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,416,000 </span></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Option Shares</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Exercise Price</span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Weighted Average</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Outstanding May 31, 2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">2,321,616 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.72 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Granted</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">146,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3.37 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Exercised</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(15,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">0.95 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Cancelled or expired</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">(64,000)</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.78 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">Outstanding August 31, 2022</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">2,388,616 </span></b></p></td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">$</span></b></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><b><span style="FONT-SIZE:10pt; COLOR:black">3.69 </span></b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31,</span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;">&#160;</p></td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Clinical lab</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,146,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">886,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Over-the-counter</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">213,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">79,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Physician's office</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">183,000 </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">257,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Contract manufacturing</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">95,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">40,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,637,000 </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,262,000 </span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926779574688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GeographicInformationDisclosureAbstract', window );"><strong>Geographic Information Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="5" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">Three Months Ended August 31, </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2022</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"><span style="FONT-SIZE:10pt; COLOR:black">2021</span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Revenues from sales to unaffiliated customers:</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"/> </tr><tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Asia</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">814,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">675,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Europe</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">552,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">471,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">North America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">268,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">105,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">South America</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,000 </span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">3,000 </span></p></td></tr> <tr style="HEIGHT:0.2in"> <td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Middle East</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td> <td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8,000 </span></p></td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,637,000 </span></p></td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,262,000 </span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GeographicInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GeographicInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926770220112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Aug. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock', window );">Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160; </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">86,000 </span></p></td></tr> <tr style="HEIGHT:25.5pt"> <td style="HEIGHT:25.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Right-of-use assets obtained in exchange for </span></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">&#160;&#160; new operating lease liabilities</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">$</span></p></td> <td style="HEIGHT:25.5pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p> <p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">-</span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average remaining lease term (in years)</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">4.02 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Weighted average discount rate</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">6.50%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less than 1 year</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">354,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">1 to 2 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">364,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">2 to 3 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">375,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">3 to 4 years </span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">387,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">4 to 5 years </span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">8,000 </span></p></td></tr> <tr style="HEIGHT:12.75pt"> <td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total undiscounted lease payments</span></p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,488,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Less imputed interest</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">173,000 </span></p></td></tr> <tr style="HEIGHT:13.5pt"> <td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Total operating lease liabilities</span></p></td> <td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; MARGIN:0in; TEXT-INDENT:10pt">&#160;</p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">&#160;$ </span></p></td> <td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"> <p style="FONT-SIZE:12pt; FONT-FAMILY:&quot;Times New Roman&quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"><span style="FONT-SIZE:10pt; COLOR:black">1,315,000 </span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lease for the periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926698781808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 21, 2021</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (37,149,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,077,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">6,075,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,916,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">7,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue', window );">Shelf Registration Statement Maximum Authorized Common Stock Issuance Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">1,810,927<span></span>
</td>
<td class="nump">$ 838,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">5,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,637,435<span></span>
</td>
<td class="nump">1,261,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts Receivable, before Allowance for Credit Loss</a></td>
<td class="nump">1,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts Receivable, Allowance for Credit Loss, Current</a></td>
<td class="nump">383,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid Expense and Other Assets</a></td>
<td class="nump">239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">981,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">165,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">303,755<span></span>
</td>
<td class="nump">319,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">13,950<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Proceeds from Customers</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">361,171<span></span>
</td>
<td class="nump">381,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">7,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</a></td>
<td class="nump">2,388,616<span></span>
</td>
<td class="nump">2,081,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (37,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember', window );">Purchased Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bmra_ForeignMember', window );">Foreign [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bmra_ForeignMember', window );">Foreign [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember', window );">Polish Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 304,000<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember', window );">One Vendor [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorsMember', window );">Two Vendors [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="nump">523,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 1,764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember', window );">ATM Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmra_PurchasedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bmra_ForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bmra_ForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bmra_PolishDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bmra_TwoVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bmra_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926698773184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_InventoriesAbstract', window );"><strong>Inventories Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,732,000<span></span>
</td>
<td class="nump">$ 1,717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">723,000<span></span>
</td>
<td class="nump">763,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">449,000<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total gross inventory</a></td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">3,262,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="num">(981,814)<span></span>
</td>
<td class="num">(845,549)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventory</a></td>
<td class="nump">$ 1,921,734<span></span>
</td>
<td class="nump">$ 2,416,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926770204000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity - Share-Based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Shares | shares</a></td>
<td class="nump">2,321,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option Outstanding, Exercise Price Weighted Average | $ / shares</a></td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option Granted, Shares | shares</a></td>
<td class="nump">146,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option Granted, Exercise Price Weighted Average | $ / shares</a></td>
<td class="nump">$ 3.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised, Shares | shares</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Option Exercised, Exercise Price Weighted Average | $ / shares</a></td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Option Cancelled or expired, Shares | shares</a></td>
<td class="num">(64,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Option Cancelled or expired, Exercise Price Weighted Average | $ / shares</a></td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Shares | shares</a></td>
<td class="nump">2,388,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option Outstanding, Exercise Price Weighted Average | $ / shares</a></td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926698601872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 1,637,000<span></span>
</td>
<td class="nump">$ 1,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember', window );">Clinical Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">1,146,000<span></span>
</td>
<td class="nump">886,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember', window );">Over-the-counter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember', window );">Physicians Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember', window );">Contract Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue From Customers</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ClinicalLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_OverthecounterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_PhysiciansOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bmra_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926773505488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 303,755<span></span>
</td>
<td class="nump">$ 319,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,810,927<span></span>
</td>
<td class="nump">838,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in Shares)</a></td>
<td class="nump">523,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 1,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 1,764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS' EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 304,000<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SHAREHOLDERSEQUITYDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SHAREHOLDERSEQUITYDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776730128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 2,904,000<span></span>
</td>
<td class="nump">$ 3,262,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">227,908<span></span>
</td>
<td class="nump">214,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_GEOGRAPHICINFORMATIONDetailsLineItems', window );"><strong>GEOGRAPHIC INFORMATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">725,000<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_GEOGRAPHICINFORMATIONDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_GEOGRAPHICINFORMATIONDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926773504960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">$ 1,637,435<span></span>
</td>
<td class="nump">$ 1,261,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">814,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">552,000<span></span>
</td>
<td class="nump">471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember', window );">South America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember', window );">Middle East [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract', window );"><strong>Revenues from sales to unaffiliated customers:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net Sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_SouthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_SouthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_MiddleEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_MiddleEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776881488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2016</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LEASESDetailsLineItems', window );"><strong>LEASES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LEASESDetailsLineItems', window );"><strong>LEASES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember', window );">Building In Irvine California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LEASESDetailsLineItems', window );"><strong>LEASES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember', window );">Property Available for Operating Lease [Member] | MEXICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_LEASESDetailsLineItems', window );"><strong>LEASES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_LEASESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_LEASESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=bmra_BuildingInIrvineCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_PropertyAvailableForOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926775980016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details) - Supplemental cash flow information related to leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Supplemental Cash Flow Information Related To Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 86,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">4 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139926776286176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - The maturity of lease liabilities<br></strong></div></th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract', window );"><strong>The Maturity Of Lease Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Less than 1 year</a></td>
<td class="nump">$ 354,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">1 to 2 years</a></td>
<td class="nump">364,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2 to 3 years</a></td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">3 to 4 years</a></td>
<td class="nump">387,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">4 to 5 years</a></td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,315,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bmra_TheMaturityOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bmra_TheMaturityOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bmra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>bmra-20220831_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bmra="http://www.biomerica.com/20220831"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bmra-20220831.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bmra:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bmra:ForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:OneVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bmra:TwoVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bmra:PurchasedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bmra:PolishDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ClinicalLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:OverthecounterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:PhysiciansOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bmra:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:SouthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:MiddleEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">bmra:BuildingInIrvineCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:PropertyAvailableForOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-01</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-08-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-37863</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">BIOMERICA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">95-2645573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">17571 Von Karman Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">645-2111</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">COMMON STOCK, PAR VALUE $0.08</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:TradingSymbol contextRef="c0">BMRA</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">13427651</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="INF" unitRef="usd">6075037</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="INF" unitRef="usd">5916983</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="INF" unitRef="usd">383106</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="INF" unitRef="usd">153231</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="INF" unitRef="usd">932273</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="INF" unitRef="usd">773818</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="INF" unitRef="usd">981814</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="INF" unitRef="usd">845549</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c2" decimals="INF" unitRef="usd">1921734</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="INF" unitRef="usd">2416447</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="INF" unitRef="usd">238762</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="INF" unitRef="usd">320283</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="INF" unitRef="usd">9167806</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="INF" unitRef="usd">9427531</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="INF" unitRef="usd">1325561</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="INF" unitRef="usd">1305360</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="INF" unitRef="usd">227908</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="INF" unitRef="usd">214487</us-gaap:PropertyPlantAndEquipmentNet>
    <bmra:AccumulatedAmortizationRightOfUseAssets contextRef="c2" decimals="INF" unitRef="usd">791859</bmra:AccumulatedAmortizationRightOfUseAssets>
    <bmra:AccumulatedAmortizationRightOfUseAssets contextRef="c3" decimals="INF" unitRef="usd">724802</bmra:AccumulatedAmortizationRightOfUseAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="INF" unitRef="usd">1234777</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="INF" unitRef="usd">1301834</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Investments contextRef="c2" decimals="INF" unitRef="usd">165324</us-gaap:Investments>
    <us-gaap:Investments contextRef="c3" decimals="INF" unitRef="usd">165324</us-gaap:Investments>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="INF" unitRef="usd">21271</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="INF" unitRef="usd">18994</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="INF" unitRef="usd">160750</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="INF" unitRef="usd">169516</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="INF" unitRef="usd">93509</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="INF" unitRef="usd">95588</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="INF" unitRef="usd">11050074</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="INF" unitRef="usd">11374280</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="INF" unitRef="usd">671240</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">972372</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="INF" unitRef="usd">591948</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">646944</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c2" decimals="INF" unitRef="usd">150523</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="INF" unitRef="usd">50670</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="INF" unitRef="usd">343889</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="INF" unitRef="usd">341296</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="INF" unitRef="usd">1757600</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="INF" unitRef="usd">2011282</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="INF" unitRef="usd">970890</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="INF" unitRef="usd">1038284</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="INF" unitRef="usd">2728490</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="INF" unitRef="usd">3049566</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="INF" unitRef="usdPershares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="INF" unitRef="usdPershares">0.08</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">13406901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">13406901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">12867924</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">12867924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="INF" unitRef="usd">1072550</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="INF" unitRef="usd">1029432</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="INF" unitRef="usd">44484752</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="INF" unitRef="usd">42446597</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="INF" unitRef="usd">-86463</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="INF" unitRef="usd">-73936</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="INF" unitRef="usd">-37149255</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="INF" unitRef="usd">-35077379</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="INF" unitRef="usd">8321584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">8324714</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="INF" unitRef="usd">11050074</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">11374280</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="INF" unitRef="usd">1637435</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="INF" unitRef="usd">1261787</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="INF" unitRef="usd">1692390</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="INF" unitRef="usd">1350757</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="INF" unitRef="usd">-54955</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="INF" unitRef="usd">-88970</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="INF" unitRef="usd">1653821</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="INF" unitRef="usd">1069855</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="INF" unitRef="usd">361171</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="INF" unitRef="usd">381544</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="INF" unitRef="usd">2014992</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="INF" unitRef="usd">1451399</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-2069947</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="INF" unitRef="usd">-1540369</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c0" decimals="INF" unitRef="usd">28</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c4" decimals="INF" unitRef="usd">6805</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="INF" unitRef="usd">28</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="INF" unitRef="usd">6805</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="INF" unitRef="usd">-2069919</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="INF" unitRef="usd">-1533564</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="INF" unitRef="usd">1957</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="INF" unitRef="usd">9017</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-2071876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="INF" unitRef="usd">-1542581</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="INF" unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="INF" unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="c0" decimals="INF" unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c4" decimals="INF" unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">13100407</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="INF" unitRef="shares">12426784</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" unitRef="shares">13100407</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">12426784</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-2071876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="INF" unitRef="usd">-1542581</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-12527</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c4" decimals="INF" unitRef="usd">-5613</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-2084403</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c4" decimals="INF" unitRef="usd">-1548194</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued contextRef="c5" decimals="INF" unitRef="shares">12307157</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="INF" unitRef="usd">984571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="INF" unitRef="usd">38836743</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="INF" unitRef="usd">-47956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="INF" unitRef="usd">-30546335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="INF" unitRef="usd">9227023</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c10" decimals="INF" unitRef="shares">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c10" decimals="INF" unitRef="usd">120</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c11" decimals="INF" unitRef="usd">3775</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c4" decimals="INF" unitRef="usd">3895</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c10" decimals="INF" unitRef="shares">201553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c10" decimals="INF" unitRef="usd">16124</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="INF" unitRef="usd">784586</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c4" decimals="INF" unitRef="usd">800710</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c12" decimals="INF" unitRef="usd">-5613</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c4" decimals="INF" unitRef="usd">-5613</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c11" decimals="INF" unitRef="usd">319622</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="INF" unitRef="usd">319622</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="INF" unitRef="usd">-1542581</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="INF" unitRef="usd">-1542581</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued contextRef="c14" decimals="INF" unitRef="shares">12510210</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="INF" unitRef="usd">1000815</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="INF" unitRef="usd">39944726</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="INF" unitRef="usd">-53569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="INF" unitRef="usd">-32088916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="INF" unitRef="usd">8803056</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued contextRef="c19" decimals="INF" unitRef="shares">12867924</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="INF" unitRef="usd">1029432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="INF" unitRef="usd">42446597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="INF" unitRef="usd">-73936</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="INF" unitRef="usd">-35077379</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="INF" unitRef="usd">8324714</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c23" decimals="INF" unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c23" decimals="INF" unitRef="usd">1200</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c24" decimals="INF" unitRef="usd">12750</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="INF" unitRef="usd">13950</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c23" decimals="INF" unitRef="shares">523977</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="INF" unitRef="usd">41918</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="INF" unitRef="usd">1721650</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="INF" unitRef="usd">1763568</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c25" decimals="INF" unitRef="usd">-12527</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="INF" unitRef="usd">-12527</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c24" decimals="INF" unitRef="usd">303755</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="INF" unitRef="usd">303755</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NetIncomeLoss contextRef="c26" decimals="INF" unitRef="usd">-2071876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-2071876</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued contextRef="c27" decimals="INF" unitRef="shares">13406901</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="INF" unitRef="usd">1072550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="INF" unitRef="usd">44484752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="INF" unitRef="usd">-86463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="INF" unitRef="usd">-37149255</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="INF" unitRef="usd">8321584</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" unitRef="usd">-2071876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="INF" unitRef="usd">-1542581</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="INF" unitRef="usd">28971</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c4" decimals="INF" unitRef="usd">34722</us-gaap:DepreciationAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="INF" unitRef="usd">229875</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c4" decimals="INF" unitRef="usd">-94891</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c0" decimals="INF" unitRef="usd">136265</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c4" decimals="INF" unitRef="usd">179744</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:StockOptionPlanExpense contextRef="c0" decimals="INF" unitRef="usd">303755</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c4" decimals="INF" unitRef="usd">319622</us-gaap:StockOptionPlanExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="INF" unitRef="usd">67057</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c4" decimals="INF" unitRef="usd">62897</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="INF" unitRef="usd">388330</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="INF" unitRef="usd">-777752</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="INF" unitRef="usd">-358448</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c4" decimals="INF" unitRef="usd">-164732</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="INF" unitRef="usd">-81521</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="INF" unitRef="usd">-55069</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bmra:IncreaseDecreaseInLeaseLiability contextRef="c0" decimals="INF" unitRef="usd">-64801</bmra:IncreaseDecreaseInLeaseLiability>
    <bmra:IncreaseDecreaseInLeaseLiability contextRef="c4" decimals="INF" unitRef="usd">-55649</bmra:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="INF" unitRef="usd">-2076</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c4" decimals="INF" unitRef="usd">2431</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="INF" unitRef="usd">-301132</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="INF" unitRef="usd">58024</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="INF" unitRef="usd">-54996</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c4" decimals="INF" unitRef="usd">118826</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="INF" unitRef="usd">99853</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="INF" unitRef="usd">-1573314</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="INF" unitRef="usd">75836</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c4" decimals="INF" unitRef="usd">72375</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="INF" unitRef="usd">33623</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="INF" unitRef="usd">5141</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="INF" unitRef="usd">-33623</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="INF" unitRef="usd">-77516</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="INF" unitRef="usd">1810927</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c4" decimals="INF" unitRef="usd">838333</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="INF" unitRef="usd">47359</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c4" decimals="INF" unitRef="usd">37622</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="INF" unitRef="usd">13950</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c4" decimals="INF" unitRef="usd">3895</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="INF" unitRef="usd">1777518</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="INF" unitRef="usd">804606</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="INF" unitRef="usd">-12527</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c4" decimals="INF" unitRef="usd">-5613</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="INF" unitRef="usd">158054</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="INF" unitRef="usd">797313</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="INF" unitRef="usd">5916983</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="INF" unitRef="usd">4199311</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="INF" unitRef="usd">6075037</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="INF" unitRef="usd">4996624</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="INF" unitRef="usd">1957</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c4" decimals="INF" unitRef="usd">9017</us-gaap:IncomeTaxesPaid>
    <bmra:WriteOffOfIntangibleAssetsCost contextRef="c0" decimals="INF" unitRef="usd">6489</bmra:WriteOffOfIntangibleAssetsCost>
    <bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization contextRef="c0" decimals="INF" unitRef="usd">850</bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization>
    <us-gaap:BasisOfAccounting contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 1: &#160;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care &lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(physicians' offices and over-the-counter through drugstores and online)&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases&lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (&#x201c;DGT&#x201d;) products based on our InFoods&lt;sup&gt;&#xae;&lt;/sup&gt; Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome (&#x201c;IBS&#x201d;), and other inflammatory diseases. These InFoods&lt;sup&gt;&#xae;&lt;/sup&gt; based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented InFoods Technology is our InFoods&#xae; IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods&#xae; IBS product works by identifying a patient&#x2019;s above normal immunoreactivity to specific foods.&#160; A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. We are currently in discussions with key gastroenterology (GI) physician groups who are interested in offering this product to their patients. As such, we are expecting to begin generating revenues from the launch of our InFoods&lt;sup&gt;&#xae;&lt;/sup&gt; IBS product during our fiscal third quarter. &#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient&#x2019;s body, stools, or blood, often in extremely small concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic&lt;span style="COLOR:black"&gt;, in March 2020 we&lt;/span&gt; began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues &lt;span style="COLOR:black"&gt;in fiscal 2022&lt;/span&gt; and 2023 have come from international sales of our COVID-19 antigen tests that use a patient&#x2019;s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, less than 12% of our revenues during the three months ended August 31, 2022 were from sales of our COVID-19 related products. &lt;span style="COLOR:black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Our non-COVID-19 products that accounted for over 88% of our revenues during the three months ended August 31, 2022, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country&#x2019;s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; COLOR:black"&gt;The unaudited consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2022. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2023. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on August 29, 2022. Management has evaluated all subsequent events and transactions through the date of filing this report.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 2: &#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;ACCOUNTING ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;MARKETS AND METHODS OF DISTRIBUTION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Due to the Coronavirus global pandemic, and the economic disruptions that have followed, the Company&#x2019;s operations have been negatively impacted.&lt;span style="COLOR:black"&gt; The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions have materially negatively impacted the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $37.1 million as of August 31, 2022. Management expects to continue to incur significant costs as it advances its clinical trials and product development activities. As of August 31, 2022, the Company had cash and cash equivalents of approximately $6,075,000 and working capital of approximately $7,410,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;On July 21, 2020, the Company filed with the SEC a &#x201c;shelf&#x201d; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; Shares of the Company&#x2019;s common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, the Company filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering (&#x201c;ATM Offering&#x201d;) under the shelf registration statement, of which approximately $9,600,000, remains available for sale under the prospectus supplement.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The sales agent under the ATM Offering agrees to use commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend offers under, or terminate the ATM Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the quarter ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company approximately of $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As a result of cash and cash equivalents on hand &lt;span style="COLOR:black"&gt;at August 31, 2022, &lt;/span&gt;and the ability to raise additional funds, including through the ATM Offering noted above,&lt;span style="COLOR:black"&gt; management&lt;/span&gt; believes the Company has sufficient funds to operate through at least November 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CONCENTRATION OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. &lt;span style="COLOR:black"&gt;As of August 31, 2022,&lt;/span&gt; the Company had approximately $5,834,000 of uninsured cash. &lt;span style="COLOR:black"&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Consolidated net sales were approximately $1,637,000 for the &lt;span style="COLOR:black"&gt;three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021. &lt;/span&gt;For &lt;span style="COLOR:black"&gt;the three months ended August 31, 2022 and 2021,&lt;/span&gt; the Company had &lt;span style="COLOR:black"&gt;two&lt;/span&gt; key customers who are located in foreign countries which accounted &lt;span style="COLOR:black"&gt;for 64%&lt;/span&gt; and &lt;span style="COLOR:black"&gt;60%&lt;/span&gt; of net consolidated sales, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $1,315,000 and $927,000, respectively. On August 31, 2022&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; and &lt;span style="COLOR:black"&gt; May 31, 2022,&lt;/span&gt; the Company had two and &lt;span style="COLOR:black"&gt;one&lt;/span&gt; key customers who are located in foreign countries which accounted for a total of 67% and &lt;span style="COLOR:black"&gt;50%,&lt;/span&gt; respectively, of gross accounts receivable. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;For the three months ended August 31, 2022 and 2021, the&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; Company had one &lt;span style="COLOR:black"&gt;k&lt;/span&gt;ey vendor which accounted for 9% &lt;span style="COLOR:black"&gt;and 17%&lt;/span&gt; of the purchases of raw materials, respectively. &lt;span style="COLOR:black"&gt;As of August 31, 2022 and May 31, 2022,&lt;/span&gt; the Company had one and two key vendors which accounted for 11% &lt;span style="COLOR:black"&gt;and 69%, respectively&lt;/span&gt;, of accounts payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CASH AND CASH EQUIVALENTS &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less &lt;span style="COLOR:black"&gt;than three months&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria,&#160;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of August 31, 2022 and May 31, 2022, the Company has established a reserve of approximately $383,000 and $153,000, respectively, for doubtful accounts. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PREPAID EXPENSES AND OTHER&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaid expenses and other, until either the inventory is physically received, or the insurance and other items are expensed.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;As of August 31, 2022 and May 31, 2022, the&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; prepaid expenses and other were approximately $239,000 and &lt;span style="COLOR:black"&gt;$320,000, respectively&lt;/span&gt;, composed of prepayments to insurance and various other suppliers. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INVENTORIES, NET &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Net inventories are approximately the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;August 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,732,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;723,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;763,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Finished products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;449,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;782,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,904,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Inventory reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(982,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.8pt"&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Net inventory &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,922,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,416,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2022, and May 31, 2022, inventory reserves were approximately $982,000 and $846,000, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment were approximately $20,000 and $28,000 for the three months ended &lt;span style="COLOR:black"&gt;August 31, 2022 and 2021, &lt;/span&gt;respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization expense was approximately $9,000 and $7,000 for the three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#x2019;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of August 31, 2022 and 2021, an impairment adjustment was made of $6,000 and $0, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#x2019;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and invested approximately $165,000 into the Polish distributor.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of August 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#x2019;s Cost Method Holding during the period ended August 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company expensed approximately $304,000 and $320,000 of stock-based compensation during the three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The following summary presents the options granted, exercised, expired, canceled and outstanding for the three months &lt;span style="COLOR:black"&gt;ended August 31, 2022:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Option Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,321,616 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.72 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.37 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(15,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;0.95 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(64,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.78 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding August 31, 2022&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,388,616 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.69 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;During the three months ended August 31, 2022, options to purchase 15,000 shares of common stock were exercised at prices ranging from $0.82 to $1.20. Total net proceeds to the Company were approximately $14,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;During the three months ended August 31, 2022, the Company granted 146,000 options to purchase common stock at an average purchase price of $3.37, with the majority of those options issued to the Company&#x2019;s new Chief Commercial Officer, who is managing the commercialization and roll-out of the InFoods IBS test. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company does not typically allow for returns from international customers except in the event of defective merchandise and therefore does not establish an allowance for returns. The Company does allow for a return merchandise allowance of approximately one percent of sales to certain domestic retailers. This allowance reduces revenue recognition by approximately one percent, and is included in sales discounts. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts during the three months ended August 31, 2022 and 2021, and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Services for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project progresses. &lt;span style="COLOR:black"&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;As of August 31, 2022, the Company had approximately $151,000 of advances from certain foreign customers. The majority of these advances are prepayments on orders that are expected to ship during our second quarter ended November 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Disaggregation of revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Three Months Ended August 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;886,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;213,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;79,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;183,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;257,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;95,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;40,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,637,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;See Note 4 for additional information regarding revenue concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;SHIPPING AND HANDLING FEES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company includes shipping and handling fees billed to customers in net sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;RESEARCH AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Research and development costs are expensed as incurred. The Company expensed approximately $361,000 and &lt;span style="COLOR:black"&gt;$382,000 &lt;/span&gt;of research and development costs during the &lt;span style="COLOR:black"&gt;three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has provided a full valuation allowance on deferred income tax assets of approximately $7,402,000 and $6,967,000 as of August 31, 2022 and May 31, 2022, respectively. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ADVERTISING COSTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company reports the cost of advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;span style="BACKGROUND:white"&gt;$18,000&lt;/span&gt; and $&lt;span style="BACKGROUND:white"&gt;8,000&lt;/span&gt; for the three months ended August 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;FOREIGN CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the three months ended August 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases.&#160; The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per &lt;span style="COLOR:black"&gt;share calculation at August 31, 2022 and 2021 was 2,388,616 and 2,081,116, respectively. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#xb7;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#x2019;s consolidated results of operations and financial position. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RECLASSIFICATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;ACCOUNTING ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <bmra:MarketsAndMethodsOfDistributionPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;MARKETS AND METHODS OF DISTRIBUTION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Due to the Coronavirus global pandemic, and the economic disruptions that have followed, the Company&#x2019;s operations have been negatively impacted.&lt;span style="COLOR:black"&gt; The Company has faced disruptions in certain of the following areas, and may face further challenges from supply chain disruptions, cost inflation, loss of contracts and/or customers, closure of the Company&#x2019;s manufacturing or distribution facilities or of the facilities of the Company&#x2019;s suppliers, partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities. These ongoing pandemic related disruptions have materially negatively impacted the Company&#x2019;s operations and financial performance and may continue to have significant material negative impacts on the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;</bmra:MarketsAndMethodsOfDistributionPolicyTextBlock>
    <bmra:LiquidityPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has incurred net losses and negative cash flows from operations and has an accumulated deficit of approximately $37.1 million as of August 31, 2022. Management expects to continue to incur significant costs as it advances its clinical trials and product development activities. As of August 31, 2022, the Company had cash and cash equivalents of approximately $6,075,000 and working capital of approximately $7,410,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;On July 21, 2020, the Company filed with the SEC a &#x201c;shelf&#x201d; registration statement on Form S-3. The registration statement registers common shares that may be issued by the Company in a maximum aggregate amount of up to $90,000,000.&#160; Shares of the Company&#x2019;s common stock may be sold from time to time under this registration statement for up to three years from the filing date. On January 22, 2021, the Company filed a prospectus supplement for the sale of up to $15,000,000 of shares of our common stock in an at-the-market offering (&#x201c;ATM Offering&#x201d;) under the shelf registration statement, of which approximately $9,600,000, remains available for sale under the prospectus supplement.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company intends to use the net proceeds from such offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The sales agent under the ATM Offering agrees to use commercially reasonable efforts to sell on the Company&#x2019;s behalf all of the shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and the Company. The Company has no obligation to sell any of the shares under the ATM Offering, and may at any time suspend offers under, or terminate the ATM Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the quarter ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company approximately of $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As a result of cash and cash equivalents on hand &lt;span style="COLOR:black"&gt;at August 31, 2022, &lt;/span&gt;and the ability to raise additional funds, including through the ATM Offering noted above,&lt;span style="COLOR:black"&gt; management&lt;/span&gt; believes the Company has sufficient funds to operate through at least November 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</bmra:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c30" decimals="-5" unitRef="usd">-37100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">6075000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bmra:WorkingCapital contextRef="c0" decimals="0" unitRef="usd">7410000</bmra:WorkingCapital>
    <bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue contextRef="c31" decimals="0" unitRef="usd">90000000</bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue>
    <bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue contextRef="c32" decimals="0" unitRef="usd">15000000</bmra:ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c32" decimals="0" unitRef="shares">9600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c33" decimals="0" unitRef="shares">523977</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c34" decimals="2" unitRef="usdPershares">3.15</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="c35" decimals="2" unitRef="usdPershares">3.55</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c33" decimals="0" unitRef="usd">1811000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c33" decimals="0" unitRef="usd">1764000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CONCENTRATION OF CREDIT RISK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. &lt;span style="COLOR:black"&gt;As of August 31, 2022,&lt;/span&gt; the Company had approximately $5,834,000 of uninsured cash. &lt;span style="COLOR:black"&gt;The Company does not believe it is exposed to any significant credit risks.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Consolidated net sales were approximately $1,637,000 for the &lt;span style="COLOR:black"&gt;three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021. &lt;/span&gt;For &lt;span style="COLOR:black"&gt;the three months ended August 31, 2022 and 2021,&lt;/span&gt; the Company had &lt;span style="COLOR:black"&gt;two&lt;/span&gt; key customers who are located in foreign countries which accounted &lt;span style="COLOR:black"&gt;for 64%&lt;/span&gt; and &lt;span style="COLOR:black"&gt;60%&lt;/span&gt; of net consolidated sales, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $1,315,000 and $927,000, respectively. On August 31, 2022&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; and &lt;span style="COLOR:black"&gt; May 31, 2022,&lt;/span&gt; the Company had two and &lt;span style="COLOR:black"&gt;one&lt;/span&gt; key customers who are located in foreign countries which accounted for a total of 67% and &lt;span style="COLOR:black"&gt;50%,&lt;/span&gt; respectively, of gross accounts receivable. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;For the three months ended August 31, 2022 and 2021, the&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; Company had one &lt;span style="COLOR:black"&gt;k&lt;/span&gt;ey vendor which accounted for 9% &lt;span style="COLOR:black"&gt;and 17%&lt;/span&gt; of the purchases of raw materials, respectively. &lt;span style="COLOR:black"&gt;As of August 31, 2022 and May 31, 2022,&lt;/span&gt; the Company had one and two key vendors which accounted for 11% &lt;span style="COLOR:black"&gt;and 69%, respectively&lt;/span&gt;, of accounts payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount contextRef="c2" decimals="0" unitRef="usd">5834000</us-gaap:CashUninsuredAmount>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">1637000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">1262000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c36" decimals="2" unitRef="pure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c37" decimals="2" unitRef="pure">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableGross contextRef="c2" decimals="0" unitRef="usd">1315000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c3" decimals="0" unitRef="usd">927000</us-gaap:AccountsReceivableGross>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c38" decimals="2" unitRef="pure">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c39" decimals="2" unitRef="pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c40" decimals="2" unitRef="pure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c41" decimals="2" unitRef="pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c42" decimals="2" unitRef="pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c43" decimals="2" unitRef="pure">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;CASH AND CASH EQUIVALENTS &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less &lt;span style="COLOR:black"&gt;than three months&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company extends unsecured credit to its customers on a regular basis. International accounts are usually required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria,&#160;initial credit levels for individual distributors are approved by designated officers and managers of the Company. All increases in credit limits are also approved by designated upper-level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;As of August 31, 2022 and May 31, 2022, the Company has established a reserve of approximately $383,000 and $153,000, respectively, for doubtful accounts. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="-3" unitRef="usd">383000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="-3" unitRef="usd">153000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <bmra:PrepaidsPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PREPAID EXPENSES AND OTHER&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company occasionally prepays for items such as inventory, insurance, and other items.&#160; These items are reported as prepaid expenses and other, until either the inventory is physically received, or the insurance and other items are expensed.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;As of August 31, 2022 and May 31, 2022, the&lt;/span&gt;&lt;span style="FONT-SIZE:10pt"&gt; prepaid expenses and other were approximately $239,000 and &lt;span style="COLOR:black"&gt;$320,000, respectively&lt;/span&gt;, composed of prepayments to insurance and various other suppliers. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</bmra:PrepaidsPolicyPolicyTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="0" unitRef="usd">239000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="0" unitRef="usd">320000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INVENTORIES, NET &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; BACKGROUND:white; COLOR:black"&gt;The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Net inventories are approximately the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;August 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,732,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;723,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;763,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Finished products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;449,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;782,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,904,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Inventory reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(982,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.8pt"&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Net inventory &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,922,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,416,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 12pt; font-family: 'Times New Roman',serif; text-align: justify; margin: 0in;"&gt;&lt;span style="font-size: 10pt; color: black;"&gt;Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory. As of August 31, 2022, and May 31, 2022, inventory reserves were approximately $982,000 and $846,000, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;August 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,732,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,717,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Work in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;723,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;763,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Finished products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;449,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;782,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,904,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:13.2pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.2pt"&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:97.9pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Inventory reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(982,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.2pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.2pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(846,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.8pt"&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:97.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Net inventory &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,922,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.8pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.8pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,416,000 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c2" decimals="-3" unitRef="usd">1732000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">1717000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c2" decimals="-3" unitRef="usd">723000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">763000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c2" decimals="-3" unitRef="usd">449000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c3" decimals="-3" unitRef="usd">782000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross contextRef="c2" decimals="-3" unitRef="usd">2904000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c3" decimals="-3" unitRef="usd">3262000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="-3" unitRef="usd">982000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="-3" unitRef="usd">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" unitRef="usd">1922000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" unitRef="usd">2416000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="-3" unitRef="usd">982000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="-3" unitRef="usd">846000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in; TEXT-INDENT:0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment were approximately $20,000 and $28,000 for the three months ended &lt;span style="COLOR:black"&gt;August 31, 2022 and 2021, &lt;/span&gt;respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c44">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c45">10 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">20000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="0" unitRef="usd">28000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (&#x201c;ASC&#x201d;), ASC 350 Intangibles &#x2013; Goodwill and Other (&#x201c;ASC 350&#x201d;). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization expense was approximately $9,000 and $7,000 for the three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset&#x2019;s balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. As of August 31, 2022 and 2021, an impairment adjustment was made of $6,000 and $0, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c46">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c47">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c48">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="0" unitRef="usd">6000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c4" decimals="0" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;From time-to-time, the Company makes investments in privately held companies. Investments represent the Company&#x2019;s investment in a Polish distributor, which is primarily engaged in distributing medical products and devices. The Company owns approximately 6% of the investee and invested approximately $165,000 into the Polish distributor.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN-LEFT:0in; MARGIN-RIGHT:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Equity holdings in nonmarketable unconsolidated entities in which the Company is not able to exercise significant influence ("Cost Method Holdings") are accounted for at the Company's initial cost, minus any impairment (if any), plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar holding or security of the same issuer. Dividends received are recorded as other income.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company assesses its equity holdings for impairment whenever events or changes in circumstances indicate that the carrying value of an equity holding may not be recoverable. Management reviewed the underlying net assets of the Company's equity method holding as of August 31, 2022 and determined that the Company's proportionate economic interest in the entity indicates that the equity holding was not impaired. There were no observable price changes in orderly transactions for identical or a similar holding or security of the Company&#x2019;s Cost Method Holding during the period ended August 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c49" decimals="2" unitRef="pure">0.06</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments contextRef="c49" decimals="0" unitRef="usd">165000</us-gaap:Investments>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company follows the guidance of ASC 718, Share-based Compensation (&#x201c;ASC 718&#x201d;), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes options-pricing model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate. The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. Expected volatilities are based on weighted averages of the historical volatility of the Company&#x2019;s common stock estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited exercise activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The grant date fair value of the award is recognized under the straight-line attribution method.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company expensed approximately $304,000 and $320,000 of stock-based compensation during the three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The following summary presents the options granted, exercised, expired, canceled and outstanding for the three months &lt;span style="COLOR:black"&gt;ended August 31, 2022:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Option Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,321,616 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.72 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.37 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(15,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;0.95 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(64,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.78 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding August 31, 2022&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,388,616 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.69 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;During the three months ended August 31, 2022, options to purchase 15,000 shares of common stock were exercised at prices ranging from $0.82 to $1.20. Total net proceeds to the Company were approximately $14,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;During the three months ended August 31, 2022, the Company granted 146,000 options to purchase common stock at an average purchase price of $3.37, with the majority of those options issued to the Company&#x2019;s new Chief Commercial Officer, who is managing the commercialization and roll-out of the InFoods IBS test. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" unitRef="usd">304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="-4" unitRef="usd">320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Option Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding May 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,321,616 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.72 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.37 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(15,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;0.95 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:138.25pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Cancelled or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;(64,000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.78 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:138.25pt; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Outstanding August 31, 2022&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2,388,616 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3.69 &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c55" decimals="INF" unitRef="shares">2321616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c55" decimals="INF" unitRef="usdPershares">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c50" decimals="INF" unitRef="shares">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c50" decimals="INF" unitRef="usdPershares">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c50" decimals="INF" unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c50" decimals="INF" unitRef="usdPershares">0.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c50" decimals="INF" unitRef="shares">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c50" decimals="INF" unitRef="usdPershares">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c56" decimals="INF" unitRef="shares">2388616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c56" decimals="INF" unitRef="usdPershares">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c50" decimals="0" unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c51" decimals="2" unitRef="usdPershares">0.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c52" decimals="2" unitRef="usdPershares">1.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c50" decimals="0" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c50" decimals="0" unitRef="shares">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c50" decimals="2" unitRef="usdPershares">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has various contracts with customers.&#160; All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company does not typically allow for returns from international customers except in the event of defective merchandise and therefore does not establish an allowance for returns. The Company does allow for a return merchandise allowance of approximately one percent of sales to certain domestic retailers. This allowance reduces revenue recognition by approximately one percent, and is included in sales discounts. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts during the three months ended August 31, 2022 and 2021, and does not believe that any additional discounts will be given through the end of the contract periods. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Services for contract work performed by the Company for others are invoiced and recognized as that work has been performed and as the project progresses. &lt;span style="COLOR:black"&gt;The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors.&#160; Physicians&#x2019; office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;As of August 31, 2022, the Company had approximately $151,000 of advances from certain foreign customers. The majority of these advances are prepayments on orders that are expected to ship during our second quarter ended November 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Disaggregation of revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The following is a breakdown of revenues according to markets to which the products are sold:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Three Months Ended August 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;886,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;213,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;79,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;183,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;257,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;95,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;40,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,637,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;See Note 4 for additional information regarding revenue concentrations.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ProceedsFromCustomers contextRef="c0" decimals="0" unitRef="usd">151000</us-gaap:ProceedsFromCustomers>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:30%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 30%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Three Months Ended August 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:14%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Clinical lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,146,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;886,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Over-the-counter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;213,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;79,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Physician's office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;183,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;257,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Contract manufacturing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;95,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;40,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:68%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 68%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,637,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c57" decimals="INF" unitRef="usd">1146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c58" decimals="INF" unitRef="usd">886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c59" decimals="INF" unitRef="usd">213000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c60" decimals="INF" unitRef="usd">79000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c61" decimals="INF" unitRef="usd">183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c62" decimals="INF" unitRef="usd">257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c63" decimals="INF" unitRef="usd">95000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c64" decimals="INF" unitRef="usd">40000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="INF" unitRef="usd">1637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c4" decimals="INF" unitRef="usd">1262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;SHIPPING AND HANDLING FEES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company includes shipping and handling fees billed to customers in net sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;RESEARCH AND DEVELOPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Research and development costs are expensed as incurred. The Company expensed approximately $361,000 and &lt;span style="COLOR:black"&gt;$382,000 &lt;/span&gt;of research and development costs during the &lt;span style="COLOR:black"&gt;three months ended August 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">361000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">382000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company has provided a full valuation allowance on deferred income tax assets of approximately $7,402,000 and $6,967,000 as of August 31, 2022 and May 31, 2022, respectively. &#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" unitRef="usd">7402000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">6967000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;ADVERTISING COSTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company reports the cost of advertising as expense in the period in which those costs are incurred. Advertising costs were approximately &lt;span style="BACKGROUND:white"&gt;$18,000&lt;/span&gt; and $&lt;span style="BACKGROUND:white"&gt;8,000&lt;/span&gt; for the three months ended August 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" unitRef="usd">18000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c4" decimals="0" unitRef="usd">8000</us-gaap:AdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;FOREIGN CURRENCY TRANSLATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the period, and revenues and costs are translated using average exchange rates for the period. The resulting translation adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no foreign currency transactions that are included in the consolidated statements of operations for the three months ended August 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RIGHT-OF-USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.&#160; Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term.&#160; Leases are classified as financing or operating which will drive the expense recognition pattern. The Company has elected to exclude short-term leases.&#160; The Company leases office space and copy machines, all of which are operating leases.&#160; Most leases include the option to renew and the exercise of the renewal options is at the Company&#x2019;s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise.&#160; The leases do not include the options to purchase the leased property.&#160; The depreciable life of assets and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amount of anti-dilutive stock options not included in the loss per &lt;span style="COLOR:black"&gt;share calculation at August 31, 2022 and 2021 was 2,388,616 and 2,081,116, respectively. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c53" decimals="0" unitRef="shares">2388616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c54" decimals="0" unitRef="shares">2081116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Recent ASU's issued by the FASB and guidance issued by the SEC did not, or are not believed by management to, have a material effect on the Company&#x2019;s present or future consolidated financial statements. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;In June 2016, the FASB issued ASU 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." This ASU will require the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The guidance was initially effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those fiscal years. In November 2019, the FASB issued ASU 201&#xb7;9- 10, "Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates," which, among other things, defers the effective date of ASU 2016-13 for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those years. Early adoption is permitted. The Company is currently reviewing the requirements of this ASU to determine its impact on the Company&#x2019;s consolidated results of operations and financial position. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.1in 0in 0in"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;RECLASSIFICATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. &lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 3:&#160; SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Stock option expense during the three months ended August 31, 2022 and 2021 was approximately $304,000 and $320,000, respectively.&lt;/span&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:12pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;During the three months ended August 31, 2022, the Company sold 523,977 shares of its common stock at prices ranging from $3.15 to $3.55 under its Form S-3 Registration Statement and ATM Offering which resulted in gross proceeds of approximately $1,811,000 and net proceeds to the Company of approximately $1,764,000 after deducting commissions for each sale and legal, accounting, and other fees related to the ATM Offering.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c50" decimals="0" unitRef="usd">304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c65" decimals="0" unitRef="usd">320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c66" decimals="0" unitRef="shares">523977</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="c67" decimals="2" unitRef="usdPershares">3.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="c68" decimals="2" unitRef="usdPershares">3.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c66" decimals="0" unitRef="usd">1811000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c66" decimals="0" unitRef="usd">1764000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bmra:GeographicInformationDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 4: &#160;GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company operates as one segment. Geographic information regarding net sales is approximately as follows: &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Three Months Ended August 31, &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Revenues from sales to unaffiliated customers:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"/&gt; &lt;/tr&gt;&lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Asia&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;814,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;675,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;552,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;471,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;268,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;105,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;South America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Middle East&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,637,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"&gt;&lt;span style="font-family: 'Times New Roman',serif; color: black;"&gt;As of August 31, 2022, and May 31, 2022, a&lt;/span&gt;&lt;span style="font-family: 'Times New Roman',serif;"&gt;pproximately $725,000 &lt;span style="color: black;"&gt;and $621,000 &lt;/span&gt;of Biomerica&#x2019;s gross inventory was located in Mexicali, Mexico, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; margin: 0in 2.7pt 0in 0in;"&gt;&lt;span style="font-family: 'Times New Roman',serif; color: black;"&gt;As of August 31, 2022, and May 31, 2022,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman',serif;"&gt; approximately $20,000 &lt;span style="color: black;"&gt;and $17,000 &lt;/span&gt;of Biomerica&#x2019;s property and equipment, net of accumulated depreciation and amortization, was located in Mexicali, Mexico, respectively.&lt;/span&gt;&lt;/p&gt;</bmra:GeographicInformationDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="5" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Three Months Ended August 31, &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td colspan="2" style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:center; MARGIN:0in; text-align: center;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Revenues from sales to unaffiliated customers:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"/&gt; &lt;/tr&gt;&lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Asia&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;814,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;675,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;552,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;471,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;268,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:10%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;105,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;South America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="HEIGHT:0.2in; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:0.2in"&gt; &lt;td style="HEIGHT:0.2in; WIDTH:74%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.3in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Middle East&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="-sec-ix-hidden: hidden-fact-8; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:0.2in; WIDTH:2%; BACKGROUND:#b8cce4; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:0.2in; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#b8cce4; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:15pt"&gt; &lt;td style="HEIGHT:15pt; WIDTH:74%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 74%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,637,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;&lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,262,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c71" decimals="-3" unitRef="usd">814000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c72" decimals="-3" unitRef="usd">675000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c73" decimals="-3" unitRef="usd">552000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c74" decimals="-3" unitRef="usd">471000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c75" decimals="-3" unitRef="usd">268000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c76" decimals="-3" unitRef="usd">105000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c77" decimals="-3" unitRef="usd">3000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c78" decimals="-3" unitRef="usd">3000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c80" decimals="-3" unitRef="usd">8000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">1637000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">1262000</us-gaap:Revenues>
    <us-gaap:InventoryGross contextRef="c69" decimals="0" unitRef="usd">725000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c70" decimals="0" unitRef="usd">621000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c69" decimals="0" unitRef="usd">20000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c70" decimals="0" unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 5: &#160;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"&gt;&lt;span style="FONT-SIZE:10pt"&gt;The Company leases its facilities. On August 31, 2022, the Company had approximately 22,000 square feet of floor space at its corporate headquarters at 17571 Von Karman Avenue in Irvine, California, which it has been leasing since 2009. The lease for its headquarters expired on August 31, 2016. &#160;The Company had an option to extend the term of its lease for two additional sixty-month periods. On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years.&#160; When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option. The current rent is approximately $26,000 per month. The security deposit is approximately $22,000.&lt;span style="COLOR:black"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In November 2016, the Company&#x2019;s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. The current rent is approximately $3,400 per month. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;In addition, the Company leases a small office in Lindau, Germany on a month-to-month basis, as headquarters for BioEurope GmbH, its Germany subsidiary.&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total gross rent expense in the United States for the three months ended August 31, 2022 and 2021 was approximately $78,000 and $78,000, respectively.&#160; Rent expense for the Mexico facility for the three months ended August 31, 2022 and 2021 was approximately $11,000 and $10,000, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 0.9pt 0in 0in"&gt;&lt;span style="FONT-SIZE:10pt"&gt;For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company&#x2019;s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability.&#160; Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Consolidated Statements of Operations and Comprehensive Loss when they are incurred. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Supplemental cash flow information related to leases for the three months &lt;span style="COLOR:black"&gt;ended August 31, 2022: &lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;86,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:25.5pt"&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Right-of-use assets obtained in exchange for &lt;/span&gt;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;&#160; new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.02 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.50%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The approximate maturity of lease &lt;span style="COLOR:black"&gt;liabilities as of August 31, 2022 are as&lt;/span&gt; follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;354,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1 to 2 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;364,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2 to 3 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;375,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3 to 4 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;387,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4 to 5 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,488,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;173,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,315,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company also has various insignificant leases for office equipment.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c81" decimals="0" unitRef="usd">26000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="0" unitRef="usd">22000</us-gaap:SecurityDeposit>
    <us-gaap:LeaseAndRentalExpense contextRef="c82" decimals="0" unitRef="usd">3400</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" unitRef="usd">78000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c4" decimals="0" unitRef="usd">78000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c83" decimals="0" unitRef="usd">11000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c84" decimals="0" unitRef="usd">10000</us-gaap:PaymentsForRent>
    <bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Operating cash flows from operating leases&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;86,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:25.5pt"&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Right-of-use assets obtained in exchange for &lt;/span&gt;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;&#160; new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:25.5pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt; &lt;p style="-sec-ix-hidden: hidden-fact-9; FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4.02 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;6.50%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="INF" unitRef="usd">86000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P4Y7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" unitRef="pure">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="WIDTH:550pt; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" width="733"&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;354,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1 to 2 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;364,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;2 to 3 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;375,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;3 to 4 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;387,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;4 to 5 years &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;8,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:12.75pt"&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:12.75pt; WIDTH:12%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,488,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:#b4c6e7; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#b4c6e7; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;173,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="HEIGHT:13.5pt"&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:84%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 84%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="HEIGHT:13.5pt; WIDTH:2%; BACKGROUND:white; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; MARGIN:0in; TEXT-INDENT:10pt"&gt;&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;&#160;$ &lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="BORDER-TOP:0px; HEIGHT:13.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:white; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%;"&gt; &lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:right; MARGIN:0in; text-align: right;"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;1,315,000 &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="INF" unitRef="usd">354000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="INF" unitRef="usd">364000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="INF" unitRef="usd">375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="INF" unitRef="usd">387000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="INF" unitRef="usd">8000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="INF" unitRef="usd">1488000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="INF" unitRef="usd">173000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="INF" unitRef="usd">1315000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif"&gt;NOTE 6: &#160;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:10pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;; MARGIN:0in 16.2pt 0in 0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;LITIGATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;There were no legal proceedings pending as of August 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"&gt;&lt;b&gt;&lt;span style="FONT-SIZE:10pt"&gt;NOTE 7:&#160; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE:12pt; FONT-FAMILY:&amp;quot;Times New Roman&amp;quot;,serif; TEXT-ALIGN:justify; MARGIN:0in"&gt;&lt;span style="FONT-SIZE:10pt; COLOR:black"&gt;On September 29, 2022, the Company announced that its Aware&#xae; Breast Self Exam device and EZ Detect Colon Disease test are being sold on Amazon and fulfilled by Amazon.&#160; &#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="c0"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c0"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfIntangibleAssetsCost
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <bmra:WriteOffOfIntangibleAssetsAccumulatedAmortization
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c79"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--05-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0000073290</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M,!Q)OF<LF[69$K;[9)TG85%;QCKA8#BCE,_H(J%QC"XSJ;^6=CC81XG,.J/
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M@_Y^R;G:G9@?J#:U)_\#4$L#!!0    ( (B!356!(!I OP8  #(:   8
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ML MX$/&I=C7(!C*O&]:;?:MRRR+K%H&J=.?4E@3$QSX=*U*'G8\#,34#!N5
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M>T9<64,T=:%SH[V!35JH89Q)#F]3\)/#\>W-Y.IF=C5!<#6[_3R=C![@9O8
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M60CIX^4A:GDCV4:?0SXQ*5FN+]<T65"N#.#]DC'Y>J,^4!]E#_\#4$L#!!0
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M7&R9_?N]>HKBS+CLX45[WY;X\>;^0HP.Q8OY%F?:E<KK3';%E<WZ0MI<Z!A
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M&86F!E'T)#H@HSG%Z,N0PI R6GE-[1)A13L@QI "*CG29T6WI0:AI$MA!>\
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MB1D<,*8->(Y.&=L;4K#^5';Z/U!+ P04    " "(@4U5+R':/UX@  !$6P
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MB/)896D&H*)>PANCQ@!HJ0^KQX^O5%RDZI/^BAS<?HY'!AWF!\I7'36 L:N
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M0PNRRE $&%)$/2F];1/KKBP0L?<04U%@*QENTV+\*HJGK[U4/'@6E%O<VY&
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M8C33Y@N6O<464RL)EKO1,2CS<K&1KSA#']>^+8BXS0(I(9.S3$&3WA1CH-A
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M@T@IA>@PT5M[53X7VRIP_H.5(J9*<S O?Z0[:?!S3H*#S'+>:)=V<,G <(&
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MQ>UX<#V^Q7/[#[L7JGRG$DR=#/84* AJ4+SBY@U++U^=PDG/G>M<,AW.@WY
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M.H5^@O,5UXF0NE%$_QYW!I:"0H\*.%WB\^W]"N(+.+P%[]Z<1^'D0W<7P+$
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MU604@&X;:KNPJO9-[%%9^G[>+.D?A-H%T'ZNE'U;N /ZO]KR'U!+ P04
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M+U4^4U=)OM1%$H6!&F511X6E>@(!Q7\3>.*3!KG+0&-,RR1.0&FH-_#&L"Y
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MJ#O6L-*",30L=$_^PA]&#?2%@>^\61KEGEYP# L]ZYYAM:5SWE.?1*:Z7!:
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M&HFN55AA6+I=C:6KR]D7!G5 F-QR 9;RD,Z%:-M(>/!G)M0AQA*%LT+,6+3
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MVXV/@_WVVF&_H-HE'(BD^9\HM.T_?=>\\EP+] H$,%B@&P@51Q]' TKI3-3
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M[WK0<T#4TZ1V%"]M!V^YTK_)FID>P"A,@#Y/.5='QR1H1WKX'U!+ P04
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M"RYP$I D/,D_ 8[^5.J7,^=>&YE75286KF5;IF,Z'7U1@=,H<1I'X.S27*R
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M!>+W%2'\=2!OD)\##O\%4$L#!!0    ( (B!3558"/!C  ,  %H*   9
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MB"IHR<7:NWO@F"FA=&1L0]AT7?#4OSS<]1;T2L-3<JFTR^TS^+_39OH!L+%
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M>TJ2),O""&!A!4F"(? TX@BF #1@2)*X]^#!^RC>O*?B[:];X]]02P,$%
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M PJ_/D3I-X/L&B"[MDLV#I/Q(IA/H@&*XE&RF+U?6J\#Y>N.7;II&."#-?1
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M0-<E?"JR8O_M9?_=Z.XG4$L#!!0    ( (B!355_/=]I1P$  -@0   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSDJZD1<
MS<;MQ!L@6'XB4$([&;W[(;C C\QB-J9G1=J&TW?UA'#\,DWF:]NYJNY==&^;
MSJ6J\K[_T-KEE6DSM[*]Z<:3P@YMYL?E4.H^RV]9:33'<:*'UQGJ='R=&5T>
MO?G/1%L4=6X^;?[=FL[_,5C_V.'F*F.\BB[94!J?*GUOYFVGIP>MQLDJ.E]3
M-9ROI'3H((8@#A^TAJ!U^* -!&W"!VTA:!L^*(&@)'S0#H)VX8/V$+0/'W2
MH$/X((I1QEA T@)K 5H3<DT"O"8$FP2(34@V"3";$&T2H#8AVR3 ;4*X28#<
MA'23 +L)\28!>C/JS0+T9M2;!>C-BX]M 7HSZLT"]&;4FP7HS:@W"]";46\6
MH#>CWOQ.O9U_-,;-/<\UWO].JOWXKIFOGY;/S04[$\X:?F2<?@%02P,$%
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MA'8MC%3VX,^Z/S6S3U!+ 0(4 Q0    ( (B!354'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " "(@4U5NZ<:DYX%  #6%@  &
M    @('I&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MB(%-5;A[+G!$!@  ]"8  !@              ("!O1X  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (B!354BC[-B;@<  $,@   8
M          " @3<E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "(@4U5LLT4/Q@(   V$P  &               @(';+   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ B(%-52\AVC]>(   1%L
M !@              ("!*34  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( (B!357I]FR(00,   8'   8              " @;U5  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "(@4U5B8=MK@,#
M  #A!@  &0              @($T60  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( (B!3552+/%'B0<  )P2   9              "
M@6Y<  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ B(%-
M56DG4:^@ @  Q@4  !D              ("!+F0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "(@4U5"^6_3(,"  !U!0  &0
M        @($%9P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( (B!357AO2TCJ2(  #QK   9              " @;]I  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ B(%-5?ONTSC< P  " D
M !D              ("!GXP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "(@4U5T3R=,+<"  #>!0  &0              @(&RD
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (B!356'3Y]5
M+@,  ','   9              " @:"3  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ B(%-52_8M%? #P  2J0  !D
M ("!!9<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "(
M@4U52_,G7M4"   N"   &0              @('\I@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (B!356<$KT)/0,  ,,*   9
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M970R-"YX;6Q02P$"% ,4    " "(@4U56L5&'YT#  ";$@  &0
M    @('5O   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M (B!355J>9Y<T (   H'   9              " @:G   !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ B(%-56VK5R^P @  G@<  !D
M             ("!L,,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "(@4U5_RWR\S #  #J$@  #0              @ &7Q@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (B!3567BKL<P    !,"   +
M      "  ?+)  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (B!355G$,GS"P,
M +L2   /              "  =O*  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "(@4U5?SW?:4<!  #8$   &@              @ $3S@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "(@4U5VG)9V'@!  "Q
M$0  $P              @ &2SP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    (P C &P)   [T0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>201</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATION</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/LEASES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/InventoriesTable</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/OptionsActivityTable</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - SHAREHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/LEASESTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - LEASES (Details) - Supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>LEASES (Details) - Supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/LEASESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bmra-20220831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - LEASES (Details) - The maturity of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable</Role>
      <ShortName>LEASES (Details) - The maturity of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biomerica.com/role/LEASESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bmra-20220831.htm">bmra-20220831.htm</File>
    <File>bmra-20220831.xsd</File>
    <File>bmra-20220831_cal.xml</File>
    <File>bmra-20220831_def.xml</File>
    <File>bmra-20220831_lab.xml</File>
    <File>bmra-20220831_pre.xml</File>
    <File>exhibit31_1.htm</File>
    <File>exhibit31_2.htm</File>
    <File>exhibit32_1.htm</File>
    <File>exhibit32_2.htm</File>
    <File>exhibit3_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="373">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bmra-20220831.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 85,
   "dts": {
    "calculationLink": {
     "local": [
      "bmra-20220831_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmra-20220831_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bmra-20220831.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bmra-20220831_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmra-20220831_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bmra-20220831.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 312,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://www.biomerica.com/20220831": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 15
   },
   "keyCustom": 11,
   "keyStandard": 190,
   "memberCustom": 11,
   "memberStandard": 22,
   "nsprefix": "bmra",
   "nsuri": "http://www.biomerica.com/20220831",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.biomerica.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:GeographicInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - GEOGRAPHIC INFORMATION",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATION",
     "shortName": "GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:GeographicInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - LEASES",
     "role": "http://www.biomerica.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.biomerica.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.biomerica.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - GEOGRAPHIC INFORMATION (Tables)",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables",
     "shortName": "GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - LEASES (Tables)",
     "role": "http://www.biomerica.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "bmra:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories",
     "role": "http://www.biomerica.com/role/InventoriesTable",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "role": "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c55",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity",
     "role": "http://www.biomerica.com/role/OptionsActivityTable",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c55",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers",
     "role": "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - SHAREHOLDERS' EQUITY (Details)",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c66",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - GEOGRAPHIC INFORMATION (Details)",
     "role": "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
     "shortName": "GEOGRAPHIC INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales",
     "role": "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
     "shortName": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c71",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - LEASES (Details)",
     "role": "http://www.biomerica.com/role/LEASESDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - LEASES (Details) - Supplemental cash flow information related to leases",
     "role": "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "LEASES (Details) - Supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bmra:ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - LEASES (Details) - The maturity of lease liabilities",
     "role": "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable",
     "shortName": "LEASES (Details) - The maturity of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)",
     "role": "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "role": "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)",
     "role": "http://www.biomerica.com/role/ShareholdersEquityType2or3",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.biomerica.com/role/ConsolidatedCashFlow",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.biomerica.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - SHAREHOLDERS' EQUITY",
     "role": "http://www.biomerica.com/role/SHAREHOLDERSEQUITY",
     "shortName": "SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bmra-20220831.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "bmra_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATMAgreement Member",
        "terseLabel": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_AccumulatedAmortizationRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from operating lease",
        "label": "Accumulated amortization, Right of Use Assets"
       }
      }
     },
     "localname": "AccumulatedAmortizationRightOfUseAssets",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_BuildingInIrvineCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building In Irvine California Member",
        "terseLabel": "Building In Irvine California [Member]"
       }
      }
     },
     "localname": "BuildingInIrvineCaliforniaMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_CashPaidDuringThePeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Cash Paid During The Period For Abstract",
        "terseLabel": "Cash paid during the period for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodForAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ClinicalLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Lab Member",
        "terseLabel": "Clinical Lab [Member]"
       }
      }
     },
     "localname": "ClinicalLabMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Manufacturing Member",
        "terseLabel": "Contract Manufacturing [Member]"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_ForeignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Member",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Table]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsGeographicinformationregardingnetsalesTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) [Line Items]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GEOGRAPHICINFORMATIONDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION (Details) [Table]"
       }
      }
     },
     "localname": "GEOGRAPHICINFORMATIONDetailsTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_GeographicInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Information Disclosure Abstract"
       }
      }
     },
     "localname": "GeographicInformationDisclosureAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_GeographicInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments according to the geographic areas.",
        "label": "Geographic Information Disclosure Text Block",
        "terseLabel": "Geographic Information Disclosure [Text Block]"
       }
      }
     },
     "localname": "GeographicInformationDisclosureTextBlock",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_GeographicInformationRegardingNetSalesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Information Regarding Net Sales Abstract"
       }
      }
     },
     "localname": "GeographicInformationRegardingNetSalesAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in LeaseLiability",
        "label": "Reduction in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_InventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Abstract"
       }
      }
     },
     "localname": "InventoriesAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_LEASESDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES (Details) [Line Items]"
       }
      }
     },
     "localname": "LEASESDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_LEASESDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES (Details) [Table]"
       }
      }
     },
     "localname": "LEASESDetailsTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity position during the period.",
        "label": "Liquidity Policy Text Block",
        "terseLabel": "Liquidity Policy [Text Block]"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_MarketsAndMethodsOfDistributionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Markets And Methods Of Distribution during the period.",
        "label": "Markets And Methods Of Distribution Policy Text Block",
        "terseLabel": "Markets And Methods of Distribution Policy [Text Block]"
       }
      }
     },
     "localname": "MarketsAndMethodsOfDistributionPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_OneVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Vendor Member",
        "terseLabel": "One Vendor [Member]"
       }
      }
     },
     "localname": "OneVendorMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_OptionsActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Activity Abstract"
       }
      }
     },
     "localname": "OptionsActivityAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_OverthecounterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overthecounter Member",
        "terseLabel": "Over-the-counter [Member]"
       }
      }
     },
     "localname": "OverthecounterMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PhysiciansOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Physicians Office Member",
        "terseLabel": "Physicians Office [Member]"
       }
      }
     },
     "localname": "PhysiciansOfficeMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PolishDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Polish Distributor Member",
        "terseLabel": "Polish Distributor [Member]"
       }
      }
     },
     "localname": "PolishDistributorMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PrepaidsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for prepaids.",
        "label": "Prepaids Policy Policy Text Block",
        "terseLabel": "Prepaids Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PrepaidsPolicyPolicyTextBlock",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_PropertySubjectToOrAvailableForOperatingLease_Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PropertySubjectToOrAvailableForOperatingLease_ [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLease_Domain",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_PurchasedTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased Technology Rights Member",
        "terseLabel": "Purchased Technology Rights [Member]"
       }
      }
     },
     "localname": "PurchasedTechnologyRightsMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_RevenueFromContractsWithCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contracts With Customers Abstract"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomersAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_RevenuesFromSalesToUnaffiliatedCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues From Sales To Unaffiliated Customers Abstract",
        "terseLabel": "Revenues from sales to unaffiliated customers:"
       }
      }
     },
     "localname": "RevenuesFromSalesToUnaffiliatedCustomersAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) [Line Items]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SHAREHOLDERSEQUITYDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (Details) [Table]"
       }
      }
     },
     "localname": "SHAREHOLDERSEQUITYDetailsTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]"
       }
      }
     },
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Line Items]"
       }
      }
     },
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityLineItems",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) - Options Activity [Table]"
       }
      }
     },
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsOptionsActivityTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]"
       }
      }
     },
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsTable",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bmra_ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lease for the periods.",
        "label": "Schedule Of Cash Flow Supplemental Disclosures Related To Lease Table Text Block",
        "terseLabel": "Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresRelatedToLeaseTableTextBlock",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bmra_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related with Maximum Authorized Common Stock Issuance of Shelf Registration Statement.",
        "label": "Shelf Registration Statement Maximum Authorized Common Stock Issuance Value",
        "terseLabel": "Shelf Registration Statement Maximum Authorized Common Stock Issuance Value"
       }
      }
     },
     "localname": "ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_SupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related To Leases Abstract"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_TheMaturityOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Maturity Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "TheMaturityOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.biomerica.com/20220831",
     "xbrltype": "stringItemType"
    },
    "bmra_TwoVendorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Vendors Member",
        "terseLabel": "Two Vendors [Member]"
       }
      }
     },
     "localname": "TwoVendorsMember",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bmra_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital.",
        "label": "Working Capital",
        "terseLabel": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets, accumulated amortization in non cash investing or financing activities.",
        "label": "Write off of intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bmra_WriteOffOfIntangibleAssetsCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of intangible assets, cost in noncash investing or financing activities.",
        "label": "Write off of intangible assets, cost"
       }
      }
     },
     "localname": "WriteOffOfIntangibleAssetsCost",
     "nsuri": "http://www.biomerica.com/20220831",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "MEXICO"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biomerica.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia [Member]"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r226",
      "r256",
      "r257",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r411",
      "r413",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r226",
      "r256",
      "r257",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r411",
      "r413",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r226",
      "r254",
      "r256",
      "r257",
      "r286",
      "r287",
      "r288",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r411",
      "r413",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r202",
      "r208",
      "r209",
      "r210",
      "r211",
      "r224",
      "r226",
      "r254",
      "r256",
      "r257",
      "r286",
      "r287",
      "r288",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r411",
      "r413",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r244",
      "r247",
      "r412",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/LEASESDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SouthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "South America [Member]",
        "terseLabel": "South America [Member]"
       }
      }
     },
     "localname": "SouthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r244",
      "r247",
      "r412",
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/LEASESDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r16",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Accounts Receivable, before Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, less allowance for doubtful accounts of $383,106 and $153,231 as of August 31, 2022 and May 31, 2022, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r10",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r41",
      "r42",
      "r43",
      "r398",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r43",
      "r50",
      "r51",
      "r52",
      "r88",
      "r89",
      "r90",
      "r317",
      "r352",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r292",
      "r293",
      "r294",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Cost [Policy Text Block]"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock option expense",
        "verboseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r23",
      "r160",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for doubtful accounts",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r187",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r73",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r85",
      "r136",
      "r141",
      "r147",
      "r166",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r314",
      "r318",
      "r327",
      "r356",
      "r358",
      "r387",
      "r397"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r85",
      "r166",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r314",
      "r318",
      "r327",
      "r356",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Accounting [Text Block]"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r75"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r75",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r330"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r389",
      "r402"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Notes 5 and 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r212",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in Shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in Shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in Shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in Shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.08 par value, 25,000,000 shares authorized, 13,406,901 and 12,867,924 issued and outstanding at August 31, 2022 and May 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r392",
      "r405"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r153",
      "r324",
      "r325",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r153",
      "r324",
      "r325",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r153",
      "r324",
      "r325",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r116",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r120",
      "r121",
      "r153",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r153",
      "r324",
      "r325",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r241",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Advance from customers"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service Benchmark [Member]",
        "terseLabel": "Cost of Goods and Service Benchmark [Member]"
       }
      }
     },
     "localname": "CostOfGoodsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r60",
      "r85",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r327"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk [Member]"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r119",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred Tax Assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r73",
      "r198"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r73",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation, Depletion and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution Rights [Member]"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r101",
      "r103",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r322",
      "r323",
      "r393",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net loss per common share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r103",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r322",
      "r323",
      "r393",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net loss per common share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes in cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r113",
      "r167",
      "r238",
      "r239",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r321",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r352",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r11",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization, Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r193",
      "r195",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r188",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r59",
      "r85",
      "r136",
      "r140",
      "r143",
      "r146",
      "r148",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r327"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross loss"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r136",
      "r140",
      "r143",
      "r146",
      "r148",
      "r386",
      "r390",
      "r394",
      "r408"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r99",
      "r100",
      "r134",
      "r302",
      "r310",
      "r311",
      "r409"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r69",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r72",
      "r368"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Advance from customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r186",
      "r191"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net of accumulated amortization of $21,271 and $18,994 as of August 31, 2022 and May 31, 2022, respectively"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r174"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, Gross",
        "totalLabel": "Total gross inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails",
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r30",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net of inventory reserves of $981,814 and $845,549 as of August 31, 2022 and May 31, 2022, respectively",
        "totalLabel": "Net inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r28",
      "r81",
      "r112",
      "r170",
      "r171",
      "r175",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r174"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r30",
      "r173"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory reserves",
        "negatedLabel": "Inventory reserves",
        "terseLabel": "Inventory Valuation Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.biomerica.com/role/InventoriesTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r174"
     ],
     "calculation": {
      "http://www.biomerica.com/role/InventoriesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/InventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Dividend and interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "1 to 2 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "4 to 5 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "3 to 4 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2 to 3 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Less than 1 year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r85",
      "r142",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r315",
      "r318",
      "r319",
      "r327",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r85",
      "r166",
      "r327",
      "r358",
      "r388",
      "r400"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r85",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r315",
      "r318",
      "r319",
      "r327",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MiddleEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Middle East.",
        "label": "Middle East [Member]",
        "terseLabel": "Middle East [Member]"
       }
      }
     },
     "localname": "MiddleEastMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r44",
      "r46",
      "r52",
      "r55",
      "r74",
      "r85",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r104",
      "r136",
      "r140",
      "r143",
      "r146",
      "r148",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r323",
      "r327",
      "r391",
      "r404"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r140",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ThematurityofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r343",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets, net of accumulated amortization of $791,859 and $724,802 as of August 31, 2022 and May 31, 2022, respectively"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r328",
      "r329",
      "r331"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Payments for Rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Costs from sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Expenditures related to intangibles"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid Expense and Other Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCustomers": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.",
        "label": "Proceeds from Customers",
        "terseLabel": "Proceeds from Customers"
       }
      }
     },
     "localname": "ProceedsFromCustomers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Gross proceeds from sale of common stock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r291"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options",
        "terseLabel": "Proceeds from Stock Options Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyAvailableForOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property available for operating lease.",
        "label": "Property Available for Operating Lease [Member]",
        "terseLabel": "Property Available for Operating Lease [Member]"
       }
      }
     },
     "localname": "PropertyAvailableForOperatingLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r200",
      "r358",
      "r395",
      "r401"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net of accumulated depreciation and amortization of $1,325,561 and $1,305,360 as of August 31, 2022 and May 31, 2022, respectively",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r58",
      "r169"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for allowance on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r255",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r255",
      "r353",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r255",
      "r353",
      "r355",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r299",
      "r370",
      "r437"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r239",
      "r358",
      "r399",
      "r417",
      "r419"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r167",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r321",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r139",
      "r144",
      "r145",
      "r149",
      "r150",
      "r153",
      "r243",
      "r244",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/GEOGRAPHICINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r53",
      "r85",
      "r127",
      "r128",
      "r139",
      "r144",
      "r145",
      "r149",
      "r150",
      "r153",
      "r166",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r327",
      "r394"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Net sales",
        "terseLabel": "Net Sales",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement",
      "http://www.biomerica.com/role/GeographicinformationregardingnetsalesTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r346",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r120",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r262",
      "r277",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r203",
      "r204",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Option Cancelled or expired, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Option Cancelled or expired, Exercise Price Weighted Average"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Option Granted, Shares",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Shares",
        "periodStartLabel": "Options Outstanding, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Option Outstanding, Exercise Price Weighted Average",
        "periodStartLabel": "Option Outstanding, Exercise Price Weighted Average"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Option Exercised, Exercise Price Weighted Average",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Option Granted, Exercise Price Weighted Average",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r261",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balances (in Shares)",
        "periodStartLabel": "Balances (in Shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r201",
      "r203",
      "r204",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/RevenuefromcontractswithcustomersTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r50",
      "r51",
      "r52",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r113",
      "r167",
      "r238",
      "r239",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r321",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r352",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r113",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from ATM (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r238",
      "r239",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Option Exercised, Shares",
        "terseLabel": "Exercise of stock options (in Shares)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/OptionsActivityTable",
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Net proceeds from ATM"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock option expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r85",
      "r162",
      "r166",
      "r327",
      "r358"
     ],
     "calculation": {
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet",
      "http://www.biomerica.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SHAREHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of common and common equivalent shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r101",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biomerica.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r441": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r442": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r443": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001513162-22-000122-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001513162-22-000122-xbrl.zip
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M]\"2(?927!Y4V&(/^CH[6$27BVUWI2>*VN<+KCL\DC"$U95N2RZ?D\KE'?7
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M.)#?-PXH15DJE9=O9T^$/Y1*H:G9+HO>K[8_M@D"I"H&L"4^;^/S9E-%J,0
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M;KJ)<=:XPDREY;#"(ZI%25;RHB97U(0(4#DI4-E;*#D&J)1P.U)YMGQ6H(I
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M4<]0$9[AR8I*5=<-K$I139("3VE.>=>C:N@9PR(U=6AXJBE$?!>1L.,9] *
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M^W0\-IYD#F7\),B,7XM S?4/Q=T)TJ4A9K)#D/.G*R!N)<2ED5*IB?. M-=
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MO7DLLF&I7;]ER/(A!X'>*&L&Q85/MN/8KRP^"5_BA7^F\1.L@SXFM6!,?!"
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M;7#?G1>J U+<C3"'$Q!W+ETYS?"LTN("RF*U\P!L.S"&7E3#9%6'X0:6Z!:
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M, =PCX;]L8MM49@OQ;>T\D8%[$9_3#/G&W#7F;U+/W<;;L.".65>P=P:,I#
M0NUWOM$:AERLPH3%3'[08CE_>>I\%*&MS;H#+;:+E%QEL56W.+.PMTJZS6:1
M4Q;W%)N35,9J=;9]A'4RIZ&SR7JX1K$E"*+QU0P;Q9^]/;AA_9-27M,>; 0J
M8<.L\Z+O)]00;#1_KS>[K7:CWI%(L]X]^_QR;L-:!V5UQ]B5K!68?C%X,!'Q
MOQ4=8Z-F((;+:<3,"\Z#P$-)>#X!C^[XH%/>%@J#\.Q8*!61\\FPPK/C$%MQ
M6>";'E +GL86B5T.>CKT#,?U,H8E^;]A@[P!/P/F(UITN/O!H:II_,GVCK.Q
M304&^:%FH3'X8M#7Z-A9+Q*^"?._(^"/R1ENT3/!%N0+(M_P&UA(H>G)#G!C
MW2?\@UVHUN>M^GHC2^.Y(78RF.M'*+6^BHH'AHO'@KAA!]S@B(HGC%;"%6/(
M$AOAN1E^+4"/'87"SU4+3O/P6\Z\AAT!#<L+C]YP@^:\/*2$V0V6V8B>/\9,
M>AHY)BPXD<UV^.$D.C^USWXQ7&;I\1/B_(-)>:T"BXQ>DNJ3WP@M<C2=H9OA
M$2OCT *"I<9J[SX>( 83,'G[&->?SJO*AA@>J<&=!LT&"?^3NPTA%=C*,[H^
M^VL:Y&RTD =[QAO5(P>2L.1,GZKZU/EOK-,C'SZH"QBP%_91BWQU<EC,:A6_
MEP.O5ROR=+7G*(GV'.EOS[%K3M^UD;!A$5IN=2_<E;H_%]=(6.06[X:VFPMH
MDWJA+F5Z<\9AG3H:["JAJ!B1[2@&H!0S!-@MPVU8/Y9;73^VS)GI:'VJC[#M
M6\AM?MJ#B774N=F2J_-QN1H3=1[#%(V:YA"[=5G/S#_'OUW4L_[?_N+\T;CM
M?K\J%+C%VFK?UML9,%/OJX^=^A462*A#E\8&83!F=*__]:*4R^$B>T[PFN_U
MQK?OW2LY=ZFP$,T73Y][Z3/A ZJ4+BOXUV/U]K;1_):Y:76[K0>N4X+/NJW'
MZ0_NZW?=Z4_:[-'L(V:"9Y "] H,CU=''<)X7QA??KUXLCTP_7!@GSS]&D<'
M<T?!8A7X_DA]\K#W#M\^DW<C]R_[[\0;^%SD[/_,<P;\V_V9@2SK]BNR'I%!
M\-C6XXVG[S^:?X #F4</7*DKP@8WES;[: VUA8&S,'@X?S<F0RI8RI6<ILQ=
MG!WR':>SDD@R1V$]()9@_'0P?C0V_I[KX1]G)_@;6;U?GLJ:1O/'P.3=+,=F
MA5OMZ(ZX;=%E'S1<@2\)(^=?UR;A>Q39+0T5SN<K06%O9(R !#.E%F,$O[P.
ML?=6P13:H2 =#X%P@.?2ZOF'T"QM"5'*+>@(E"SQFF:-XPK8/$4M"".0)Y7(
MLTWUX9;((R_HN[8W ^J\C"4\D!,3%4/'?G:HNYF]=%3;*'#_5^*"P(#C6Q_(
M;@V+'2WAQ@6!DK*@:OIXO+JY/HW#K2D9IA"JA"C6C82J&%.H1&!B9[KVSK#X
M'I;_O[TO;6[<2!+]/K\"K\=>=^^2-&]*\DQ'L"6JFVM=%M7V>%Z\F "!(@DW
M"- X)-&__F5F5>$@"=X'2,$15DLD4$?>F965*5,3Y@FP-2-X26Y$.D)XJ77)
MMA0O30&XWZXLW8J!(GGTLVWKR\K2:C4A 3B+CNR/%=,G^$X;WIGH2Y'HVXH9
MN8[H:YPM&1C.PC/KU6.)W/H/\G6/+T9SA%'DS+$]O#&VH )X.7=>3&B6DX6&
MCL@8S'@YW;R\%>MB 2]7DKO.9!&IG?%3@!UY R8+265^V8&2^(Y2;K[?O1'T
MJ[QXMM@;.T_PQCZD*Q!URNR7";M,V+U-8;<5*W$%87=6K2\G[.;8BV?)]N+9
MB8:>YM9/F$!X]&;;>*J2PO(\?+908B:Q:[E0K@''8CDY<_U+'D<C(5?"SG<[
M0@@7J@?%R#'ZVJN@;O=6([#NO+3*\_(B9SN!IF8*R!1$I2:"9T<KBU(5E\ND
M42:-MF+6S95&Y5RU--N4FRF-R)R#'WAG.NEN^]P*2]NJ-S'WLF#\.O["RYS;
MOEZ_9F>,RJS.&,O=8X^U5NS!)WG7^ N8@Y,[?=!3AX8YOE!^F(#G#Y+.HT *
MJC?Q6^L7!,8);R4Z#6%.%.\@NH:'I1,AFC-(0S9:U"@HG>/HO'".Q3"+4H7'
M/!N^T'UXAK_@1>MKPI<,%C@,^M9/UE^B2IMV4-XIVM* EC,]9D&9658Q-Z.N
MHC$5M]VP3N(!@U,[+GZ]3==RU7[B:TJ3U!<OK*S9;:)26;F8M3UBCC=^,'$&
M2\=^9B.L/[9F,<-EQTMI<<.'Q_N'UN/3[U3=&IOH/=RV[IZHSN&;+W.X9K^%
MRJQ^"QL285CQ>F7J35WA7R ZL0N2TTQN@?2FZY'Z4STJ35=0J.2L;GB^(W0N
M5K.A,GNBO=$?J(>'U*.(EXO%48!=#0^5)_;O><3:M4$[) -+;%$I65'[SF&B
ME!TUC<*%J6)\S(^BHG<PR&\#1C?:$M=MFSK*<H^Z3Z$RQN*T+X;+L&^3K&O+
M^U!0'Q8L-8B5_*CUD:;Y0Y]_J+,1V Z&**3G8%D_QP,K@%=O),MB2/V8>HX]
MY(7W1#\$KM7[L$-LF**8MHMEC^DQJA4HER? A'T.:642G @(Z@'%-Q !"H#!
M'AZ\O[AXNGUW!1+JHEBHI4!KK=F"H5)++N>]LF1((8-?18F8*'R2BJFV)=K'
MU+0+R3BT?7V789\/TWAF0=\RR3,JU9P&4E:M/A:P)/*>9P!4JTMK[)9<P5=:
MP W._^YC;5+S($?,G;&VX8REHC)FJN-.3IP3!5\1'J[GJ.B8YTW#8J)R:T&Y
MP6YN VQ[-B42!0:B$,?^9[RR; +\>TQ^26"7E?ZQ_JS\PL09"\I\A(L*I%CQ
M,T&$KNQJ%-<O9AY=*_P.'A/\ EAI1I8\)[0PNZ;Y$BY']6!+/IN]Y)[$9Z07
MK<(;',[I\CZC0C_\ G\*[;":/W-0,36CL]\AE,B:[50J]15='\S"QY9Q0#AM
MRT,!VC49+^*_IO.S_(@I=7_:=T_-N\_M3S<MI=GIM)XZF>>#E+5FEY+*K"XE
M&].@]'W6(M]4%(&?2)"4:Q?&C*SNK7C8C@\;C8-](RN+4_0=_J8RY[9I]\?B
M(Q*\6+(\L/Q)RW,LB1:G09WM$'E*!SM-JH[N*I>V'M:%?_]??S\KEXL_-3N7
M]%OIIP\Y8(E+I5(K*N&2706_+95^4B0V:&IJ!Q(= U^3XV#C7MY.UV%]F!EC
MC9,@H*^IDZ4!^J>'_7!9W [$W5FV%[%CNCYWO3SF"I<1C1'TJ"S>"K/'74-P
M_GC/20=T'#S?PVZ4\ $\8?04]DPF$G=XK+[HA6LXX)%A4TZ-/L Z]QX3/8$#
M<VB(B)"UY UR$X^@2:Q*W'1_T_K/3?ON9]0A6&UZN_)CS4XDE;-=R(_*^O(C
MC4UDI^4',D&742N(@#GF>PJA#Q"Q]7/$7W@*\:HQM 'G^3CUF/V:=YEVH?L.
MNBV3-L(U,3.Z-I-@ETY/CX'/<S;E9I$/1$R,,I&1]!)1"]X'&ZE#RL>YBVUL
M>['%.8L=^0Y($A2\$9D-8 Z62CV<YBWW;,O++<]=+E<A!:4YRV-[4=U]N671
M^;&8=IQ#YQP"'< ?6W>M"87'YCABR>Y6S,\Z KVS50U37;,%4656"Z)UM<.^
M&B*O=+LWTE (U0/%@'D 34.AKW9Y4Q@>OL$6D5/JI#M69(\A%+DO Q8T@XQ%
M=:*A(;(*&S\%S<:Y@C$\;"R.,7<<B.))@"BTF,1J4$@.'-OO#]#@_8-10QX?
MS"TW,&-]#/W#:^Y Z9GVB^BN([?H4V<_;!@$N^+-S?FNR>(#719T2XKNPQ&"
M#08([<.$L_((Q\'2(^8D[^K#HU<JMA72*5JV._F(<&X'\U_R]CO)LB8A_V6W
M<G'%-2X\#S]T^.C 4F[-'BK5XAH=_3@M;]#2;^8 J8S[3%K4=[^V.D]X[MUY
MZY&?ZII-5*JEI?J;S*>Q:&^_1=28/LU[3>>Q,%7>L_/X+S_LE9IJJ'X3S?WX
MUEQ>(M5XYF;U@)DZ=4!5+>ISUHX\Z&#TWR6%%@X8:-QP2!Q151!FH"P#+\EV
M<IA;J@VH@;,#8MLQ8$)F]=4^[R@7.E2@I8>,FOK%>]WI[-G0V(3NM5^L2>=@
MOEXYCRJ6\DJ*!4_,O/$M.:\A:.Y?+.:X V/TP!S,@(0-!;HF7XXH&_#)P ^J
M3VF;[Z41PX'(>']9\8>^DN<3W]UJ:C."[#D9]O7:;(T.%IQ-FYC&_%O7GVOF
MK%9GY:RN*LTJ2TNS?429(JGIXH/@HM(J0H[SH8)'S !!DF% BSP^0XFJO@5;
MHMN0=)3,9!]/>) +H:A,!(%$(5U\D>).P,:8,>.&Z((7>Z9/:;7OWUUBP@P7
M LH7L81W'V8$OM68J/P!IX=E4/-0U\LIX _XD^:_\M[HX4<?<LK(]"D@S!^3
M86$0P;[I!3D'=A=3/FGI(%0U%@T?8^:O@TW:'-5R.9NZ@9//&[*BB,6%PEZ'
MAJDZ$J3XH<LTWXFTPG1!6 "L7)\Y!>7*P+P)2\<%:0PC/U/YQKPOMDC:6?5P
M<\L<N&9:9[4R+VM\$>.EP#A(\,31(V83/#1Q3 %^JL70>U[K9$)3'6>,="0R
MQI&F)V:D#KC(=]U(5,",]^+E#7T9[^P*#CF2,[Z*:>DB3""(,^0Q,8N(,,O)
MU$2G.M+(.%A^.!HFBF"PP;9P?[!,RQZ"'X/I>\")9.M0U@H*F'$ "#<<:F+3
MZ*/CIL.SFB<>"&!TL+0>/Z_.RY/6VPR1INCPA@C>BUZ[,V.!QZ?<CZM+[EG6
M)7>YC:6Y2^[^>&#;FG/-[/-J=<783V< ]L,G/+!"V<1 P-&IQDBDF+4M)$:P
M,S!Y483"EXT*K3%T*N-%[SYVOC0?@>N:G=85&,2W#ZV[3O.I?7]WA/$B?O[_
MGR_FMU*C7BY5SDJ[2 &HKID979V5&;T]@@W"6QL1?0KLRSG'/KPM-#_UZ?O@
MB-%Y3(^R>1JELYQ"F\_SY*#H]F,)//!DF C$73?,FS$<<9Z$)]K"INF!097G
M]B8?5)B L>,7+3H1^6B8.^1@'K?(4B8S4TS%AB/3'C/&PT_DT 0.C^+B^LFL
M=#V@'32SA+%G6"[((3[<>YNPZ7[@42M<9&@4,Q4FX0\HZHOJZ.B+AAG0-C<N
MT8?%I_L.>J)A2L4G!'J^HPWPSJ<8QLVCV4CFM:TSD]NA_'@*/+?A*#0:\6R=
M#KJ>;1/ @<=QN?!#7?IWD<_@K1ZC.S"* TN*?(/0Y1D%=,9GN-_R/3Q##LQD
M?#X>MAL(0QC,X,ALRL!PL=DXOU5*YKG-^(-\,L3F2*7&XT-I?,.ZF,L8*69^
M4,<O[,1W)QN8!]EH+PRM$?15T?7HATG^X1HBL$FRG(&@AK8E2"""NN ^011&
M<A"!*PZ1)/@B+02+C:PI?,RE=QT#XQ+ZQ&!R.C$5)QY&! ;T30Y[2$F"X<!Q
M&)D@)0/>$:PGN %YQ_?$K.$D*N=$ <4@6N 'NT5/F6;"IRFJ02XB"#$,'@:#
MQ%#OQ4A%5TSP:2B2(X,SZ/\\(UY<WW%L/*R%&="OC<$V),4IB.(,7PL=>,YA
M*@PR5L8&1;]]A_+_%-;K(<$)/PY#Z2$3RBB*<(SDW84H7/@"^./$P7'6)Y!)
MED?_%_337_S865!./&-*]<)L(W'/XN@<K^VJ]C7SU:OUG:KVRA94>QKS_:*R
M6Z1EK78R4=S@JGL33 F,J^BSH=KBZYE3@S>IFO:*:0CYZGZ7G73+1]H<PGJ*
M&361L,WN$KE.]?Y_=<TK!]7%5PXV$0C5+0B5I'CT[E"Y?LR++&7R'Y"4P908
M8MD2<?SL1DTH:=?D LN ?AUA;#6':5X:,U%0H?GN>QBP)D-A9JIC\FVSF;QS
M$3#)]GAEBWP1B=5%8WH8E:.(WG;Y9LU4^^K9PC#1W,B.-F"Z;[+[WFS.Z*"0
MY.SA-H7!2 &\:&+0[MBVM@6VQ3@:/],$2C9'6'? ZI.NP+^Q3I?\6R";%Q>K
MU8J1VF- S#?-ATX+-FJ:ZLAE2P=I>6VP?[YK8(63&:5&BX4R4N>,0GKT35#K
MK')&]<P.46ITN0)Z8KGK%6M[0[5W-SCQ2#(M.2/P>- R;9ICE'7P#D"2O("U
M<.644I216DI)K27#!P]XN+K;8YL=+/\W&;)J\F#+L@6A5Y;260.1^XBU&"U1
MMZI\2BSDGK7NV:AZ9ZT6=<S;=]<K>>:S+;)F> [P:1P^\J".\:,F1NN$,1FA
M#K!;N\R9Z<3S$P*L UH!#[M>FL[\7*:=UY2Z>]OM*]XP5+;;3BP34V])3$G3
M05@.TA B.R@I OF :>U<A%4*C?+Z#<R.P$L\)+=^YC&LM7@VX\_-^+-X2/XD
MQ+MMZX&.$9,;"4HN+"64[UW+C$B%UWSD:\Q8,/4LZ*[$@QNKR4ICCVHR<],E
M@M93GGOQ&4Z,E^?W2MN0F?&\IHU7C/0K.L;F3,DCP]'#G #M\]7E[*N*RS2-
M?(ON9>9T;P$JF2-]DE:"%#C;,A2*A?-:YD_OR"BXI+0/DQ>0%\D@:[3_SL[I
M3M'$V-!EOPZSK[&$.A(7;]0@!<-<BZ0^.P]Q+8LD3;[Q>APTMREAUC[Z:$53
M9J6D5#9M:+14"XVS]8V64BVI)W4M;+CZ!F(;J]0$BV8A3*2?KMN5M+;=MO-9
MG])=]RFMU5-RA+A<IL/9V8),AP7]ER/"((LPK,7$26#+>M&O(8'7[OZ<R=E,
MSAXH5:-^_N8:3J]_UXA+W\U_*ML:*/N9_7QK/V.9^%N]F59;LT1_=5:)_NU=
M#:MOX6I8+7T]-R?T[=4J=Y%SP9U.K/$AVI?,K^5;VZ"0_7[.FB-58F*50JC>
M7W!E%8M,4+D_-]Y1=/[5]%II_4K&*3P0.YN18 J4L  &Y1."0:E0GJ:@@O)D
M>ZI)-2]'CHT]D8A#HA525NY;N@GC/(A%8*7QY?F$%X^>??SQQBN9U-;LKU K
M)E6GW4PSG9A6B3**K(*T.ZV2EHS@6;HTIH%4;%$85&T*GN%59Q=VD(G#:,]R
M=_<IFSGEQ?!XE?"A^H<=ELZUW;#T!-7"UB=D<5 8S *>N!P8#"N%#H>X)A#B
M]SU@;T:M$&PL_#3$6L>2F+7@N:!%N:4KCFV:>=OW9-&HMG5MVZ "VI\ZU'-R
M%]T>4RLIU^P+4BNM6(WT$:M>^^R1U^7"A:_9D6;A0%N3MNM7%7UL_=JZ^]I2
M'EN7]Y_OVKLK*)K.9C.U-=LSU!:W9UB>C"1AKT)XZ2X2A@4>GU40T-B\0-3Z
M<[E8U6 6&]#K%CC>E:9I2O$6/HKEJ& MLF<OP<7E?I%L2^RJIJCJ&*F@%RW8
M1S7ZQ,,@;K%)RX@* ]$*> N:Z_M/_ N4PR/;L+Q(IQHL@\^'PZ+K/>9P3P[6
M:-.2^R2+<:^VIOF.(VH-J9X8@L:#M7A8T)WJ[Q]%=][M,MB:W1=JL[HOK,M@
ME949+.U5^(+*J-YX) NF8LDL*F[E,,]W+,$N5(;5(OAA\Q')?=1A=Q3V,'BF
M]M0]L.MZO!"<@N;(  \E7":KNSH,RZU&RK*Z>'R #7_0FL3YJ=!O9 WQNJ_T
M8KA.53P5GRH8!AM'Q-Q:VZ*BFYI8*A< 8(&!4>6IV$0*=@80UG!8U3!1QL#T
MAAL9$WC4IT@+IP0I.HBZNN/D^7B!6R-HE$Y-J_@"9*=(ZIBE8(TF'"TW4<4T
M60ZBF'$8Q\,X*# <V.3!\!QD&EB5SU08C20DEFOERWBV3=":$P!G6'*4:M+R
MHJ*JY\M*MVY4W*Y;-S!6I+?+3%B;: 1"+4<$+(#NPEU0P_8N4_JP2RMHO<G[
M:.B3BD#46#T.N1E6-:^>UTJEXGE55#6?_B)?W$7!\]J:]?IKU2W*VNK*LC8E
MS7(ZS*$.<\1G 0&^V,XWI$)T<8$5NO'JQ/BHJ R.AHAA/=LP!#<#HE:)Z E#
M@Z$LZ#*@_7!4LAI<:;!@#UK\M^\P83,DUB:,\KJ+)>$4S30LJA1MJMVP@1Z6
M09?"D;>7BRJ%2+<V-R<D'(H#<'A'A@=./KT3'=EV5"S7S.!QV:P/ZS.J#AI.
M%DSC4;'BR->N-K!M,=((O.^AJC&?]ZV)M!R\?[J,=/T#B+JVB17" 98>%H:&
M;3A^'X,8CJC+SO+"<V81B0JP?&%8VYWO/+(]:70^#,8N< .8=<)G!\F#WOF,
MV3&($CP=[_Y.\%*Y_0I._9!>PJ*O?0 .(AY$(N@Z; SF$$1%N "4-JFW8#(Y
M$58V+RB_H19T;0P0^#T@0NH^+'0< @OT$G5EPE:+ :%V5=?@M#L'TY$1G:A0
M3;ULW:Z<7+,Q1&UQ8XCEI5YM93E938.<G+!)9_:KGK1]-J@5O?[IQ*64!G-.
M)&JEQ!++JO[,^YN1$2VY#\U?H)F($TOF5CQ,B*95\#I*A)'#1CR024Q+K;R$
M1E"=:.5XFWQ1:8W9/O7NLH&+__15Q\-^;&2/W=G/#+,QE4HQ:\.UCS9<YV^E
M#=<,2[64;,26Q5>GTKQKQA8K<[9XM'V]:FMV3Z@M[IZPO#:KKZS_]I7RLM)Q
MI.&J?3#4^QP80%TBLG#QYHRJ-:OGUQ97SU^>1!HK$]6^3KQ7#?2%%? Q?J5T
M':9^T^V7*(FY<<>"=T FCR=L<SSESNR=+M<_ZM]=QF'\VEKZ*NK7UJRH7]NL
MHGY<F-WW!!>M6#1_>=X[6YE;&^DNB%^J%!+O.=)7\@I(_2Q^!80N6NS@;A/-
M,_,6QX'*I<3!4-X/%-)WPRNH%U];5"]> BSI,E&E.!.&Z;A97SFU$O)/=#AR
MRP]'6A.'(TO?A<ZDQ%%)B8/2YESIL;#;Q"+I4:JF6'K0XDY)>BS90B!=U+^5
MKB<9'::,#DM+*RMPWQ*U%?\N25W]O5O5ZJQQ_ IKA>)CD3/293@]#L"IN_N[
M@E_Z#.(,+JM'1KY;IO+W!"A+.X7E1 F!_8/S<+6?&IO4#Q !$#JV%.?YOQG>
M0!YAMEY%1D83\T%<IC^IKW-.-7.;5(I_FZR7B:1,))V<2#I+C4@Z.UM2(.W
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M?,%@D,?FCEISH04I(9"<5L=AHZFFYLL0FI<82X+]N<K\&N(;9'$T87=R<YT
M4OS"&=/YA30D(=$H>)))F@2FF0=F''OO/I9SE;.S7+U43TBZG+NS3<[U]K"S
MXEDI5YJQL\1CO6T;UZF- *Z9^=A8-?,1P!(9U[$M^)5[]B(JLZ:AL.JX6U,*
MF^3\7[;NGI3FY>7]U[LGS%5Y>+R_@]\O6YCZ_^8S)1MK9DHV9F5*;HD*95AR
M S+>$R*+A1)'XJH'?8\,'4^EV?GZ ]?EH>5QW>Q\(B70]PV=DC#CWW=:EV J
MZ*AF<QC$X:<]GM)EIL&>^7.P#;!9*)3GV3EE $:,HBK!V9TX*1.AO<G841";
M!,/#]WQGXDA(1.E@F/!PZ  Y&A.@/[!D7S/AL%%/,KPW8)ZTTW[;4O[7MQC8
M<:5Z+B1Y0>7 $O1-OE3)*>^N V)K6RZH) ) _M)ANN$I-S;>_%?>/]DC4(F5
M<OW#A7)+)BPG?8Q%Q)X$X,X<L/ .C%QP#'!NBC,[[$_?<'C0<1@?$8.]08Q0
MX\.;?'@T_T/NX-''G#"%Q?&P3A%K9CRC[0Y?#I@9Q.%YSAP^& ^_P\H\VZ&^
MJCBQ8V"8/B>.==%1L/B]<E>><(L +(]5N_X(AZ6_\4184UV/GQ2' N:%KC 9
MZ(688R$=T*Z7_HR,A],M=@OHU(PLECL[+LB?OF%9=!K2 SFC7,$^R64JU=!X
M+YWSY1D8;S.&P6N86D!. J;[]0RT+)4Q4QU8(Q#*'89J<1 ^0 *Q /.?57XZ
MSRNE8A+-*'DED6IRL%8'4()[Y@[3%Z;W<2?BH;-2[0-?O3B[D)]7RT!RK0!>
M5Y@CD'O'3P)RZ"[A608Y7[C)/F"(LNFYYQ?"F?"-R=XA[1.L1WX7F!R@8O)W
MQ(E])$#O@HT/7T;0H1&NZ+3'Q=D,*Z(Z0J\/-].2N0V WR% 5)Q!1)&P"*N8
M@!X2^%S<"J2"2P$TINKAB<$(3R$\;_+V'#KJG,1-S"=]-MB+=%0%>P9Y"9YD
M7EB]SOBI!JA-^-* L9(U74RO\32.R3P'A%/(TR/;-?AYRAO7=VLF/C<:*WHR
M#T!(S@.1$YA,XK10HQTT@P2;*_!9'(/H:5E/9M5QTYF"#\[-3;/3:5^W+RGI
M\#A3\-<BI+,DPVD#BDE!7L)D77IQ@DI"W5&Y4C;ZOL,SWE"FQ2-D)3('^*WC
MV8E<$_*-7(,N8UB')G(:CP4;;"I2(T]\I;DA\O2%DZ!.2\-EQ-&^W>S2&?XZ
M=>2SM!CJ8( 3CX]!#[= ]WACK.MS!8H23#_ QLJ1E*4'3"#*]8[_E@J>+'MJ
M>W?_U%(J%^(,G@Y@OMS?7+4>.T*_*JU?OBZ99;6=[23+(67FX6-CQM%KZ>RL
M?'XNOEB@,U<FBB#?:@UR2I]PZD2B_D$^3N0&_0JIH>2!K'*5M+;)%1U3Y$)3
M2/L3NEEH&,+R"<N+RPP4J^O>+,6[[P=;=GEVB>N$&@5+D\%\X9^D[M?@G3UP
M0&G92F_O/EZM0NBYF!OM8A[2?#JIKT\G6&'JOD< OJ,S2_B#SF;:Y#.WK<C-
MB;DG.;5R)7?>:$S3N3SY[)&+)<\E21J ASH"@8LYCN!9!CF+"[BB$=UM>=W=
M/N#$\J0JB0_@>[F_2J%4F]X<F#L+5GMVH-769JR6<E )#==HJW7R%>41/'97
M% ]4.H'9A\*I^72KW/=ZS G3*KG7RP]J^PZ=TCJVQIB^\NW^+='LI0ANT/H?
M*5;&]/N%1"N*?)Z5YI2RP;/^8'?"K)4\N<?-/H@EX&DK\B2&X.Y[E\1&!()Y
M&VS4DY0/A6= ]OB:C .)F X/3#(5L(TUUT0^9%\U<WBK1+A:N4BB %5N<QB_
M;"+@%"6=P@*)OV^O<S5;_C.S^XXZ NIOAU4XUS#ENT-'O5AVL.V:\5,E23>V
MXZL7HG+$Y];]Y\?FPY?VI=*^N[Y_O%WZ-N.6]C+7B)]OD*^,66F/KT$2VS_9
M7O>J?7"+;U%&S!R3.>\R#<76B^WHX-9/G?L+.^)>YK5W6)^"KS,EU0A ]NZC
M;;$9E@-_KZ"$$$^HA1M4B*0D]YADQIL"-E:H<2\6AF'7S!K>,"=;B:411].-
M,6&8DHVW3,F5=2EY<<KI_%J008GNUBO>O5!-69[;_30.%]/$0RE*$(Y*1'XH
MI3'3'&%M9*M/=(1_XU4+^;> (J_P7JL5(P7@@2=NF@^=%H#2--61RY9.S.;%
MV/_YKE&IO)O5SJ=8*".29_13H&]DP?E&]?L=]$Z@49>M$$\5RSV,]B'4X*M:
M +*$*OIB!XE%](O?IZ7U&"WE8*7R-[CYD"RWT5.\Y9YB:])37+;7U!$39SDC
MSM02)P8JEF@H$Z.Q\BY(;)4&&1F%'1>%E4Y/R!W2$7B4Y2PHS,8-9KRA;*F]
MGF$:Y,$'E=<OCI:[YZR1F&3KBUR)]998Y3% \AC6>'!L"[ZA%D$;R:Q8FZHS
M36/5M396J)R()&NZAKJ.?-H2'-/<S6YY('ZW*@2YM;,/$![6F-EOVS,L];-!
M\7NNTN<47"PEG %D_+-J-\@W#)5,JAR;5"GO5*K4&[7-6J#OV&,[&4L'RR&.
M6.:+93P^@\<K.^7Q6FW)'JBG0(W'L,:,8S;FF,T:32WBF&HC(:%H%UHQBPG$
M$7]G.]Y :=*Y=!8<V(ISDYGF.Q%"M9T*H7)]=H^%S.'/'/Y,4AR7I*CO5%*4
MBID3OQ?3I&/[FYDFF6=R\JS>V"FK5S)//DUKS/AE8WXY2P._9'[\]I7EK:'K
M)E-:JNO-$T_K)>PE6>_IR.%+K<F_279D:J&]GKC$VR]YXS4_ #)E(-?XO_D>
MB(C\F8!^&J5I/G/_]T/UF8C)1,Q;M,C.BKO-8]K,(BO5L [##)F'7Z0H/WS"
M>4C@"K[HN1(HB?[+A3*\K.BVWS79Z4N<+24NK86'^;=#]HZ(MR2,=BN+2KEZ
MI;%V1"4J<=(6K,CD329O,GFSNKS9;5Y)*5>N+YF+Q2^;_$BWY9>HL"E[C1VJ
M',+6:QM4UZUM4(E6Z>C!)WG7^(LA%2,8Z(.>.C3,\87RPP0,?HB35@  7DO@
M0IF"P"3=S1]]HJ<:D>-/> >&JD!/U@[#RCRWZCCZR:PJ;4M-^>[C*E6.SM>O
M<M2V@ 4\VQE_QJI2R8S0*">=6$;W-@&HQ97V&AL4"%QVZ?7R_-PPP.4GP^9'
MA$'-:5YDRY!34.7#R3[O0'4YT?$]L6E.V@J>S"SSMP:OGRC+;L"PJQ4FVX!E
M'T1?U0<3JS!;.A9F'&&]GCLVN^<33TZ:75;R@/R[WCY*\\W_F<PL.]$2OIF<
M)D?5B["BG*;Y0Y_749,-:GEG,WA<'6+%_K_H@]R*8F"- FS;+K%[=$UFHY4'
M3KK)[*FTB]T/%:]2.I"WMP^JH/%F("O7_IX_2LH+?M=DH<";5K/36JKAP!Z*
M>\_W.)9$FZP&N#26]]7Y __'4/?<>L0S^M9C6=B>JADFM7PI*/?6_+K$ U6?
ML#7*Y*(J[I\^]IWI,:[6>J9M.PH% +#@+R\"[(QL+$.H#)BJX^,>MJR!;TN-
M6J.D_ I(^5D%#0Y+(-<8E5S;>38LEE,N04R">K<,-2>JTAH>+,;E?0EP,U@1
M$'YHV#2J>%X(V\=3:5-<0&Q:]CHR'-X\*;;A4KT@J/=I<MN6+&3NV;RYO<Y+
M.V//>U'H.)S0>[$5K%B'+V ?-+!)QGFJ_RQ;WQ"P@^9%E2+-7HN#F[TR1S.P
M4P../C5]?$I8X-P9N06":H8,"%&U]=IP8/--,$ITT0R.=S ",,.#@ ( -)^.
M12?$DK#F9&<)3C\C![XYYY_,VX[+L!'%:KOJ87L+WB9(=!7X;<"LB4FF%FO(
M5?$EP8ZHF+SIVN!K@0'(]!G3Y'$:,0"-2<V/^&HY><E^%_1CJ@;E?./UK+2^
M\1J7.PNKNI?KLZU6[+5+],%W(_K]CM$,Q1Y&J^ZHO$%M9S'U%9]YSE9FQ\,*
MR2V#I4X@'72 EDQ2,*_H&J^EG2JK::?]M0%<2CM-M'*KYV;VX^)>#PSB=UU#
M-U1GG N=+B# P!F*"3I5*16C_$R")4;;9[G2M!:#??J8XL/K^),VBS<@0PUD
M6RP8/91E(!, 5*)M'THUZD'&9 \]L0[9!7QC:;(!\Q%Y@ O\B+UZS,4](G+5
M!<)D!CJXK!4VAQJTI,.140.K_-6\9PN%U05]SFN2^UQ\(Y#CV* J[>X!VHKN
MAY>KJ_%R94^\O)B'I1:-:_XXZH$9>H9&B+TQ+%WU<\IGAI;?.)D:<EC4.6;"
M(7D K?%:"<KG8?=+CG2^'"H4$873I)'::C1230.-3%:[M4'FB( W"3[9)$BT
M+OL*$@*$./6H<(-FH[ML&[1)4%$=4\GS:]M!83KG0",AK6EQS+-ZN-5-Q!>%
M^?T819K$CQ#ZPK$<[P5O9Y4]@&9>ZY %R]L'YDI+M6\Z48U97TT:UO;7!/M\
MZ8Y1U]31UP$OB#=/DIUJR?ST'!5CNGD3.]=&A257M=RBI&@$]L5534T<*U#=
M5WR">@C'FC63[^^IWV"V$?4\YCXN-U4E^T;;]^);LG4OAGF0GQW9.PB_)+L7
M1#JWA-W@8>I,')W;<,,VU&-%$UTL84P1), F,E%;._  A.T0.TZ1]D4?9G>H
M0S4UK41$(Q/X]!&R &]=B1 =^L/HRD7':C2]+<T1UHK#Q-;YB<N,5M_4:IBP
M8O?R:*M22V_19)N#G^/%--0N05,*SF80;3 !PKQ)$XSF2D2J#K;'X@V,X[;4
M4!TKW:##,;7?&<%'.ORA>3B8C<V>C6'7=UPF2,-U;0>&04'L@G4.8V C9HM:
M>U-7'\DN #-J_MWQM0&>/_G8/QD!$8+V676,H'<X=@-BV#1<L6QO^]!2NKXG
M\.!Z8/QA"U*[;QE_8<C&#9<BPS0QX^$RVMTT:'-%A'L?;]^,H'78 &,\0#;8
M_AO#7S3*6)(!NF>Z# YN\XQ]:^?I:XG-QFIBL[[;PX>U3QXZ_FAD$GZ!CS75
M'6 (^F6B<TS0KDJ(BYEV27(L::;%$C28V2EA+&B!M-W6,DN2PMEJE+.XKW=B
M"ZV.-F"ZC_W?+@&SUX#8*+K#9!'WD:/XR:9%'%,WF1)P0N)E!?Z=3/@\F[H_
M6M7JK+&#E.*S8[D]>A^J+\GZHMY]J-@XSW/&2?JY5")W'!M3%[]VA8S4WN%Z
M<W#99;XQA_-W:Q!B::<0+Z,7$R9YGQ;0EP\(M>^N-SBJDX[\G/MN"6=URUYX
M*]<*25J$?Y6D1 B9>U4AAVZ+,N6'@&/012>4NR_L51N@ T9&XL*DHWVM.J:L
M\(1I0K\%GI/!W"5$2)PFROLAB439L6/%=1BUF($X9<)^F5+U<:1-:M9M8NW@
M>G4A(N>5OC@_IM(7B9?$C\OU.K &^HTA)C#\]@R:IX]Q2 PFAAJ((M#O08-2
MFM:'8_2H,@\J=<;\RM#+W*%-W:&98;KR=%-PW7>0U>>[/E)L-+G4>)1"@P?J
M0&24WGVL%HKEJ<SM/4CQ-^?[3,EPW7 U/.I1,#][8XE]:E9M!H4-Y.ZNP'":
M,G>)U.KJ!@&H"2E\)=C^$;C^@3E:-+DD7X[$ID:^P]Y]K!=JTZ&I[U-2BV"I
MP[(MG7R=KW;R=;;=,]/)[:U_:(KI%9$<*P5^\"L =D\8\\F'H9% $Y[$3]]P
MIG-S54:A@&9-/)6Y>$,'I*7B:G1ROM8)Z;P[@S<RC^)68#8[$MV"37=H\PTQ
MC0E50/7D9*?;Q=Y'Z$KHYO;=5>ON2>329?YV=F(9=]&/ Y[+6X*K'D;.U1#R
M;))[YCIS[GO7!MJ"OY-OGW@=J+9DH^$C\]L/+>-+F*96YC'4S;-2=NB+'HLX
M/S(0I,SSSH3I6L+TRF=W,-W3"S.?V2WEE\X1I?7#B=+3-IC+*$PKVQ*FN[66
MCT2<'KW+< 1'2IF(74[$HH7Z]&+/D:R;]JW/C-29J*^@7*UF1FIFI&9&ZO%+
M4+P$-4>&GBU9^SY1AE824Y/Y5V_3-JVB#*VM($,K<_))3]TT32J0+V"R=',F
M :5TM LZA'!>$Y")%O#A()D)_4V$_K7MSPGN;MI]*;.:DVO>^)9,N@INO8\$
M;E)M21_I:=Z1@R2SM$]$Z,YK]U(]VU3@9B9V8KZ$,1SYO'(^UH6<WV7X\*9V
M^J1L9GIGIG>F!3;1 E\C%E_K%8N7-JF^TKQ^(QMVI%];(9R^_;W9Q>FYJN'(
M;<T]*H;4="U\>REY6U)#@M8/B\E,$<V_]A&HH'G>1Z6TRB'I:5_P*)56;/12
M3&%MY::FV0Y5[12M/O!FMBOK, :=,62+E8GBG%2Q'>O&VI9KX!T!K(/BV+['
MJX^.5,,)QNKZABG*@^KTG"SG&=;2A#^"3FB>^GH$16A7PO^^.OVL9.=$$$K8
M'(B*F;:/^'!!:!D];*;@1>LABO*J06G5=1K)[1)W1]=4KIPUE5M5P*>OJ=QN
M*7J5!G/ T4/#HW!BT](OZ;L^LS3P6^9U35W0<&ZU47=\GW'C#G1UV8'N\O[V
MMOUT"WY,1VG>78%\O'L"L[%U=]G>:6.Z!;<15^E,MR:^9:>ZM<EE;_IL%K83
M([GMI_;GYE/[_FX9Y!W<A-@*)BN;87)?79[6M4RPLPNO4 ]3DZ4*_V+)^6?;
M?.:E^$S65TW>\(>AF0EO:*9J#'GM;HS9]$7/7(?JQLOZWV3]JLX8\$"ET$'H
M=WUXX#C:!FV"]%2T YI&NL.4%T:EXJ=QJHR8Q7V(69?)TV>%JH2@:W#)_W/V
MGY_1&%(7W=Z.BX..WW7!R@;4MK#1^^I-8A,'V%=GBV4ZQT::6Y!J;ER(XI6=
MKY\ZK5^^@FI66K^B@DZ%1)^OF8DEE\%;^KCOWE(Z;.2)]GKGLWJ[JI9E^Y:&
M%?('HF=K\T5U&("H4?U)^82>O >CF#VE]:H.%9T]RT8<K7\K5\QCF@>#F0 H
MD$VB%IS+VS=T&;4PL4W><76H_B5:G/=\LV>8)DS:'8O/98>,Z8+Z*6+\VZN[
MIF!Z_L']3>L_-^V[GRLS/ZV*3U/:M[G]U+J% 07(;YMWX!RBU?Q#1[EJ=RZ_
M=CI@<I$%#5_=_-YI=Y3[:^6Z?=<$2[IY@W;U5?M)/O/8ZGR]>:)'[A]:CV2O
M3;+W(3O0[X /C158\7?;5]R![9O8S43E381Y=13D$3PC]'D?'MZ91C7'V S1
M('/R#V!0$D4OAC=0P*Q1?$OU=6J2AMUTL?T)_18V/ND9V.8%>TZZ80L4T;I%
M436-<S].;=G89(TZNH =%NWE\J ZGM+.*6UX7RGQL!^LZ9&-;(?W;XEM?_)\
MX-U'FBM<YX+582,@V%J3=^41L\"F4=MBK\V?@\X=/;JB3MG3HJ'8K3H.2]"\
MQV'HM]A8LB@E-AB";22!'$6-:E@4%P-!J.=-V_[&6S$%2R5121).=7D[:9P2
MZ$?EO7N"MD6RO6>7F0;K<0RHKNL/>:,DV=8ZBB,8U?6[?Z!8!7Q@.T-/M:A[
M*-BYW_@0*+ IUBKZ=\/DO.$1QFY]$X894F^@7@\;=,+8CD%-?$13*)MWS7$P
MS*ECXR!C.#(-+HUY-Z(Y>\<.;6(:T2UUC$VC/&HU%/:,XK,(('-Z0JB4BS\]
MPC:4:_X&?53Z:0[9-7&2V0@M3.@*8X^AG$-+G]7,L$FSX-?6XZ_MUF]+2>=]
M0HZKS_]\,;_5*K5&J5XJS]&@AS2L@FZW0*:65B"FI.[FLOLH%LAZ+WK6<]K&
MYE(@[\=Y^P6+S4>?G-G,F,:,=SK] 'ZSQ-D\FQL8M(L#Z@:*2;#0!A88:'UT
MB;G11_(++#EFVB.8?:1ZO.%8V&R7<4$S5)UO6"-?U9]5,A)AQ7W+!MAI02,P
M<%5\_!O<.MW7X&$?^5TT?AO9(*2PX+Z&@FWQXB?@_'XT *$,FL)R?Q"'%'QA
M]C-S\C!!GJ?6H%YP;+\_4'3'[[L@6N1S%C;.^[ <U"R2/R"X1H:GFC]J\"I!
MT%2[MJ/"H(8X+M')[!6JXT?42J#3/=GP3 (>5;,1MAO3N7F\! 8G@, %? 3R
M9&!_,X2V('!CNVO48'^!3@*AK><4;)C,<N ]NICWXB@]AFN2RH"K D"\(74O
M]0KD<QCDC,M#([EN;"1G\];:)F#="E"!1!#9-.H2317Z#6%CRXYPX@@2R ['
M%YWY- "X,[0MG  57=?6#?E['RP;'()/(72AQ@*]B5H.F,7UY 8&/I"P D.,
M>3<'#]O081= :D ,",'#$=$#CAH-+D48PE?ZP0UI' $//&WT+0Y\9@VHK1XM
M@JDFV&D(FQ=FFGGN!L&.1\P>F8P6;^)Q*@S%#VHQ-8F_16PBNO$=^'PB;3(7
MF6#D&$.,[?5L#8\S7=Y<$"P6U=$&.2G2D!%S2(E#;"JIFL9?JF16LJC%.;5&
MQY\.ZV/+3!M&I:J(SZJ9(V214&3 22'GY?N^H3,I]L;*>V'27'U^$I;,AY!$
M8K9AV[H&YG'_X?JCC]RU!NS"[\I3*)U'L S,]A!M,U&D*'WPOAV4H<#R8#2;
M$6YTJ5DC0,%Q#%[0KVL#O2GNV-*!N5DNPIV&U3/5X9!O4PY!# !&6N+:^ [B
M-$_])KE\UT#D@H",#PYN/89:6<1(?@&8N2/R>G!%B!?L%,YM8;$-74=K5 &I
M/@9QZ_295#V\'2CO62I6 EQ%XYHJV,$#Y"#?Y28G$(1$F]Q5%, HUT)<B A'
M^U,G')BDBB^:EJ-5+,2IXJKT!U&0&^-\V)R%9"V%:3Z0:SU;]D#-\<:2((SL
MYUAO5H-Y.9)B()[8LX'E.'$][A@<!'OH!C@> ;WF<"F4D$ DZ3@@,8#*'5B9
MS,) )\LS1D3M!=@G[YZ)$7#'%M!'I\#0T'A'N4P>"RT#N0HSY,$($:(;%S@'
M5+8#S@@X#'+_M 8)A, ! LWYC*%?!P0PN!E#'WYEF&/TC!5'T<&)02OHDRIT
M#1_;X'T_1Z"9L)LQWZK*D0["0^U&QV<R?R7H""K6A(@CG(YG(P)7,V#F* $7
M!>4W3G;"IS-)Q81>I,N]\V]L+)B6CN$YX;W_W ;!($T9['SNC\@>%&U&^>4$
M[O[8Z+2%Y"S S9-Y#"=0V06ER<DC)]D!^Z!JGLC\Z;(^C,7;M])G#HA&RV=N
MN&?./M*]2A0"4:3K/JT,GQ<^."S2T94_??#9F#.C3VJFN-Y]O.)0$Q#C(=@7
MQBTE1K+4PC &F<I!\V=QEBA-4(^,MK@RF>9*$=K@#V,O=31!?2FOJ4F[.K:5
M2QI5)(J0\7=M@G&KJ\193<?XR[9 M'QB0,]MUU%!J5P!TZ*-YH)WP@V]2WJ;
MW!^0Y<H7U0&#40^^[F@#VS9!^JI<1'\15G5.^6H!#SNNJ#C\Q%YAG5^XR=31
M@+;!BA)CPYJ_@ 7JH;80O\#XW@ L1-?C BH^V"V(;Z.O6G'5!\CS_,#D"^ #
M2LA 1T'G$)2F,'H6B)&S_ MCWT0K:V0IB1ENY#$4HZHVGN"?&9(2=<00#0L6
ME4:N$)%Q>6\[ 24(S>?9(][[FR]:QG?H1,VA, @7&]>LZ_@HQ.G@3+F%IPS4
M6,%PL/XAJ@>'(G 8T#'0I.%-LB-986*MH@6U8>EDS),\$C3$3",@T*@=S_4=
M:C.P]['-0\\W2=@"&/C>PWWV:-^P;K3+I8 & ]\;C]!S#N-( 5Y(NL)+^<N(
MDLO1)U="&RK_!;J0()J_-5Z9_H&#L(^6%+I, 3=-[E%.AGVG+=M3<(.B:;#:
MU>TA65ZH@XFN0C5,6' 9LRC34:Y4V(OP?K!F6@Z]/+T#H:4 T0HA6E<]E2]<
M-(67"9>!C' ]'QP<Y&]8(*:J4X]W29&<^./4*NUF@8!@J%R,XKCBX XE[I7B
MM+!QXYD\%$Z!1 8O8.;AHZ%\05!Y9%;C?&)12"&X'<5B3!</C5 !HQ/]M= I
M*,@TM-XK\-N5IHY-VEWAH07F]?55,S"O-1-L?7*U9#0XD'U"/UO4 5I^A3=N
M$("@_PSVPNDXE+VT.MF-W&6F5*"(#[1"O0 X[]T/$^"A":*@"59 >9<C3)=U
MY&BP$L_6;%.VGPZD$'6T)\U-+=W1E[$\$84-7Q*YO  (J8-#;5+)<3K#!ZB_
MNV1,L@&L8#\T'1AL_XLV4J5(P?**$#+T':R)KT08MCQN)6P%,LF%;(^(5*!Z
M!Z0($',0%X_01)1H:0ZB=BPY3N_")%Q&8T_#J)SFOD'(K]+# VH%Z2[<N50Z
MR"E.2:UD*:E92NIQ6<[7P0$I60^^AM(<K HIOV50)_ ,I7D4.#DB=!?XHW/=
MG+BUC>I=O/<LM'S,3A)>&Y_K\WR7CSM[+W3\:QK?&)?U]K,AY.O<93TD^8#H
M\()(!N5OCJ7G3 E7H&.",*/P#L.DJU!;H \?4<TNVKNH8B9U;.B'<F<3U5O<
M$XXH.ULZE@OW%1C((G2O*I<W[68>PW/D\^<4,.8'>8[K5S3Q@T \'3G2Y::X
M/1)QG@/#@)]81EX544+<-.+O_<W5TP<>8^?J3Z3]"'7VPN3HZ%'#]H13S:9<
MZHB[OM!1;EL"9GPR:<N$/CD-!RL+W'N8W&)]VS-X])ICD>OEJ<@"7WB,V@@R
M- <,&I)2U/4I9-)GHF%::,W%;2EB''1] HL1I9 T>O%/?KL&\Q<863<BYJJ\
MEQ$]W]0H-/.,QBAFLY+S-S3Z#C:C=C]0R) ?F2#RP31#8<&/&-#($C%L[G.!
M0$*9U>\#BO$B%F@4QP!GADG#,7"\>K9O2>N5(F2Z/*LAZU58HGA&&%WU2V .
M$ROPO!4>(C6 !*-Q=Z2FP0M&- -A*UT]>!J$LVHQ<.71Z01Q@["*2QSAZT0B
MLJ9  <AFCZ<QA('?23:WD+HS.IZB8T(;05&FH]*A%5"LCY(,C7@0:N[ &/UH
M&F"M46C5'F%X 6^,\@,Y.FT94[XU$S[',L=GY.?183+&)'C<0!P4@BW/ J\!
MI17%7WTW=G83TY#A:83PP&#TX$ 8B3657L&AC\WHC!11*CVXR&%R['B'<C5!
MNIDZ'MJ(L('!0]W>BRT/92Z4T@=E]O$XXJ+\8>+<?_EC_,CQ/6FNWU1SJ(IL
M,_B][X 9YHJXSG9.Q"E\-<2#YCT=B7?'XCR<>"Q()A#2C%!%<EZD%DR?EW=5
MC0[Q<PM.SG-+'YU/G]O@$7H.Z,NV33Z.@*'=\WBT:\'9>L:$RQP!4'P-))P>
MTZ BHOREH#R,,2X_1>@\4YNK;KQEW0L1J%#2:(\'<0)#/QQ*TDXA\AE_7MB\
M(5ZCY[1&C[KD*<"D%$P%2D";PZ1,5IL;,ZYTQ?#F^!AI9Z@"H6E(=@[(Y:N(
M30P_8&G"&L8-3T(&PX1X[(>&\0P#(7HR-A#.0ZU4?/\-S]\9EU)(]$.#SN;(
MMAFHSYB2SLD7-^=;DBE#2.%<(*5>N!<16EEH\.3]$2P9#^)EB(J[<&3PB9@6
MRE8,>*J86$ /,WW&R:'ZHAK>(N,'?!+\D+Y&B,<]$;[)22,HU(H%\<2;9T7D
MOL 0[IMVE^BL=*YTFH\8B_\U7U8L&X6L9CN P6?#\?'$W=+9T-"2>V%2+/.6
MPI) MD5 C^QZ"0B"=P1+(X8N[W]M7^5ARD#94GR5,[#@7^ 1X$"\K2]H5# Q
MJ(O@=4S5=6,'T/PAH##IZX=6,GE\>.H0OB^TQ'A:HD2/MR;7,\+8.;?9IY9&
M,18Y/$$N1T<ZR.7!YX&CG Q,9+)0!$A DC%1+%<X[P+/,JZD*?826)*@SIDK
MI69LKZ %:7_"Q@2[8(:JX_9 S_2-(,U#@ /YJ3>90C -_5!Z$ !0TM$0/0 $
M)?>#0+* ?\VP@V/Y>[G> #8B9$"A>BS*CN>3WL 5">Z3;5;IY(E@,7OW#C/I
MG$\2W)N7 I,^$?&+/.?C,(RZ1K8&>)97$J;8-[>4XP/4@#GYYCC@B. <@Y_0
MA2J?]4#1">N5<MMXYECT$9DZ%4]I [Q;MI5/Q'N0012W*()P'EFK\U,*,LJ9
M\J=B( ]E.B6\:;*\,]55P62"L[,-N3TG(KC2&8M0R)S\P"G7A&-;VC3,M3VZ
ML$H"4N8"3BJ&,*G;,\@7YSE<JNN"_Q!FEA>46]L-+->82WG9XH:(+AT:\C$I
MBSJ<"R5S$.\:TWL.6#FN1QH,] PC4Q(AZX3!_&CJ)MZ/'E-<59IBX+Z@PH@M
M1MA2-#TR?6 O620'.AX9U$*O@6UV:+$9O1!1JIY7*Z4M72G<\]EC-3M[//ZS
MQ_W<TTS!Q=C3N\HZ7;MQ[6HL3PO5U5%#:JN7?N^8IW3(MD3->RE4)'URD%N+
MZ;:LGF)7HK$:H=)UF/I-MU\LD<+%C2<U6N-07E&#7WED,Q(."8/:%P>0;A%%
M$U5(J%)('?%+&QHSS1':+%:?*G3BWUB.5OXM1A!E3FLU6F<7]L^</,AY4QVY
M[$*1ORVMN'C=U'^^:U0J[S[^[6^1*M(#QI\K%LJ@2^'+2/W8^'>R]FJUGE!(
M5Q$;NR  U0I5 2KZ;4:970D]3^>S8NX;8.V?[VH!',3./7L$@V)1V(DEB>_%
M7ND)62&V^'WP-9_P0IE=.%T\Q$'(A]C"YOX6DEW/QGLB8$YCW5K$)WW04X=@
MW5\H/TP0W0^2U6:8-0*WM(9)$RTZ"U&-, N(W7Z2DIPW*%9:$Y(\PB]_"Q$R
MEPR2RBEG5)!F*FB+:JW*^RO&?_LP _=8_3?M0J*<D<?VR2-FT*5(%LQ&]FQ4
M9=C? /NEX\%^QNH;(?N[#--O!-/?[T[#=V$&S$*U] OE[]TS36/5)8"X$Z!M
M *#+2&[3FEQQ&H!81R9P=DO/]J?;=6P"D5*N5*UCSPQEKX2Q%S$3!TL8R\CH
M/J/[L[.,ZC.JWRK5*]3"209/CX '.&U$?RKE>C%CB[>XO=.6]M.4'J?Z\QVZ
M$$<G-N\G;C'LRH]>PF]>3+*G0)WE4F43H;N+@$6&W:UAMW&>(7<]Y!Z=056J
M5$\/U]N>]&08N]0H9I''!3!ZD#<E?W#%3<E3BS]FIO8$5YQM9,R<L(N5D?$1
MD7&YULC(."/C8R?C]PVR2&?E0&5D?,K;.VVRSF<1N]CY/E9(4C5/N0TZGL!2
MY_+\^NDGY1UFGQR8E5*:DW,$#'E>2VG@(Z/SC,ZW2.?5C8Y',SK/Z/P8X]JU
M3+JG+H?VZ+G@".B^5#E;Q<THU1#7,[F"OCK!^/X3]@M8S]'@(%G H;. E$R0
MY4(9!E5TV^^:+#U$N;,4MK5AFQP=.#K@;CL=NEY9(? ;8^N3B2AE+)NQ[#&Q
M;+E>SE@V8]F,98_3NZPT5G O,_8]//N>"O RE9K$D<F);?@/%OKYN/T2<?.*
M#X65 TNE2JU\7FF4)TL'3FUJ/N3B, MJ/46@%E_/3!@NP@L=S5&(A,J86EC&
MFPIH4<%;:M#]:@RIXY'R7>A[R/XYL0DG<+14G4V7]Z5P> .![T)32<ZP<)12
M4!Q6Q5+)HKB*W9M<O!#B5%P?R$>T)IVW@6"PI=>"M=1A2[IC/#,K4D"T.Q9%
MB7F14M^)-7.(]=AHN@9O"WO_=#G=?"-:-K.@/%"O5$,3C=9[5 $="]HCR_/.
MH-BVF2G/MJEZO'T3C"3*P&/->$1U6',S8*BM]MJ;4:5LJGI@% LKE0Z<?V]F
MDY\)=7BW(/[69.6(Y)C@6DT4NIO+N>?E@/Q+Q0I5R VX/;<2B4\S;:56B@S>
M6'OP$I;,G<O$U7 7Y=KWO"_)5ODT.C\@ SC''S)9:'>RQ&_8"\D*2D!S;  W
MFKQKYMXKVAY9S<;[D6R9WGH=,<O-2C4N5ZK1]8?48AA),P A$R!<7'YQM_#;
M:BG&W]I73U\N&D4"RZ?[QZO68QZ@<]-\Z+0NUB[$>(Z%&)7((<F75OOSEZ>+
M4JW0J&$Y>25BP<>_^TGA2RK7"K7O9Q5[?6A>7;7O/N<_W3\]W=_R&LGRLZ?[
MA_@'-ZWKIPONI@2?/=)TXL-9!ONTB;XM-,]&*5G82JQ2T'F (($3VAEZ&)/0
M$M_S3=$3''ZU\YG0$X\+X,T^SEL;PF)P^HB6,AODHOKG><+I\.[ OYU"X?.+
M"2\N01FB>RX#E J-ZLDQP#H8F,4H\T5'H7+V_:'@A$M<N,):X:R>[A4*ZDOQ
M"BN%0R%9D"%&1(Y6Q:6.HP/55]U8]97/"O79HC,-VB_U\G9YC8?MK(Y>L4EA
MDQ'@41)@^;@(\)3E;JE2:-0SLM\]V<\O<\XE&EHGQ^N!IY=-RINS28E;_QF;
M[)A-IJ*?\U3%VMA,4B9'A,P)?VMM4-0*Q8RP]T#838Q1TT$096 KCZ*9T'&9
M0LO8XIFT/1JBS*1M)FU/DK S:;L\49X5RD?/G\= D]^=#/%M2'#\%""CMQW3
MV_?+QQ<2@POS(@M_[U:U.FNL@Y/8)X(^Z [RP4[VEP=KAYDF6$PYY3.SP'HR
M*=>IJ0\-RW ]M*:>V73FSCR.GSH$S6#\G;(BY,X+U?J)02XB'$1^>))LX%^O
M M]2KEZ;*GR[#)RG%=(&<$Y/BL.B')\Y )FVZ$\"(CNEOF)I2C=E=+<:W66J
M(E,5>U(5Q<94":6,93-5L1?J.ZMEFB+3% ?2%+6I4XCM0HZN?9\2M];.,J=B
M&RP[%2 ["7CLDO(67%VL3:N1+0?#UH[+'K-$?60N4QUM0"&P*_;,3'LT9):W
M7MCK;<%N"W[+D=/<+N5!I5[:CB8Z@?L[6_583@ >NZ2[<GES?^4$0+RQMW*L
M,BW3!>GCR<I9I@LR77  NBMFNB#3!0>(4F6Z(!&Z[\O%R>Y:&6-N'I\Z 6CL
MDNKR">&G92KSG41=GU7J'ZV57[7/RDC+53VL5:K%\_I9?;+HX1X7MCS,8]73
M7(F ?@0!:AP!LJY24G$UD5VT614U>?"\O7)IXH""RJ75:M\'M<B2 34!Q1C4
MXL761$G"96NMA476=)_AAB-+#0:E0H==55=TUO4DT'%?WU6*1;X3A!E\2K75
MZ)M&A7^!6#-9'_ 7?:].11^7+G'XQFNQ+0QPIT7NI$R\3$@4)PI&/03CA!A)
MYK08&PO@ P^(("_*A^1WEV1*.6I4#,T9% 24C"O ]/+EJ;F21Y@MOX)5 )A"
M*;8D8*3G\%VY&$JY[PMS7D<!%DRTL0 #/&/!1Q1$,-;E_:_MJWSI/,#^#*$3
MK8LW24%O@ZE6%$AMO 7 7%Y@\\IX-G3 D-*V@&394D)I^X6>#UX:<@(JNH2*
M05"9::$D%&R>D!NKVRR-M4LUQ_B=CR.JQQ87<K"8-AB!2KERGC1MV'X(DI$Z
M)KG;<^PA%7 UK&> &WY64):U"?9#0MN9Y1_=#6HIW[1_^=J^:C_]KC3OKI3+
MYD/[J7FC/+8Z]U\?+UN= %#=4P'6VI"*EV,%=B#Z!PUA:<8(+% 7:$V#MX&V
M3>-/W] -;[RX).OV8;>#,JRUVG;+L#:2RK"6YQ2!*<=N#3;*NXX'\FJ@C:1>
MD:F)6<7ALB>PI \J*UP6+B^ZP3X;B+NYNDF?++BX&85\:?^@W_$U]KC!L4S4
M.O4DO\8-]HPHTT24M^IX%D4>=/$+LSKKA43E25\EZ<Z@P="I:<\5@L.JRR,W
M&O["P'R#]0'DE[K=' /NWF";/A6\0,(),"46)TT 7**$FVAZM7LI=RS$/+<(
M1P0[L[7%DNBB-F7IQA<M\71.6.NYXG1/PDPH94+I*(02Q\W\S)],-AVK;*KE
MSDM3'<JW5?#WC<1ZEH?V;[;S#8.0FCHRL/*;86FFK_-/-K!C:VEWJU.A,186
MV5_-3\\4QH96[&K%*8LIQ\Z)Z85&KEI:H;)&)H R 90: ;2BQ9K)H93+H7JR
M?7J8]N%;[+>\00A\V?/O4BT6"$_,:MKI\I5_#)P?X[,_-#^W\I\>6\V?\Y]:
MU_>/K0M%-5_4L;OTL72 ]JUC?WUX_Z2(QN1_+Q;K=4W#5:K*P&&]?[[[^]/]
MY;N/3W2.;_>42QN 0R:^>HR)+?OI&CY=.QL@-W'T2(Y3].0G1RD>EYC]9(V5
M@:HG^U=3B=B):=?+\IOR71CPPQF3\Z.^"[SO(+?28>Z(:9C&;HX+BD!7X@#K
M0D/,]C+ACD[GI$?,P.0T3YCNNT!.)^PD^?7?F-)EIL&>,2]']6BM:K_OL#XF
MFXM>WNS5<+VY?C+V67;]7L_0#$PB\VQER)A'+X<=E^DE!]]RV)#>PJ'HX@#K
M&YIB=__@2W8I3Z[O@!8?T*^P,).I+E^>A9I]S%2GH#S9"J:WN[TQ324A&9NC
MR\8V3!-[,Q?Q_6VK;^._/=_S'2:7:UMN3GEA(/C&BLO8-]R2HQHN0$?7#?P>
MYND9EFIA[@_F\]E^?\"3\7%7N )O'#[A1J?TW0"TS:=;^+4'M&OUETZ]WYV<
M2'F.:]B4HHF$ GA8\J+/24%L:7!=^0XGSN52MXD_@38Q/S;"MFH :DH?G;K1
M4^/72@ITYX6G?@/APUNVXW*AHL&TCM'U/9X+ZPT,,91BVNZT#E"^*X,(+_-$
M5\NV\ES:R L!E 5;Y^(N+MDF/8-W'\-,=-5U;<V@.P<O!H@5U[.U;_FNBMN-
M7I3)P7XUVP<AYC"-@7P#<P$SVNUGP^5?4_[P,\@6&_:)&>S.<T"%" 2QN9'J
M>(9JFMAVON>",.R.%6V@6GU^=0?6P[BH, VU:Y@H+<3,?(OORW523A\*N\VD
M2,M%P)U0=4E0->$/OP8D+$O9C?JVR1IXI5J91]:U8GE'9+V(;-M6H-A([W69
MQ7H&#DL)X6KL+DA IR&+<*YLG(47S"*T;@.NG,447ZF<QV^@O0EIOMH=#\S)
MS_3?'O2?$8!ZOI2HA-=91[X#1"]X&1X".8,D+JS!T<15BDR8KRO,5T41ETK+
MHHA++Q++( _!)4 Q9ZI"R(]4"AID,BH1H]>!4Y3)J!W)J*@U$_J@B^QTH9TQ
M/*T-A*$"U.V;'C*#!;H97M 8TUVN\W%)KLI5.Y@2L"YN79"NAN'JU5#9BR]&
M9&JP5^9HAK1I2M7EE'HF]U8Q8I=%^UFQMCVDGQ5+2Z'\A# >$2JE>J&\\ )A
M8N3B^EKYU+QIWEVVE,Z75NM):3X^-N\^MVY;=T_+W1?<ZN+W7B%@"GI+@P[\
M+T?<U;5L=*;!O3&!^(%0!QAD5!T'/0T149P5D]VNMMX JEN:9J.KJY>/[:?V
M9?-&:5Y>@D_YU+[[K#S<W[0OV[N]MWIP"ERE1@7W^=E(=8+J*5JT;(40OWA_
MU8,/..W!R/ 0F)E#=&W)'1?^+<II<>45HTFB>HY)_B\;>=R<1='[U2*?NX.#
M<DH>PMXT58:T73!^*;JN?F,@R2U_V 7/&IY#0WA(+U%)'M?UAR291:A"[?68
MQL/GL"O;P4G48>!ZDVONQGQS0PRE&ZYFVBZ%Q@D(N!F,\2>]PV?1Q?$!_CX+
M6 6EXX-"2E[V@A4[HFMK:*RC\M%#K<I?(L #!&V]H.!1!]VBQQ.-8%Y [L
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MU?S>^*#X(TJ7I1(5^.+$8LDA%6Q_YVLFYK?<@B>$\:O.V 7! ,*_;6D%*09
MOHC'/QDV3R"./9"#66%:$12F%#0N++!H!TI 6@Y-&P"X1H%26(V+>;MBO2+L
M_8G@[0Y0L?:,5X6I\ BOLP$3Q6=ZMFD&S-W2\2TJ[P'O\0,;-P .$ @S170O
MADEQ'WED^HY*=XB?;4\TF1NJ?]B._ CG?H[!-E861"8-F89+5@"9#@/;!%0!
M--\_8X3\&>M]< -:9T.>U40+"LH!N%S!OG^&38+-H%A M3"R/\16J6+UX<-[
M/7L^U-V$M66CR+G7R,<71Q&!E3J/+\'&_Q.H-X@+X]$ VK0. U+HCGG2&F44
M$P_B"<E FJ"1E+IH+#DGCN4PA=/#7T9+K02/8,"<@]EX]C^>F Z,K@&V0:&T
M1)0GW:)]'XEFC;>2:#9IV6P_#G_8!+3)_57V:5!.3U^-68JMUXD_C\-PK$O#
ML?6O+^U/[:=.1*0<\<W!]6X)3K869%S2\O@%%\0VYF<[EN$.4%Z[@<=/8:$_
M@["0,^4B_7*QBXC\DD!=J=.@K,%>_#[L$U@O?O_NX]_^]@_/^?BW6#NM6O!:
MEVS2O&>/+A0J:2H^$"*+/I(E3>O?!U_SVJ47"AG@T0X#XGLN!/G;,XJ@*F)#
M%W0#9;HDZM]"0/= KN1=XR^&7;(0TO1!3QT:YOA"^6$"S#]($,^0YT(:TYP3
M<)]45=%)D>G??93J^\Z.VFY_HQ*H?XL4M!6PJA3*9]_O89MSMQ324F2=,UJJ
MK4 #9\4"5?D_%C+8!.57%'VA"RLS4/XC9ZI)SBI/,F2UT*@F4P+ ?-O4+FK_
M;H4RQ![J1[.'2=C7RCM?]Z:+/"I1,2$&TK;H%9ER%9F4)BH_,*=N(E2%W1IX
M$<)8J_RG5!AX0#+@'D]X$(NX^P!(W 0 _WURYL-R,B$%H$\DNN5CO4B;2F8-
M',D>,FL@#9Q_+-; $1#T$2O^*>%;"E1^:66=G]YM_G>FWU-(8I?,\<)#NP??
M<7U1 Z3#SWHX+"K%\/*IZG15B[GY^U>3C>F^#!53*/^D_%O5ON&!5*>@M!W5
M,A)H-Y,^:=Q#VL1)9A*DV23( @1I$.+EP$XHGWAL(#,>4DAW6S4>.AX6QNJ8
MMFIE=D-F-V1V0V8WI(C*3\EN* ?QA?+)GRED=D,*Z6Y)N^&\6,^"#JD529GQ
M<#+"(C,>3II3MRS$RX'QD 4=3E,>I #VR72W5>-AU:##$JA/&:IAC=.8/NP:
M:Y-K/*\4:BE8XQ*H3IL$VP8QI&C!RU%&FN14J5CB6YK_4VECHKW*;[_JJJ?2
M]0L7FRT&XHOJ_%:+->61]7U>WU+IY)^H@@6_P^%>Q 14.HRUQA3.S@KE^M[9
M>;GLRF5P%?T)Z"VT[SKY?WUZO $<\G8*RI6M^7A%=AGSH!3<"1#I_KL$RZGB
M;0%SS<9;Y_(+Q]N3^FI;]G"LM%X]9E&QGHXV8$-U-B+3OMT9 ,#M7C9O$K=[
MJ9J:%"DWAO6-FCR=TN:O6M=DTI5^2@+!%59U-DX  @G4?M/\E(C^&[7+S"/?
M=@+B'QY;B=M^P"X]EI= ]LH1;E^)8[VJ7%*YU >USV(6QA5:&-=8[/@]+VOF
M\=N=AH45GQ0"&*\J'*D/UI*W0P&N'PYC:!P'%M8D5_[/?Q->> 4$PUKJRF3:
M3(B)U37"BY%\?>$("?LIK?Q&==4W*I65WZBM^D9Y]3?.SE9^9<$+A!K\!Z]$
M[[)FQLQV>.O?UI\AT/X[RAM8'>0HF]+NN1K(V5NM!E)+4360J>(?L8&F*H7,
M* TB<*C&WYR&HF5;[">%"EQ=@%CP!@BH+D!?#N%ZCFWU XH6?T:(9 J0]:1*
M<HU8!1#X/.4%0#I M,VGG;36.>:B4=$0^52-K^4Z2O%:3X^L;P ]X5#8!D"4
M@55]EPK#!8UI1#,.T3[%YL6FNFR@FCW>PD:TJ93]55#:^Q:\I/M8U]3W!C;U
MUSB ].>R1OQ,E*4+RG2O)C<V9'=1^3:ZV!%X Q>_@<4@SD,J[U:MF/);^^KI
MRP5 J88B_]/]XU7K,7]Y?W/3?.BT+D"<F>K(91*F^9O6]=-%OEAHU  V8845
MJE#I.7+0+ZWVYR]/%R5\"+_09WSQD\*GKIX7:AAN?VA>81G^_*?[IZ?[6ZZ!
MY&=/]P_Q#V@9L4\>:6#Z:%;@?OJ4;OME;.+4!1:;DA"AGP&%6K%0+9\(%)8O
M;/^I?7_;>FQ?-G-*^^XR*@0(?F3P[I^N:H4J#A.'J?@P7;25O/M*X:SZ9C=?
MK9\TZ@_$%L<L:*Y4CUT(-S2HX5KA17(GI4[&61EG90IG%>[:=3AUS:.27?S<
ME[ X9F'[:2Q%[3QH"5>#MH]QSQCTQ)=BX_AU7/Z([P4\7PQ+MU\P7!6MOK<F
MT,70_ .<^4BQ\&/GQQGY\IF!G1G8AS0#RH7SZ=T?#4]M@9^6# =4U@T'I).\
MCLN6.+ ELZ*-\5:9,:'=<<:3&4\>,4\>L^'__L$Q+,T8J>8T6W[(;,_,]LQ"
M4&D-01VSV$E#<#=]\-L75Z5^YQE'[5?)I&_C:X0NL\CE'I' @Y6Q^[FIL!73
M1\EOEH7?KC:;RS<9SV0\D_',:CS#XX;707?X]>.&&?]D_//V^"<2Y9MBHME1
MOCW<6-KCO9ZINU+;ON9S'@/B["QUW7!'ICI&NK 8S&:\7@R8JC,06<K?Z"]#
MUYDE_X*GKNG"J$V]G7'%CWB#12N_HPL?_.E\#Q[)%]]1V_5_OO/=?%]51Q>7
M]G!H>'2'H&GI>(_%L/H,\,[<=XIO&7PHW]7?*:^N<6$9YC_?>8Z/R_HQ/O?'
M!:NI3*^F=+C5%*=74YY<#=W$9:[7>ATQRV7W>,-AY64HB[!4G5Y))34KJ4ZO
M1'.8ZK(KQO]M6X@E'.XWPQM<^B[(+>;<&&K7P([UN\=:;7*%#^J8".C);FIT
M00: IUI] X14TW69MSHEK0ZVNEQ4=^BH%[\Y(.M!B-[W)I=R:;O>ED$T8S6-
M)5?3U#1_B.4EF-X<VHYG_$57[M<AM 6+;)Q/K_)L$I&/X/Y8_AJ<OVCV&51T
M/C4Y7F&\[WUU.6SNN_Q^?=N2UZJN;>=^Q!P5)=0-<L+Z-!^N]\X'YC&TJ>7R
MM>G,N*!&;DC?UZ;:?_>QIYHNDR.*MU<;\-)W'!S.<#75_)VI3LO2,>C^[F,^
M7ZSE*Z6IT9<?6Y9HX(,_P-.V?@V?N>\^_C(][MH#XZK%L.5BN;+)P"W0.-[X
MDJ%(,]N6SEY_9N-W'XOX7Z-2/B_.@,:/48W,YW)8#^2UI3'WXS],P_IVX5*=
M&IA0>:6_^1U3Y,<\GF04SRJEPBL1"WWMC4>P(-<8CDRBF/@8G(0B<\A)7=MW
M:,[7KF,:%V*;1.P:WN*"U2F*^)+13C_21\&'AHX?]PP&CA'.!HL8>-[HXL<?
M7UY>"B[3"GW[^<?+]L]QD$R^S'4-C/KCQ%R1^4=$#1/SNY[J>$A]B,AROEC/
M%TMRD/ [10P?V8L>>>F,B#;^370UP<R(NQBD9@*N]"Z8,,V@,ZBHE<=A4"KF
M2P$,Y#<;P*!\A#"(T<$68% Y1AC4M@N#ZG' ("9&2NN(D=+6Q4CM(* +0<+Z
MJ# CFQ9?Z;"0UY%I:(9WRX9XO*Z#_TJ%ET)KJ(,-8_']%EC4H!_MX0A<4_32
M7@W0NE'WS;8ZGJU]XV/QA4U-$5G=CQ/+VY#D2ULG^?H;P%M3UZFB&MAHJ@$V
M[J4Z,CS57(##(T%@XRT@,/3<*#: SSEL@*,]@_^K@4^^D"&/!)UG;P"=CXQ[
MFRW5L<"]=$]&F)X?A_VP4QB4T!,[9>H]D!601J.O5#IQ7!_:<D@ETLNGCO14
M61NI)('*B9/ (2V45"*\>N((3X5KO^6(7JEVXD@[M';>+?;JIXZ]5*G9W>*R
M<>*X3(]'OVW,G>T=<RD#P/F)D^[A-?_VS['*IQZ#29'FWP'V3CZJDE;-OP-<
MGGJP)"6:?P>8._481QKBV"G)@2J?>GCCT/HRE4@_^?!(JM1L*DG@U&,LJ8EC
MIP7AIQZ(284WN^401'G_,9BWI9UWB[U3#R"E2\WN-D?\U.-*Z?%FMXVY_<>4
M-@% ,5]LY,M;!<#^ S$;!O)+6P; T<8S'AD)UP<P&<=/CFJY_&(AYURZ\]E\
MNFWV'48,OIAE3]S&K1Q=,,-UO(M'O'3*48I_WAJ6,?2'BY!Y2K2T6_E_=,&.
M642AOF9$L4VB.+KP!U)!8,I]9G;?44<#0U/-"*ZN;8<9?6M)TVT5.KFT+:R1
MXE#9@$?#_?9I_(E9VF"H.M_B=F1'-9DK+OC?L44DLXV%/(U';"(4((I53#W\
MIJ.^E:.+ &4T?[0TGY+LW<K1!=".A>:;FF;[E@=DKS'C&0N%[6<Y,RC?8;KA
MK4KW6[554BGNCR[ZF)'^L9/^6E)_(H%E"Z1?/=I@[?)$B 7&[GN?;5MWG^S%
M1R8[(L"./X)QUK0ZMN"HNI_&T6\B@N+>8K\"*=G.4H Y62U0/=J,RHP53H45
M4N(+5(\V(35CA6VQPM.+S5EA\?GFB>N%HST3RY@AY<SPC_^3SRO_][?;7VO_
M[__^2QOYK[];M7/]K\9S__>Q]?7*?_G<<,X;/Y?_^/HT=LW&L_97T?Q?[W]*
MO_Y9^6LP^&KVKMC#CX^_?/WKZ[^-P=7]F7[C_>+<_OOVCE6]^JAI/#\4U=>>
M?OWOD7NC/VJ7]5__IW>KNLZ_?NF\_/D_G2_?V!?]\^#/)__W@5MYKO_K]_]Q
MK]JO_ZZ,.[]\L_ZG]N-S^?<_ZG7WS/NW]?.W?O-K:UP^O_UR?WW[%= W_'W\
MZ5&_>FTU'O[4_M6J%'_VZZQC-KK,&SY]OOSCU[_*G9?:W>.M^=FH_?C['X_N
MHV'_Z^;KS;=__C_ELO.8SW\\3I?IK1V=GJYD?VOGG:>+R:,[I)2JZ!H8T6,W
MQC/6U8Z7(O\TOE7_L)U+4W4G,M"N#-=SC*[/]6-_X"V1@W;J%'!T1W9K40!9
M(P^^HPU4E^E/3!M8MFGWQ\M2P8D3P=&=86TD!AX 7%:&]>IQ'M_ ,G3?9/<]
MGFU\R[R!#<A_9JX7YB!'/V7L3AVRJ!RP3<,=!,I@<=3J:)*.:D=[+-%\41U]
MVK5M#4>F/6:,+MW<CU!QO^D,F]K1!=OWF'^:T=!R-'1T4>H]IJMF-+0<#1UM
M<+<)P^J&"3[@,^LPS7<,SV!NZU4S?9WIUXX]Q/M+OD=!5# RQ&6E!^9T!JK#
M/HUG#[ IN9R\M5D[NO#?FZ68E)RFUHXNS)AB);+3<CZUHPTCIAY3VW80CS;<
M%Z1M?O)=PV*NV^'#10-\ER9X%IIJWJC=MVV='6T\[RBPG!;]>'3QNU6P?/_,
M'&_ * ^:[35"ET:.KA]M8.^(<)T2OJX?78QO%5P_#,8NC*):[GVO9VB++C:<
M.%L?72CN^%"=%JX^VHC94C:9C7F'FG>K6CXV1?<=P^J_;=8^VGC7D>$[+?R=
M1:M.',%'&^3B*1%MM*V9Z[5=UV?ZO8/_XLW2F;<^5ZET>>J"_.A"9GL\<C\>
MTMII6+5^= &W/1ZI9S3":>3HPG4+JB50N,897]S^Z]A/11I'%UU++VJV?+38
M.+I@V +4X-=-UU#?O%W5.+K85^HQFQ)/J7%TH:XE,-OR'7NTL S/B;/LT<6T
MTH[8M'#LT06OED#LG>UX@^80(*$MELDGSKA'%[LZ$ORFA7^/,D:U +\=VS\X
M?M/"OT<97SH"_*:%?T\M-B0C>;>&KINLI;J+2A8KN\-Q2GCX[-2"3&G"<4KX
M^.SHHE7!G7AT@AQOW/&[?S#->[+OG>:S:I@8HK^VG7OX4O4,JW_#5#=ZE_J3
M;\ $5K]MM9UGPV*7JFGT;,=:& 8Y<68_M>#6LA'E'=/<Y*O)SQ_&H2_5\Z72
MJO0W^=(VZ._40G![/=%(I40YM=C;X3!Z.&/!MPR.3A=OAKHQC Y!:OD.^R@6
M10_(8>1WX< XTM2HOJN_"S8Q,:SAVM5RJ7'QM7,U-:H277+2R _,"58=FT$W
MGH%V)@".;][Y0Y3(]H1N6'I-,?1/##@UV16S[*%AB6\3)IP+VYE33@P;17>P
M[P6P&\'H<S"-7\_<?7S0'XW7"UBU[3L:<_F? Z;JQ";P*"SFH_S9M?7Q1UXD
MLW7UN?FH_ I&F4[7DY5+6V<7RJ?R5>O3V=F5DL_#@S\.O*'Y\?\#4$L#!!0
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M$6X]LLP<R[6#1TO^D\Z,E;?X^-9Q+ 79X>63YCWYL9Q?A#EM=HZ\[DFX-IR
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MST].[*>/+BXN2O;_SA^E*.Q!7NQ1Z>O=;4<=P"$H(I,R8*H"@*)+:G]XBU7
M;"97VJ5$/B%^*WJ/%<5'Q:/CXLG1FRG5"@YOBO*>8 .VH:[8EE^RV0A>%2@:
MC@QAD/W9@$#]JM ?$E 4#!Z^<XKXM_CD._E>P2;%!M($]]? $%7I#"!D!444
MW6LW I7H(SR$!*E Z%<23Y0B"RA]D&]A@S?*(>PP_O,0FNF,7"RC]"$#*BN
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M\Y:0*OKY7B>&R.T$V26/*_%V*8RLT0E"LDM9,PL=AM7G 39XH51,84B/&R$
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M&*H5:_04A9:KX-%)#:;U[-LQ,I59+AT!^)Q3950XB,8M&A];JMSEOZ6#G=/
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M<,BG(YOS991.^#40"=@_:G=9AGYH^7<N->!BQNCN&SS97L1N \Z#P'ET671
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M 3J/=[MAP@F&@0652IQYYW"9,R[T/PVYS+=\-&$C"?5#R?./%!:8[FS%E:Q
M1"&F9=";D99*!5I *0\29:I@Y"5-UUR 0UYT\B""U3C<+E8%(K42(IW0>F4
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M2@7F?;.))C<GS$N@NVOPD6VQNOT\HUN"OD:LS=H#QP+(1R@C4[N?Y-: 8+Y
M*1VSV<(58LL9_N50[9<#O.NKGZSX3ZN:B[O#H:!-36=6XXN# *?S!:2Z%/81
M8P;3-?6&H-%L0$*7NA[:TS"W!C=XVZ(FB&U0-#<7Y)[?I87O$3^[+U$X#QPR
MFM%S.\3N;52Y94K\9,4AS1D_<M*H!5/U@R!E25VX7R/7<<-5'9F4?GGO-T/%
MW,$RB:D6M!%[7\\0&;ODOH\1Y8#]I/_@**74G6LR(5X@+Z:2Y+3M'$?80UZ*
M9H>D)H=A96I9'?E-L>5LBG_M%/%+3%:]\I.CV1WY26)8F<:D?!HEI=R2I5+G
M2!*/T(USJ0(%L+Y0ZY+4L-JNE,S>2Z<:*(F63S5?#A;7 X"5E#19H^$6-=G)
M0RG924I9F.=!X#RZGD>);^>XP8I3@7!WSBH5-%-75W.8(4YSA-^.Y70ZM/\$
M8*7BT5_;I+A17_Q0F"\<YF2X#X@I!0)B(M;A8-]C&(W0386M]U'V&-&3.4*L
MKO]=C!CLEJRFUZ48K01ZJ=A$H9%Z@1$2CF83ZBE"^]KEA+JRWT18I?+1&Q1A
M_6GH=)A3?TK7B!=PBRFIM VB+V4H=NC4DP(PE9VP9FZSYW;0!DH)F0YY=F5
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M(<H^8#.8H# )K3#>YA&A[!,RB0D1@(0%,2VH.^G*[ 65%9WWEH30@3P/24C
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M6=D6J1C#7$^Z!O*00P?H<N2:6NX^T+[)CVU&C6G<+UM0:>ZNL7F&%M<73@]
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MS#1Z?V[A.^TG90F1[EWW5J&6RDCW:^+BGB^C1Q]A,G>7FUB#9L')T^VJYE1
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MLB.&U#+,:: \.%!UU2&K:AAWU 4LMM (3-0>HVCEZW&[16+17(,(DEGM?3/
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M+J6F)9Y<(0EC >;FPM >?N8U\?#JR^7O MP)LK^_"QZ.DP_'T"?_V""?&<J
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M]^$U3$X.4816ZOF0$"Y%SU%CIX,(%\ZAD$T!43YG GP8Q\#Q_? )WY  J0;
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MG4KJUMI][NA*@++,\LBD+;.7^+T$.8=ZIO+0+\6%T7)SCA!P_!_1Z="S]'9
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M>OQ\.P)^OOTJ^/E6SL^WW<HL%@77%H%+?&K;T'<1+<]^.^ TCV$>1,K+&K2
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MKQ4L&2B^ TT+"I_DN1AP]J=UR55@M;O5.%/-G2AL!)1YS;ZGK/*;?R\)]CK
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MP9K+RNL0N'"#$[/P1^IDCA6+_)#OI<$3U>V;+B17TM\RG:YD%9.QICP=X/D
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M25Q[-AIDPYFJ@@4&L;?!8H9HPR8(C^_-T[3VXRIR MJ?X)8TFN#Z5=+QH)@
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MGA,8(;3R -%/+Y]A^! Y^ZVW7D30B5>X J54*<B":S&=0 :T%%9[_P(*N(
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MZ>BB,C^K#XKYA$TQ#XK$3<%>TULFW<<EFI?N!?T&_<<].N_PB/\/4$L#!!0
M   ( (B!3566L@CP+RT  $Z^ @ 5    8FUR82TR,#(R,#@S,5]P<F4N>&UL
M[5UK<^.VDOV^O\+K_;);J8GGL4EN4LG=DF79HQM;<B1Y)I.MK11-0A(R%*D!
M2=O*KU^ #XF4^,"C08@>5]U;\=@2NG%. V@T&HV?_^=IY9X\(!)@W_OE],VW
MKT]/D&?[#O86OYS>35_UIOWA\/1__GER\F\___NK5R=7R$/$"I%S<K\YZ?NK
M]=3&)S-B><'<)ZN3_PQ7_W7RZF09ANN?SLX>'Q^_M>EG AL3%/@1L5' ?G'R
MZA5M,&NR3Q!K\*>3V3(Z&=OAR9MW]'\_???=3^_>GMS-^B=O7[]]FWSEWWYV
ML??YW@K0"=7;"WXYS4EZNB?NMSY9G+U]_?K=6?;!T^23/SVQ7Q0^__@N_O2;
M'W_\\2S^Z_:C 2[[(&WVS=GO-]=3>XE6UBOL!:'EV4Q @'\*XE]>^[85QD@V
MZG52^0GVKU?9QUZQ7[UZ\_;5NS??/@7.:8+;R<G/Q'?1!,U/8LU_"C=K],MI
M@%=KERD4_VY)T/R7T_L5L5XQ!%__(VGB/]AO_B1_]GTO\%WL,.S/+9=U9;I$
M*#P]84W?38:%3MQC?X4(MBW&WQG[Q%EE V?_U*OAG[<605ZX1"'5QPV4%=YO
M3X?^0SJH5F@:TI]75):4SOMMG/T3R!2F2PK TG<=.@\,OD0XW,QH(V]]\HY;
MSYHFSF*;A8>T;P7+2]=_E,)R^^58.Q#=SGO3X71\>3L93 >C66\V'(^X52O[
M+I093H=7H^'EL-^C#??[X[O1;#BZNAU?#_O#P92?X-I6P'1]WYL,WH^O+P:3
MZ>"WN^'L$[^"AU\]@YLMKP;CJTGO]CWM[NAR/+D1H[?\VY #XWK0FPJPF7X<
M=&B.;VZ&LQMJOM/>Z*(_C@UD,!(RLKHVX&:[NW-F(%3(X .3Q&]A^U^$A*]G
MVW[DA=3ONJ5SE(U1<+Z)?]IPZU?3!*2FM3/!S+IW$?^2S-,6W Q=.@P%-:YK
M \Q$D^$IJ%GA2V"J#+T'ZFOXA%I3W#2W.@=?A+3!\9JYV4'/#O$#\S6$-"O]
M,IR531#M>(3FQ%_9OA<2RPZ#1QPN[2@(F2Z".'(V![G6(7]!K/623B$>V]7%
M6QJ"%A9AVT(/A8'EBEJ#2)N 79E&:_IAYBU;KDU=OCEU^0H*N,P9#*D8NM<2
M[)),VY!C8,9VG&%$J G[\UB(BZU[[.)0>*QR--6*-WJ!0@L+[.BX&@-=^PZ<
M3&&5*UO0O,Z)*EK;". 0398M4>V*WX)0Y\*W(S:8>YXSH$Y4N!GNQC*W6K6-
M9&ORFJ" S1KLE]=4I8*RZ"E$GH.<3%W6K'0D)AZS5*+KVP4A+HM3^223X5KW
MR/WE- I>+2QK_><VPC">7V*/MH8M]]8/,-.W=Q_$2U 13:9>0/6+ UES*[B/
MHUEI>V<,YC/DAD'VFQCX&'0AD6=RW>D% 5U>^A%A01Y-^I?+V"J<9[Q'BLI;
MQ,Z4H3\>T%V,#::?.%O'$:M7]A*[6TMA'H(<B:'?B)9/'$1^.7W- L2T-W-$
M_^Y<)T!7:ANK&E(7!<6?E"60Q6KH@&+_8:&E!^HI>&'0"_L6(1OJ/7RPW @!
M$\HG,YNRS5!<:]AY3CD!E.?8S>B5&Z#)OC68(!M1Y:BW,4)AVBWH<5HG:N<H
M'#F?]8"E-+Y1H5&*QVS'MQDA:-X*37=DU!7A2%EYV_;@NB5H;6%G\+1&7H#H
M+# .EX@4.@',%8_$K<-VY!QRH9=2^TYIP$E.G1IY+&.L Y25D_/?$HZ+3S?V
MUVI3XBWQUXB$FUOJE,>; KK\KIE7!C]%UHKJ#'OU@*5D?M?ZTC9>LZP'ZBI=
ML^#(!"^6U*^^HS,"ZQ<PD?6R=NO ,=/8@%?*X_=J,Z:LCQ*$S* "#2Y*UK+)
MC9^0?[*%(F7D!P5&Y.@(+6^!J0>;J$U'^>#)=B,6%+[R?><1NRXX3QPB.T(@
M#W@IL_]HF=F<HS3R/5N+AU(NHQ/<5<"3DO5CRV0EBFCQ'[M!1P9 MG>6B7,5
MW449&JYWARYZPY4U@KH8LZS#33X:HAZXS.(TM]:&!6FH.TM_0R(J_T!A37$N
M'LFF]P;-5E\6^^+"%"IJ+3><!ZNUZV\0FB0GP=I);Y;7+:HY\(,:W7($]]-\
MC(\X7/;3=(Q,RPWT@42M+*.[0C%6&T"3CY/N,PJPT=_JI6? -@@S'"05H[4)
M.(-!4NT3;^=GVIJIU5#@M,*<]&TE&^4='Z,"P[!DCZETS*L^$O4-0:-;&.EQ
MIQ+<+@XX.4]FM<))+) E"OAQ%CGR;'BBZB29/=@5=6-J$(.(;\ME;OGVY\(M
M+&WY6I6"NAA J,,-RB&5'9:^%VNG)<EIOWFSW#79[O[P*R(#L*Q)Q7@<)S8O
M:F@6=H9>WUIC.AM#QW,JI)AV2L1(J\3*6,I2S[:C512'%^*(/+O13M 2>0%^
M0,E]VVL_8"<KX_G,>H*/T@E)-[L^"G(MBJRI!*D)RR'WD#.PB$>7\""G^ 6:
M8QM#KYT< HV&<\1XYH$/9N\/XQ!I=X0Z-B>7(61VZY_SPZEGK9W!1G&F9UWE
M,[$*%.5'Y>%1Y\]G^Y=:VK[KLE_$X^7J"UN$7==_9!!=^N3"C^[#>>0>)H]K
M.H(4DFTXUBU]6T8,8(.AMVTV.MLNQ=!.*,KD 3S 4R.HBZ&!.MP MBV*FY8+
M1.72KC"]Z,\NBKOC.;V53T+\=_S[RI1:?;L9-;6ZN>#"L=+V3BBG>5[#O:S=
MO7FBXCXO;UN&=SAB%',#!+#1D9D0:"=PB*[IQMK9SPFM4!UXZ$LHT-$%7P9J
M^>V4\JJ?"Y-2_WA,XFX[<<3T%I&X:)N^F'*EQ(YRSP4FR!459;)C98)>%"Y]
M@O_>[;#@23Z0U,W5NQ8[4\=Y!TH-@R#23V8JQ7P<"XC*##6 .RY /(ZCD!6/
M91<U=).9%_5L&"W@!W#!Q6 ,:[^HJ\+-MD)#FJ)555(4EJVTP!ET'&+;K&FK
M;R"F>)B206$P4M3W SI 4U7 IZ=\VQUB9@\4B<C/CPD]'EK$R>Q*CL$5\8/@
MEOAS\,/)?,LFPW6E1I@GI "!PCT/R%S5M$Q$H&GNK99C>$,E,(YJL ++_)<Z
M^$&NRZ[-QL\;N"Q6YZSH5I_I%M+-?JHM]-$/GU#3TV2C?1?.DSF!-%5LBD7O
M:==9/:P+.KNX?AQTU<-OO2RC(5 A3ALP,Y:]== )W1.NX> &E^W6SK:02Z4B
M9[L<,%VLY208'6LRRV,>':A$#>DR#HDR[)!*LX-3+ZQ#7DX#:@H)5NJNSJ[N
M2Z+AT*.-TM^P604_8 =YT!%&'HF&R>6S\_+R.34PPFSC)2OKQ.JD78G[!TYK
MB8@.\E@&%(A/(T7<R/?\XBJ@QSFMEF-\GJVVW#QQ-4 !.CGRH5BV>%_2GB5W
MPR*J9;JZ^UYPCN8^2=/@9]83"@9/U$!]]AB"139#NL+$98'857D_WD]EH&@)
MY^K1U&3X2&"MUDH6U)U.%3ND*J<#XYQNRN%#AE523(<MA&V@!"B)DU_(..\(
MA=JV2<6V.T36'BCRI[HP&]KLXDN6 G)N!=@&YJI<1D<FV J H(YME0F[P&X4
M@F=55$GIT$"K! J@2J'L:/N(6-(E<GH/='5>H%&TND=D/#]("] 4H1 6WR&Z
MQ:%5J9:H?#>>5UT=\[&8;,/[*=DA(V,;Q;F]]<.="C73B4MW[I6H=+.'">HS
M0S6LV<2@&#Y1]YG_?*W=:^X"@0>89 0IW3&1/U!H* 9 '0[LL\PXPHI87:#D
MOSH/'=04ZH@C#@%]9C@RAU$@]1DK^G#I$SI)><E-2WLS(Y874(63>U?QO]R8
ME2L+>ZR_/8(#.E5=1(0]EQQW6E.1CS8T-IM* #:B>8P5E&ASQS,E/=-D?W62
M.N.!U,*5S4D ]2I:3@2/7:="6889;>NM3]Z=RJZON1S[%JO!\<B4=AFVS:>/
M&NO1??= LY*.U"Y0?"2@2\^= -.Q!2%3*]:<*1(*<]BJQENB-9MG? ^QHHY/
M6!N%I;*.XT9T88B5<E8.% 2%BE>K;A#;EL*OGGOM'\G]QCI[K;@[E0$$]RJ"
M9-&]\C* 6OBKEW4<8XZ7R@;<P-Y"T%1(40^_W'*/HO@,-]7\<!I^,&&__I\6
MEBN$=&PJKH)*(;\79#[>T__"7U$UH8]#2V5T:DQ6P)3+Y3V*[C1[<+DM"D"I
MH9>RG(($'>P0.<MQ2OAKZSC>12634.FL56/UB<.2$\?.4%E-"0FGJXP;^5TL
MM9I$I7R@,RY-$_]MO(XS&0=/B-@X@"=16/YQ>-[-0U$,5)/3Z:&FB:4:Y+].
M@6.I 25C K7 @GEST!/!"#W&?X$/:_'([,34SH<>3#TW\('>,K_[0COD7W$@
MJ)"X#[(G>SGG/KIS;CX#:_/<6J4@G6PY<=O*4K[.+;K>L9[2;L:JZ[FGQBFT
M&],/+X(*EQI II^OY^()'V_E=T[4[BY O6@"GN-8$3PY<HK*@9&_JI#LSP>>
M Q8Y@2?J*,MU<D=/\HFHTL&M/8+,%''L6\'RTO4?3U6S1\;SK"E=-39J1:FM
M&*R]6^*SV@?.^>8N8,4MMP5->M37>4B>H]'3,0D%CB4&4</ZWB(D##'86?^+
M%U%'I;SU-WL9K=^BZ3E_14EEDV#F3Y#M>S9V44&YF6]VL&M1\3B<',[)0 ])
M4#DD,F:7?S5E[[$48.NIDV0V3JESZ.6MIQ9K@[6'XVX%5(N2][2 C:!6E.GU
MI"T[J,?;T/M6VR>WKH>7X_2UK20"UJ>[AP5T@*E1W-<Q)32C#O$NE4K4(SEK
M8P]F:2K'6R[DZZ"_"F&8MWO52H5>L\MB>Z]MY9<L/>8@+/YK633$>0$X,96L
M?U6X;YCK:9H[K>^5#%[!1W(NSKGK$$'4<&+RH:J'#[-JI[U$I.'+XH(#HI[\
M,D0E=@]5)=.@B,]<&ZSAL=LZ6:;+0X!R70#1\/LGA]K=$K2VL'.1JI*N/'1K
M&Y_'ESU@JH%[+B6>E5'PP2ZQ$D!8RZ&ZL<-RC:U[[![DG%<\:-O8B/$[]!*$
M-B-CT.TOZ1(SIIV3VLY@+A5JVL6''K_ER$JXZQ7C%=9QN[4VS,=@ 4O;)A&5
MDQIL&PL[EQ+/:G+G@]W@@[>'*@]6:]??(#1!\=W)-NVC1O2SLHHZB"$>R@6S
M!5;*FW7K(PZ7_2@(609'Q=JOP1SJI7?1:9!&VMB[N_RG\L9R43IM"2+XRJ=,
M0E3"K] T></%8'92G0+/(SNI%F*C=Z6H6Y/&RGOVEPBS%QY"RUM@YNKHV&(T
MRS.]NY ?)84SY69<C<<(#W2D?::S5KAA9U_L"2>601R_KJ?;"*H%FUT9--E"
M#<Z ,47-:X2QM>%9V(0(S@IG2,I/'U;H>8D]R[,-^@QU"CP/GZ$68J-O)U)-
M;82<^*DH=HF!JHEH7W<UUN"3U!KD':G/P#%*]O+0FG UE0V=+6%ID<M,._9
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M-9N_W[];99_?-?^]DR?V",& XD8\R\V>JPS.-SOI/5:M6.N(4='$2+Q9HG@
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MJM>F,^+Y#8NW.CUDGKM<ND$<^+VU2+B9$<L+:!\8CO"7]NLD'6\UHLJ;<K7
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M"Y'9H$96G_XX)C/_L>[N@R!5N3:[X116(I+QU'(*[H%.\4P])K?$?\!>[9/
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MP0/S0V?>]/I>S<6>4+7$*(8QJ/ 59?",#\<,$ ^&[2#FX7WE] )D;K,!U#4
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MV?U[='.WYT2!,53"\$F35\%JU+%/F83_EL=9'-@[V?Z/-"[3-9:F"@GPZ<I
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M7%)XMR89%I1LP:>IR"2(&"Z96-&,A40'AX<-.%*.VE"L4L*WVC%&P@ACD:W
M;!GO(!99$2K%.2("RB/&;\%:WR(.Z)@ZUM]NZT!RB%E"HWWN>FU.PW7&),-:
M"(_ WH1+PF\I8*H5RW,%%%\J=D0DA27-*,(KX91PM6/$J".BCR3\1+(M.!GA
M3(?ADM$8 V("R7ZCX,4Q"VFFJE.SJUITP#'%E0Y2E) 6-"\X6&WA$Q=WB/>6
MZC!;9_F:<*G<]BBM4(*_3BB8IY%AGAPMCHLJS+-Z;:?]BNU"^XH $HE4(@4/
MX^V<E(PJ>'.2+0BG>;WF;1*Z+3*A2>GH< G]/1&5WL:E%P3>===HIYNO"NL7
M9Q1,NB=GRK6:'G@SE1"G3CTKZ"8TEMJ -:#<2+_I=EH)VW%'MAL4@+5!@ Q5
M8HW7"2HWQ&XF2D1[56?T\YIE=(6+-5?,51SGV(DC<@PH6//T*#K>\WVOPT?=
M1;-YWCG155\/"AI.;<LO2C_<_?_+'NR;\++TXWIC')?]BA3*Q7U%$L91UZQ<
MK;ON$*8VEC2CN6J$KLPD20"GX59!DGH-+2FV!DUJ6LPXX2$:5,2(%;'5BD*O
M=5(V4N F0\I6EKVKUZJUW'A^@YYEEF2!2[]R*1MDOGFKV+WT_)'M&T-O.K5F
M<[L;BB0A:4XUU&<DEQ=:N]W1<.=)DCPE(>Z5%UJK?$Y)%.V>%R*+:(9S17:A
M2=S5T#E#&A&#S'9Y)[9S-0FZYFF*XX@IVADJ#'N5/'#< _2+H<+\%/Y*H'>,
M1^).THT$,Y60BX1%/9A9HY'C7NV<6HS?CQ5)'PY,[7%0CE2ARP&5>.=286'\
M$4E/2]@T#S7\ZO-:R-Z!D,M!O?S*D3\C1]7%Y?.])E"3Q5O%G#JN;514<27O
M!-F.4=U_81W]"09MT,R;^Q-JWB@/J7Y312XO84T9J8],]?#KS7W4S&=VXH_$
M_S!D_T_TOT3T%RY9WQW?WP>*'Z7K(SR]N^"%4BSP0FUVROO]DTW'#W5*_N.S
M]LOFR@5_7:F_ ^JU_D^& ?;HRO+A9_S%%I47E*&($'*[\]8^'W?:8!C*LUG]
MY_ [4$L#!!0    ( (B!354MFDY[?@0  - 0   /    97AH:6)I=#,R7S(N
M:'1M[5AM;^)&$/Z.Q'^8^L-=(MF (>F%ER Y8((E@CG;:7/]MMA+V-;L^NSE
M O^^L[8A@::]:WII3Z=*8.3=V9EGGGEFO;@W#FXF_6JEMZ0DZD-/,AG3OKU9
MLCF3T&K6FKUZ,0:]>FDS%]$6?Q+(Y#:FE]K(G0:&[_QB=]J)[$)^.[)NG,F'
MSMN K6@&4_H GE@1_K8+-Y9W[4P[C62C]=_P>99T>_7DZ[CKS?OVW=BY<H(2
M^;Q_Y/O0.CV>?G%H(#&[YY=:2+FD:8YD8'N!,W(&5N"X4YC=>OZM-0T@<'>P
MT.8U0IL7<%OS:X,:^/8@CVVVSAOZ:V5J^6 -W5E@#P]S5-%4HJ_"[2ZS=N-'
M<$<0C&WP+>_*FMJ^X=Y-[ ]@#0(UTVPT7ET&@7T7&-;$N9YV?EUGDBVVW:?^
M'5ZM0"@XIZ%D@L,#DTN02PKOUR3%A.(M>#01J02Q@"LF5C1E(='!X6$-3I2A
M-A"KA/"M=HJ>T,-(I"LP&\9[6(@T=Y7@&A$!Y1'C]V"M[Q$'M$P=\V\V=2 9
M+%A,HWWL:L6GX3IEDF$NA$=@;\(EX?<4,-2*99D"BA_E.R*2PI*F%.$5< JX
MVBEBU!&1+^DG"GXL"-=AL&1T 2/&"0\9B<%=+%A(4Y6;6EMFH@..*:9TD*(
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MJ'0X   _4 $ #@   &5X:&EB:70S7S$N:'1M[7WK;]Q&MN?W"]S_@9O%O;$
M6I'LV$YLQX LR8ZPMFS(RF1FOUQ4D]7=M-ED#Q^2>__Z/:]ZD>R'$LGIGE&
MR%(W62Q6G3K/WSGGY:^7[]^]^L__>#G5*GT5O6RR)M>O3K].LU'61(_W#U_^
MP!^]_$&N&)7I(JJ;1:Y_^?W#Q<G#WR^./CX?55I]>7A=5FF4JV+RR^GYP]\^
MP<5I=B77SM5$/_\=+OBDDR8KBT/X=B[???_FP_GEPT]G__?T^>'AO'D1T=]O
MCMZ?O?O'\^\NLYFNHW-]'5V4,U5\%]>ZRL8OHLO3OU\^/'IW]O;\>:*+1E<O
MHO='%V_/SI__M/_HR;R)#K(B.GR$X_&EOUU^^/3QZ/CT^?>1RK-)\0O?]NKE
MZ-712Q45:J9_^9]?\R\__O33X;,GSYZ]>G]Z?G)Z$AV=GT07IY\NCR[AC]?_
M>'?T^Z>7/RA8D1'\/]^J]_CP9AMG]?KLP_O3B[/CHS@Z.S_>O_LIXMS<_-9,
M\(&*3G2NKE6EHZ2LYF6ED$#WMFB*1VDY;W0:C191,]71ZU+!02O'T4E6P6DJ
MJSHJB^@#_#;2571X&$>/#AX]VJ+Y_W<QJN<OMFA">.0O+L^.WYU&9UM&CGB*
MQ^,LT?4=3.QS6S?9>&%G]O/^S^%9[DY.[CX#1GA^^?PP*[Y_=;C/V[GYS^@2
MB'9>9462S54.A(NOA_2+Q'SLCEQ43U6>1R,=J29Z].0P>I<U('NB-_!I'9U4
M^W%TG#4+O//W+)]EQ:0IBSCZU*B&AC/'.(Y4D=+@R-/-@RI=9RFL<022"'["
M*R=354TT?EEIN"BKH^-/QP_?YN5(Y?M;N/*/_MC*^RL\4PL@M[J,INH*EKFP
MFU');S6N?=TFTZC$=8GFN>*OZ9<ZCJZS9@J3AD_PM[)M:'&']J!>RJSZ._\
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M#'FH.P_P);0J0:R;D^0=+!&5>!Z!LWX&=M%8H0+W JNT0PZ<PWB)XAH/RMY
M=",7%D-WB-GI =8]P+"-&G.L*R .Y%O$6\X*+P1FQ3P+7C6"YPH+\E>Q\'2M
MRN=.,YRF>-?CWC*5-+$5[T)KTUL.\F#S^"'S[[FIS/2/>(YT<9]OJD:$LWVG
MK+;S"LQ=D9_&%D:U@FZ<96C[DK8QTB"SO LZ?B[<E"J;9*P+LIFUHP;'TYTX
M[8%2L]*O:M60.2OZ<"JO-.L'&">RM@%ON;T:QTFFF0:CXZM.V@9U!0ZD5!T_
MT?'I!]][Z#1H.H6G'Y#L4"P+Z<4^X=QTRBL-FLZTW&7^]'!BA6@Q9H*&8W@#
MNZ,2S-<<E35KR5I'@IR@X&][C-1_WQXK0*4.3;XU7"0X@V;A+]<8 Z0UPH#3
MK#9ZOO"_>(FU%QO%-"'N6_N#!Q8I^[.S<('=7(KE]N2RY199-2V1IY+?G)?!
M+ RJM .S\H:X(ZWO&S&C9SO!C(:,*BN9LZ+C-5XGG V!XG5XA]G0H:A.TW>)
M=$]7/.@/6.LUZS@&?,N[+#1?,WPLT8CF1T[%;<.Z$MR+ \&=^$^%LK5FWR7<
MZEG=J!Q4>@)G1%>\?MY1Y;@_+PYZ"@9-(6$,I#+@XP>,LR,X2_0.;#FM4>H,
MVPL<2_Z*NN5#I0C6< G'FL]+=#:D[!"BL!<H)L+BQ !%E\NH3JIL)'I=UPG"
M(_K\:Y6A2^N9ZARF7CD7Q#)VT3%> Y+V+5?K'3!":05!BWSQ R>HGZ.=7Y%]
MC?0@%G6@<ZX2C:E.C.*K(A_D=WCXY/'3PY\/#EY9F<,;O9D9O5;D^-14#VNR
MXG%&+&'LM,^1QI>2\7T5%D,Z$A&J@Y 0\PHY,$2"(%X*#4\2,Q_F-8+;RX;F
MH:)YWE9@S+*8Q:G4Z)EJS(1,_*@?"]I1\?#33HB'(Z3Q>:Z!,G+/Y%RM J']
MM<RU!D15@2DR8>ZH\OE4C>#"!"%8%5Q@HC[EM8D'&H\C:BP]=ZV!5+48DZ5G
M,4,,F;"/NNJ-X6NL<U6Y&%/@3&?OJ=&B!PZ?B B!;_GK%,':3'05^$5I,>V3
MR[DN#'?37Q4PE<!?Z<]V+-:LB5/ P$ DVMQMM3FZ#ME 5K(_P(:MX%'D@=<<
ME!*!E)*4Z/OD11LD1S2<0PP9C,!,5$D">Y*-<HD(5V61)7"^F^NR^M(+:.<8
MH+9:A45:9 4\;\:OZGO])@I)@YY@WHO6*_,0$]9Y7@3A&YGW'FY9VE9L_L-[
MXBY:FWD*UG9M)*V#  JJ;+P*L;6CS.;GW6 VJP4*JY8N%L6!"V/]@CXR%W
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MNCSJX2WF,GL'5PQ-#URU#E<;</ Q*72&]*<S1'OSMJI;50BLHB/G]A_3XLR
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M.#,Q+FAT;5!+ 0(4 Q0    ( (B!354K,-G;3 T  +&&   1
M  "  >K2  !B;7)A+3(P,C(P.#,Q+GAS9%!+ 0(4 Q0    ( (B!3563A7Q
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M:70S,5\R+FAT;5!+ 0(4 Q0    ( (B!355",)E%= 0  'P0   /
M      "  ;^Z 0!E>&AI8FET,S)?,2YH=&U02P$"% ,4    " "(@4U5+9I.
M>WX$  #0$   #P              @ %@OP$ 97AH:6)I=#,R7S(N:'1M4$L!
M A0#%     @ B(%-5;B@X:AT.   /U !  X              ( !"\0! &5X
B:&EB:70S7S$N:'1M4$L%!@     +  L N@(  *O\ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
